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 Abstract 
A novel brain malformation syndrome was previously reported in six 
individuals from four families. Patients presented with profound microcephaly 
(OFC 7-9 SD < mean), severe cortical dysplasia, profound cerebellar 
hypoplasia of both vermis and hemispheres and brainstem hypoplasia. In 
previous work, autozygosity mapping and whole exome sequencing 
suggested variants in peptidyl-prolyl isomerase 1 (PPIL1) were responsible 
for the disease. All patient variants were homozygous and cause the 
following PPIL1 protein changes: p.A99T, p.T107A, p.R131Q and 
p.G109C;A101_D106dup. PPIL1 is expressed ubiquitously in humans and is 
part of the spliceosome, a complex RNA and protein enzyme responsible for 
splicing introns from pre-mRNA. To gain an insight into the mechanism of 
this disease, PPIL1 WT and mutant proteins have been expressed and 
purified from E. coli. This work has shown that two PPIL1 patient mutations 
significantly affect protein stability. Using SPR, a further patient mutation has 
been shown to abolish an interaction with SKIP, a protein which is thought to 
recruit PPIL1 to the spliceosome. PPIL1 is also a peptidyl prolyl-isomerase 
enzyme and using NMR it has been shown that a further patient mutation 
reduces this enzymatic activity on a model substrate. Currently the biological 
target of PPIL1 peptidyl prolyl-isomerase enzyme activity in the spliceosome 
is unknown. By studying published cryo-EM data and using NMR and ITC 
experiments it has been shown that PRP17, is a plausible biological target of 
PPIL1 in the spliceosome. Taken together these results confirm the 
deleterious effect of the identified patient variants and provide novel insights 
into the role of PPIL1. 
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Chapter 1 Introduction 
 
1.1 The development of the brain and associated genetic 
disorders 
1.1.1  Neurogenesis and brain development  
Neural cell fate is determined early in development, in a population of cells of 
the ectoderm, by signals from the notochord1. Next, the neural plate folds 
inwards and fuses to form a hollow tube, the neural tube2. Around this time 
the patterning is established for specific regions of the nervous system. 
Before fusion of the neural tube is complete, the anterior region expands to 
form three primary vesicles from which the brain will develop: the 
prosencephalon (forebrain precursor), the mesencephalon (midbrain 
precursor) and the rhombencephalon (hindbrain precursor). These vesicles 
will further divide to form five secondary vesicles, which provide primary 
patterning for the central nervous system3. Formation of these structures is 
temporally controlled, with early migrating cells forming forebrain precursors 
and later migrating cells forming hindbrain precursors3. During formation of 
the cortex, the earliest migrating neurons form the deepest layer of the cortex 
and later migrating neurons form subsequent layers of the cortex, resulting in 
the characteristic 6-layered structure. (Each of the six layers of the cortex 
contain a different distribution of neurons and pattern of connections)2,3. The 
brain originally forms with a smooth surface and later acquires the 
characteristic folds (gyri and sulci), as a result of rapid neuronal proliferation 
and migration3. 
The neural plate is established by rapidly dividing neuroepithelial progenitor 
(NEP) cells. Mitosis initially takes place in a symmetrical manner, increasing 
the population of progenitor cells. At the onset of neurogenesis NEPs acquire 
the identity of radial glial cells (RGCs) and mitosis shifts from symmetrical to 
asymmetrical division. Asymmetric division of RGCs results in one progenitor 
cell (RGC) and a second differentiating cell with neural or glial cell fate (the 
two major classes of cells in the nervous system; Figure 1)2,3. The cells 
which undergo neurogenesis to form the brain, NEPs and NEP-derived radial 
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glial cells, are located in the ventricular and sub-ventricular zones of the 
neural tube (Figure 1). Shortly after they are formed, neurons migrate away 
from the ventricular zones and further differentiate into specialised cells with 
a range of different morphologies and functions. (Production of 
neurotransmitter and neurotrophic factors trigger dendrites, axons and 
synapses to form establishing neural circuits. Non-neuronal processes 
including gliogenesis and myelination also take place4.) 
Many factors are essential for correct regulation of neurogenesis. These 
include maintenance of apical polarity in RGCs, which is essential for 
maintaining the asymmetric division of RGCs; (apical polarity refers to the 
polarised organisation of RGCs which contain an apical surface that faces 
the ventricle and basal surface that contacts the pial basal membrane). 
Temporal and spatial regulation of the switch from symmetric to asymmetric 
division in RGCs is also important to ensure the correct number of neural 
cells are produced. This requires correct orientation of the mitotic spindle and 
segregation of cellular components and cell fate determinants4. The fate of 
differentiating cells is also tightly controlled by many factors such as: 
transcription factors, epigenetic modifications, post-transcriptional regulation 
of gene expression (e.g. pre-mRNA splicing), signalling pathways (Notch, 
Hedgehog, Wnt and Fgf signalling pathways) and the environment of the 
neural progenitor cells1. 
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Figure 1 Neurogenesis during cerebral cortex development. Neuroepithelial 
progenitor cells (NEPs) undergo symmetrical divisions to produce radial glial 
cells (RGCs). RGCs subsequently divide asymmetrically, giving rise to cells 
with neural or glial fate (either directly or via intermediate steps, involving 
intermediate progenitor cells or basal radial glial cells). Progenitor (NEPs and 
RGCs) cell bodies are located at the ventricular zone (VZ). As cells 
differentiate, they migrate away from the VZ, through the subventricular zone 
(SVZ), intermediate zone (IZ), and cortical plate (CP) and marginal zone (MZ). 
Intermediate progenitor cells and basal radial glial cells populate the SVZ. 
Neurons migrate to the cortical plate, with newer neurons forming the outer 
layer, in an “inside-out” fashion. The MZ and VZ are primarily transient 
structures in the developing brain which are absent from the mature brain. 
Neurogenesis is a tightly controlled process and key pathways involved are 
indicated. The figure is taken from Fernández et al. 2016 (DOI 
10.15252/embj.201593701)5. (This is an open access article, which allows use 
and distribution of material, under the terms of the Creative Commons 




Cortical neurogenesis is a tightly regulated process, however when this 
process is altered or disrupted cortex malformations may occur (Figure 2). 
Microcephaly describes a condition in which patients have a reduced head 
size as a result of impaired brain development (Figure 2) and is defined as 
an occipitofrontal head circumference three standard deviations below the 
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mean for a given age and sex6. The cerebral cortex makes up approximately 
55% of the human brain and therefore is the structure most commonly 
affected in microcephaly; however other structures of the brain may also be 
reduced in size. Microcephaly is a heterogenous condition and can be 
caused by environmental factors, such as prenatal infection or exposure to 
toxins, or may have a genetic cause. Genetic cases of microcephaly may be 
primary (present at birth) or secondary (postnatal onset) and part of a 
syndrome or may be an isolated finding. In addition, non-syndromic patients 
may have either grossly normal or grossly abnormal brain architecture. 
Abnormal brain architecture associated with microcephaly may present as: 
holoprosencephaly, failure of the forebrain to develop in two hemispheres; 
lissencephaly a disorder characterised by loss of gyral folds and thickening 
of the cortex; or schizencephaly where abnormal clefts are present in the 
cerebral cortex7. Genetic cases of microcephaly, with no major changes in 
brain architecture or further syndromic features are referred to as autosomal 
recessive microcephaly syndrome (MCPH)8. 
Due to advances in next generation sequencing there has been a rapid 
increase in the number of known genes which contain mutations that cause 
microcephaly. The genes identified encode proteins with diverse functions, 
although many mutations have an autosomal recessive pattern of inheritance 
and influence crucial cellular processes9. (However mutations which cause 
microcephaly are not limited to an autosomal pattern of inheritance, for 
example, autosomal dominant mutations in LIS1 lead to lissencephaly10.) 
Interestingly the proteins encoded by many of the genes identified, have a 
role in the mitotic microtubule spindle or the centrosome, an organelle that 
contains the microtubule organising centre (mutations in these genes are 
mainly associated with MCPH)11-13. In addition, genes have also been 
identified which encode proteins that function in: DNA damage response, 
DNA replication, apoptosis pathways, cell cycle progression, cilia function 
and RNA processing9,14-16. (However, mutations in these genes may also 
cause additional symptoms in tissues beyond the brain.) Mutations in these 
genes lead to reduced proliferation or increased apoptosis of neural 
progenitor cells; therefore, reducing the final number of neurons. It remains 
unclear why the developing foetal brain is particularly sensitive to changes in 
processes which are critical in all cells10,11,7.  
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Figure 2 Types of cortex malformation. Diagrams show typical brain morphology 
of affected patients, viewed in the axial plane. The table lists features (size, 
folding and ectopia) associated with these disorders. The figure is taken from 
Fernández et al. 2016 (DOI 10.15252/embj.201593701)5. (This is an open 
access article, which allows use and distribution of material, under the terms 
of the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 License.) 
 
 
1.1.3 Pontocerebellar hypoplasia 
Pontocerebellar hypoplasia (PCH) is a heterogenous group of inherited 
disorders characterised by reduced size of infratentorial brain regions; 
including the pons, cerebellum, and olivary nuclei. This may also be 
accompanied by developmental abnormalities of other brain regions 
including the cerebral cortex and basal ganglia. The onset of the disease is 
usually prenatal and results in global developmental delay. PCH is divided 
into 11 main sub-types based on: presentation of different symptoms, MRI 
findings and more recently the genetic cause. PCH was originally described 
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as a neurodegenerative condition, but has since been expanded to include 
nondegenerative sub-types. All cases of PCH currently identified follow an 
autosomal recessive pattern of inheritance. The genes implicated in PCH 
encode proteins which have a wide range of functions including: RNA 
processing, protein translation, mitochondria function, and golgi membrane 
trafficking17,18. 
 
1.1.4 A novel brain development disorder: molecular genetics 
and clinical details 
Homozygous variants in PPIL1 have been identified as the cause of a novel 
form of microcephaly and pontocerebellar hypoplasia (unpublished data, 
University of Leeds and University of California, San Diego; Table 1). Two 
patients from a single family with: severe microcephaly (head circumference 
of 8-9 s.d. below the mean), severe cortical dysplasia with a smooth cortex 
surface, profound cerebellar hypoplasia of both vermis and hemispheres and 
brainstem hypoplasia, were suspected to have an autosomal recessive 
disease (Figure 3, Figure 4, Table 1). These patients also showed profound 
neonatal hypotonia, poor feeding but no seizures. No variants were detected 
in genes previously known to be responsible for congenital brain disorders a. 
Homozygosity mapping analysis indicated the mutation responsible to be 
Chr. 6:36855995T>C (GRCh38) homozygous single nucleotide transition in 
PPIL1, resulting in a p.Thr107Ala (p.T107A) amino acid substitution 
(unpublished data, University of Leeds). Sanger sequencing of the patients’ 
and parents’ DNA confirmed segregation of the PPIL1 variant with disease. 
More recently, a further patient also displaying the clinical features described 
above, has been found to be homozygous for 
Chr.6:36855996_36856013dup; 36855989C>A (GRCh38) resulting in 
Ala101_Asp106dup; Gly109Cys (p.A101_D106dup; G109C) (unpublished 
data, University of Leeds). 
Independently, homozygosity mapping also mapped variants to PPIL1 in a 
further four patients (two families) suspected for autosomal recessive 
                                            
a Genes tested by Leeds Genetics Laboratories (NHS) include Brain Malformation 
Disorders Gene Panel and Pontocerebellar Hypoplasia Disorders Gene Panel 
(see https://ukgtn.nhs.uk/find-a-test/search-by-disorder-gene/details/3836/ and 
https://ukgtn.nhs.uk/find-a-test/search-by-disorder-gene/details/6597/ 
respectively; Appendix Table 19)  
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disease. These patients also displayed similar symptoms. Microcephaly was 
less severe (7-8 s.d. below the mean) and these patients did show seizures, 
(myoclonic, focal or generalised). They also had less severe cortical 
dysplasia and pachygyria only in one case. Otherwise symptoms were as 
described above. The variant observed in the first family (2 patients) was: 
homozygous Chr.6:.36856019C>T (GRCh38) resulting in p.Ala99Thr 
(p.A99T) and in the second family (2 patients): homozygous 
Chr.6:36855922C>T (GRCh38) resulting in p.Arg131Gln (p.R131Q) 
(unpublished data, University of California, San Diego; Figure 4, Table 1).  
 
 
Figure 3 Axial MRI scans of a patient with severe microcephaly and 
pontocerebellar hypoplasia. The MRI images displayed, show the brain of a 
patient with homozygous PPIL1 p.T107A mutations. Scan A at the level of the 
cerebrum, shows large areas of fluid (white in appearance; black arrows), with 
only small regions of cerebral tissue (grey in appearance; white arrows). The 
region of the cerebellum is also filled with fluid, in the absence of brain tissue 
(black arrows). Scan B at the level of the midbrain shows that this region is 
largely unaffected (black arrows). Scan C at the level of the brainstem, shows 




Figure 4 Pedigrees of the four families affected by microcephaly and 
pontocerebellar hypoplasia and discussed in this thesis.
A B C
Family 2 Family 3Family 1 Family 4
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Table 1 Patient details†. 
Family 1  2  3 4 























Protein p.Arg131Gln p.Arg131Gln p.Ala99Thr p.Ala99Thr p.Thr107Ala p.Thr107Ala p.Ala101_Asp106dup;p.Gly109Cys 
cDNA c.392G>A c.392G>A c.295G>A c.295G>A c.319A>G c.319A>G c.301_318dup; c.325G>T 
Patient details               
Gender Female Male Male Male Male Female Female 
Ethnic origin Egypt Egypt Egypt Egypt Pakistan Pakistan Pakistan 
Pregnancy 
duration (weeks) full term full term full term full term 40 weeks 41 weeks 40 weeks 
Weight at birth 
(kg) N/A N/A 1.75kg 2.5kg 1.8kg 2.0kg 1.7kg 
Length at birth 
(cm) N/A N/A N/A 50cm 45cm 46cm 48cm 
HC at birth (SD)  N/A N/A 26.4cm  (-6.3SD) 
26cm  
(-6.7SD) 25cm 24cm 26cm 
HC at last 







Diagnosis age 6 months 2 months Birth Birth Birth Birth Birth 
Intellectual 
Disability Severe Severe Severe Severe N/A N/A N/A 
















Absent Absent Absent Absent Absent Absent Absent 
Seizures               
Onset 6 months 2 months 
 
3 weeks None None None 
Type Generalized Myoclonic Focal Myoclonic 
  
N/A 





Neurological Findings  
Hypertonia mild mild mild mild - - - 
Hypotonia mild mild - - severe severe severe 
                                            
† The patient data refers to unpublished data from the University of Leeds and 
University of California, San Diego. 
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Deep tendon 
reflexes brisk brisk brisk brisk brisk brisk brisk 
Spastic 
tetraplegia + + + + + + ++ 
Ataxia - - - - - - - 
Investigations               
Metabolic Neg Neg N/A N/A Neg Neg Neg 
VEP/ERG N/A N/A N/A N/A 
NO 
electrophysiolo




















N/A N/A N/A N/A N/A 
MRI               
Microcephaly  
(-SD) -7SD -7SD -8SD -8SD -8.5SD -9.0SD -8SD 
Cerebral cortex 
(Pachygyria) - - + + + + ++ 
Subcortical band 
heterotopia - - 
 
- - - - 
Agenesis of 
corpus callosum + + + + + + + 
Cerebellar 
hypoplasia + + + + + + + 
Brainstem 
hypoplasia - - + + + + + 




abnormalities - - - - - - - 
Miscellaneous               
Polyhydramnios - - 
 
- - - - 
Lung hypoplasia - - 
 
- - - - 
Short stature - - 
 
- - - - 
Optic atrophy - - 
 
- - - - 
Autistic features - - 
 
- - - - 
Dysmorphism - - 
 
- - - - 
        Other               
   





died age 3 
months 
died age 2 
months 
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1.1.5 Investigating pathogenicity of patient variants 
Identifying the correct disease causing variant is critical and can have 
important implications for therapy or genetic counselling (e.g. prognostic and 
family planning advice). Recent evidence suggests that reporting of false 
positives remains a problem and it is therefore important that appropriate 
evidence is generated for variant pathogenicity19. Linking causality to a 
variant in rare diseases is often a challenge due to the small number of 
cases; this may include just a few affected families or even a single patient. 
In addition, researchers are often faced with several possible candidate gene 
variants and must examine the evidence to determine the causative variant. 
As recommended by the 2015 American College of Medical Genetics and 
Genomics and the Association for Molecular Pathology published guidelines 
for interpretation of variants, several lines of evidence should be used in 
order to implicate variants as pathogenic20. 
To be implicated in a rare genetic disease, variants are typically filtered to 
those with a minor allele frequency less that 1%21. If it is possible to obtain 
sequencing data from parents of the patient, this can also be used to confirm 
segregation of the variant with disease. The location of the variant is 
considered, for example whether the variant occurs in a previously implicated 
gene. Examination of the phenotype, is also used to help classify variants, 
for example whether the phenotype is consistent with the available published 
gene information. Recurrence of the variant in other individuals with similar 
symptoms is considered one of the ‘gold standard’ lines of evidence for 
variant pathogenicity. However, in many genetic diseases are so rare that 
this is not possible19-21.  
The likely effect on gene function is considered. For example, nonsense, 
frameshift mutations or deletion of essential splice sites may suggest 
disruption of gene function by creation of a null allele. However, this 
evidence must be examined with caution as these mutations may not always 
be pathogenic; for example, the affected exon may be alternatively spliced 
and therefore the protein is still produced20. For variants which do not result 
in a null allele, such as missense mutations, the effect on protein function 
can also be examined. Specifically, amino acid conservation between 
species and biochemical properties of the substituted amino acid, such as 
charge and hydrophobicity, are key lines of evidence for predicting variant 
pathogenicity. In addition, location of the mutation in the protein structure can 
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help to predict the consequence of the mutation. Various tools are available, 
including Polyphen and SIFT which make predictions based on these lines of 
evidence. However, these tools have relatively low prediction rates with an 
estimated specificity of approximately 68-69% and sensitivity of 
approximately 13-16%22.  
Animal models may also be used to demonstrate a genotype-phenotype link; 
where animals which contain an equivalent mutation in the gene and display 
a phenotype which resembles the human disease are given as evidence for 
a variant. However, this work is often slow, expensive is not always a 
relevant model. In addition, this would not be practicable in cases with many 
different variants in the same gene21. Biochemical assays can also provide 
important evidence of variant pathogenicity. Assays may be based on patient 
cells, cell line models or purified protein depending on the availability of 
tissue and the type of assay required. These assays are highly valuable, 
providing not just evidence of pathogenicity but also insights into the 
potential mechanism behind a disease. 
In the case of autosomal recessive disease further criteria can be used to 
filter variants. Variants are removed which are homozygous in healthy control 
populations. In consanguineous families, autozygosity mapping, which 
identifies regions of homozygosity in affected patients, can also be used to 
narrow down the region containing the causative variant23,24, as was used in 




Peptidyl-prolyl isomerase-like 1 (PPIL1) encodes a single domain protein of 
the cyclophilin enzyme family. Like most other cyclophilins PPIL1 has 
peptidyl prolyl isomerase activity (PPIase), the ability to catalyse the 
transition between cis and trans isomers of a peptide bond preceding a 
proline residue (see section 1.2.2). PPIL1 is highly conserved across 
species, from human to S. pombe (Figure 5); although there is no homolog in 
S. cerevisiae.  PPIL1 localises to both the cytoplasm and nucleus, and has 
also been detected in extracellular environments including plasma and 
urine25,26. Expression of PPIL1 was shown to be ubiquitous across all adult 
tissues (with highest expression in the adrenal gland, testis and heart)27,28. 
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There is also recent evidence that PPIL1 expression may fluctuate with the 
circadian clock29. PPIL1 is also known to participate in the spliceosome; a 
complex and dynamic protein and RNA complex responsible for splicing 




Figure 5 Alignment of PPIL1 amino acid sequence, showing conservation 
across species: Homo sapiens (NP_057143.1), Mus musculus 
(NP_081121.1), Danio rerio (NP_001029350.1), Drosophila melanogaster 
(NP_523874.1), Caenorhabditis elegans (NP_501118.1), 
Schizosaccharomyces pombe (NP_593308.1) and Arabidopsis thaliana 
(NP_181157.1). Conserved residues are shown with red letters and strictly 
conserved amino acids are highlighted in red with white letters. Sequences 
were aligned using Clustal Omega 
(https://www.ebi.ac.uk/Tools/msa/clustalo/)31,32 and rendered for sequence 
similarities using ESPript (http://espript.ibcp.fr)33. Vertical black and grey 




1.2.2 PPIase activity 
The transition between cis and trans isomers of a peptide bond preceding a 
proline residue (prolyl peptide bond; Figure 6) is a slow process and all 
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organisms contain PPIases which are able to accelerate this process, by 
stabilising the transition. Unlike most peptide bonds which are in the trans 
configuration, peptide bonds preceding proline are also found in the cis 
conformation; up to 30% of peptide bonds in peptides and 5-7 % of peptide 
bonds in folded proteins are present in the cis form34. This is a result of 
proline’s unusual structure, which means that steric repulsion of the Cα 
atoms, either side of the imide bond, is almost equal in both the cis and trans 
conformations35. Due to the partial double bond character of peptide bonds, 
the energy required for rotation around the bond, between cis and trans 
states, is high, (approximately 80 kJ/mol). Therefore, in the absence of 
PPIase enzymes cis-trans isomerisation is slow (usually 10-100 s at 25 oC)35. 
In folded protein regions, local conformations and long range interactions 
have a significant effect on populations of the cis and trans isomer, whereas 
for disordered regions or peptides the preceding residue has a large impact 
on the ratio of cis and trans isomers. Aromatic and glycine amino acids which 
precede the proline peptide bond typically result in higher populations of the 
cis isomer compared to small, electron poor residues36-38. Due to the rigid 
backbone of proline, the peptide bond isomer can have a large effect on the 
secondary and tertiary structures of the peptide chain. PPIase activity may 
therefore be required for: correct protein folding 34,39,40, modulating protein 
function 35 or as a molecular switch in cellular processes such as signalling 
pathways 41,42.  
 
 
Figure 6 Cis-trans isomerization of a peptide bond preceding a proline 
residue. A peptide bond may occur in either a cis or trans state, where Cα 
atoms are found on the same or opposite sides of a peptide bond respectively. 
Interconversion between cis and trans states is an intrinsically slow process 
and is accelerated by a class of enzymes called PPIases. 
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1.2.3 Cyclophilins 
Cyclophilins are one of three protein families with PPIase activity; (FK506 
binding proteins and parvulins also possess PPIase activity although they 
are structurally unrelated)43. Cyclophilins are characterised by their ability to 
bind the immunosuppressant molecule cyclosporine A (CsA). All cyclophilins 
contain a conserved cyclophilin-like domain (CLD), which is a compact beta 
barrel structure capped by two alpha helices. In addition some cyclophilins 
contain other unique domains, which may allow further interactions with other 
proteins or targeting to subcellular locations40. Cyclophilins are ubiquitous 
proteins found in both prokaryotic and eukaryotic species and they have 
been reported to have a range of functions including in: mitochondrial 
apoptosis, mRNA splicing, interferon signalling pathway, and even stress 
tolerance and virulence of bacteria39,44,45. Of the 19 cyclophilins encoded by 
the human genome, 9 are localised in the nucleus and all 9 of these proteins 
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Cyclophilin Yes Associates with tri-
SNP (U4/U6.U5) and 
is incorporated at B 
complex30. 
Dissociates with U4 
snRNP before Bact 
complex51. 
Table 2 Nuclear cyclophilins.* PPIase activity was demonstrated on a model 
substrate (suc-AGPF-pNA peptide) by Davis et al. (PPIL3b and PPIL4 were 
insoluble / unstable and therefore not tested)39. Domains were annotated 
using the Uniprot database (https://www.uniprot.org/)54. 
 
 
1.2.4 PPIL1 structure  
1.2.4.1 NMR and crystal structures 
NMR spectroscopy and X-ray crystallography revealed that, like other 
cyclophilins, the structure of PPIL1 involves a compact eight stranded beta 
barrel enclosed by two alpha helices on either side and with a short 310 helix 
between the β6 and β7 strands55,56. Although the majority of PPIL1 is 
relatively rigid, some of the loops linking beta strands show significant 
flexibility. The loop between β5 and β6 is dynamic and this is thought to be 
important for catalytic activity. In addition the loop linking β4 and β5 is also 
dynamic, although the role of this is less clear55. The structure of PPIL1 is 
highly similar to cyclophilin A, the first identified cyclophilin55. PPIL1 contains 
a single PPIase active site and, as with other cyclophilins, this is positioned 
on the β3 and β4 strands55,56. However, compared to CypA, PPIL1 also 
exhibits several differences in structure. PPIL1 β1-β2 loop is five residues 
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shorter than CypA (as shown for other cyclophilins including: PPIL2, PPIL3, 
PPIL4, PPWD1 and SDCCAG-10). In addition, PPIL1 also contains a shorter 
α1-β3 loop compared to CypA (by three residues), which results in an altered 
conformation of the C-terminal of a1 helix (this loop is also shorter in PPIL2, 
PPIL3, PPIL4, PPWD1 and SDCCAG-10). The α2-b8 loop also forms a 
different conformation compared to CypA, and instead shows greater 




Figure 7 Overlay of PPIL1 (blue) and CypA (brown) crystal structures. Images 
were made using Chimera (http://www.rbvi.ucsf.edu/chimera)57 and data from 
PDB (2X7K56, 1ZKF). The b1-b2, a2-b8, and a1-b3 loops, which differ 
between CypA and PPIL1, are indicated with arrows 
 
 
1.2.4.2 PPIL1 active site 
The PPIase active site is defined by the following residues Arg55, Phe 60, 
Met 61, Gln 63, Ala 101, Asn 102, Phe 113, Leu 122 and His 126 (see Figure 
8); these residues form the hydrophobic proline binding pocket or lie within 
4Å of the Xaa-Pro peptide bond in model structures of the PPIL1 homolog 
CypA39,58. These residues in PPIL1 are strictly conserved compared to CypA 
and most residues are highly conserved across PPIL1 homologs and other 
cyclophilin PPIases (Figure 5; Appendix Figure 59). Residues Phe 113, Phe 
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Gln 63 and Asn 102 all form hydrogen bonds with the substrate39,58. Trp121 
is not structurally part of the proline binding pocket, but is considered an 
active site residue as this residue forms a hydrogen bond with the substrate 
and mutating this residue significantly reduces catalytic activity of 
cyclophilins58.  
 
1.2.4.3 S2 pocket 
A further hydrophobic pocket is located adjacent to the PPIase active site in 
cyclophilins (Figure 8A). This pocket has been named the S2 pocket, as it is 
thought to bind residues two and three N terminal to the prolyl peptide bond 
substrate (i.e. P3-P2-P1-Pro). The S2 pocket is defined by residues in the 
loop between β5 and β6 sheets. Further residues whose sidechains are 
positioned around the pocket have been named ‘gatekeeper residues’ as 
they are proposed to control access to the pocket. The gatekeeper residues 
were originally described in PPIA, and the corresponding residues in PPIL1 
are: Arg72, Lys80, Gln81, Ala103, Thr107, Ser110, and Gln11139. The 
identity of these residues is variable across the cyclophilins and it is 
proposed this variation affects binding specificity of cyclophilin substrates39. 
In PPIL1 all of these residues have sidechains close to the S2 pocket, except 
Lys80 which points away from the pocket, due to the altered conformation of 
this loop compared to PPIA (see Figure 8)56.   





Figure 8 PPIL1 active site and S2 pocket. (A) Surface representation of PPIL1 
crystal structure; electrostatic potential is shown using red (negative) and blue 
(positive). (B) Overlay of PPIL1 (light blue) and CypA (brown). PPIL1 
gatekeeper residues (black labels) and active site residues (red labels) 
defined by Davis et al 2010 are shown39. (PPIL1 is shown in the same 
orientation in both images). Chimera software 
(http://www.rbvi.ucsf.edu/chimera)57 and data from PDB were used to make 
these images (2X7K56, 1ZKF). 
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1.2.5 Role of PPIL1 in disease 
Several cyclophilins have been implicated in disease. For example, CypA 
has been shown to have a role in cardiovascular disease, virus infection and 
replication (HIV, HCV, influenza A), cancer and pro-inflammatory diseases 
(rheumatoid arthritis, sepsis)59. It is suggested that CypD has a role in 
collagen VI myopathies, reperfusion injury (of the heart and brain) and 
fulminant hepatitis. Increased CypB expression is also associated with breast 
cancer progression60. 
PPIL1 has also been linked to a wide range of diseases. Firstly, PPIL1 
overexpression has been implicated in colon cancer; western blot and IHC 
staining show that that PPIL1 expression is increased in a significant number 
of colon cancer tissue samples. It was demonstrated that overexpression of 
PPIL1 in NIH3T3 cells and HEK293 cells also resulted in increased cellular 
proliferation. The authors also showed that reducing PPIL1 expression using 
siRNA reduces cell proliferation in SNUC4 and SNUC5 colon cancer cell 
lines61.  
PPIL1 is also implicated as a key regulatory gene or ‘driver gene’ in coronary 
artery disease (CAD); this is a central gene of a network which has been 
associated with significant changes in gene expression observed in CAD. 
Gene networks were assembled by integrating several types of published 
data. Genes which contain SNPs associated with CAD (from genome-wide 
association studies) were included into the model. Secondly, published CAD 
eQTLs (expression quantitative trait loci) were added to the model; these are 
genetic variants which explain variation in gene expression levels observed 
in CAD. Integration of the above data with known metabolic and signalling 
cascades and known gene-gene interaction networks lead to the creation of 
gene regulation networks involved in CAD. Genes at the centre of these 
networks were considered central regulatory genes in CAD. PPIL1 was 
found to be one of these central regulatory genes (driver genes) and was 
located in a network relating to antigen processing, including human 
leukocyte antigen complex genes. It was further shown that reducing PPIL1 
expression in human aortic endothelial cells, using siRNA, results in changes 
of expression of 656 genes, including genes of the antigen processing 
network. These results suggest that PPIL1 has a direct or indirect role in the 
regulation of gene expression and may be associated with changes in gene 
expression observed in CAD62. 
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PPIL1 was also shown to have elevated expression in T cells from patients 
with Psoriasis. Psoriasis is a chronic inflammatory skin condition, caused by 
unusually fast growth of the epidermal layer of skin. It was previously shown 
that patient T cells influence keratinocyte proliferation and the authors used 
differential gene expression of patient T cells to try to understand the 
mechanism for this. T-cells from patients with psoriasis, show elevated 
PPIL1 expression, compared to both unaffected twins and unaffected 
unrelated individuals. The authors suggest that PPIL1 may have a role in the 
abnormal keratinocyte proliferation observed in psoriasis63.  
Taken together these papers indicate PPIL1 may have an important role in 
regulation of cell proliferation across a range of tissues. In addition, these 
studies suggest a direct or indirect function for PPIL1 in gene expression. 
However, the exact mechanism involving PPIL1 in these diseases remains 
unclear.  
1.3 The role of PPIL1 in the spliceosome 
1.3.1 Assembly and mechanism of the spliceosome  
PPIL1 participates in the spliceosome, a dynamic multi-protein and RNA 
enzyme, responsible for splicing introns from pre-mRNA (see Figure 9)53,64. 
In contrast to the majority of enzymes, the spliceosome does not have a 
preformed active site. Instead, the spliceosome is formed by sequential 
binding of spliceosomal components on the nascent pre-mRNA, followed by 
numerous conformational rearrangements. The spliceosome is composed of 
five stable small nuclear ribonucleoproteins (snRNPs; U1, U2, U4, U5 and 
U6), the PRP19-CDC5L complex, PRP19 related proteins (NTR) and 
numerous other proteins. SnRNPs contain specialized uridine rich small 
nuclear RNAs (snRNAs), which stably associate with specific proteins30,65. 
The PRP19-CDC5L (= NTC) complex is a multi-protein module and the NTR 
proteins are further proteins which associate with the PRP19/CDC5L 
complex during spliceosome assembly66.  
Introns contain consensus sequences which allow intron recognition by the 
spliceosome. The intron consensus sequences include the 5’ splice site 
(5’SS), branch point site (BPS) and 3’ splice site (3’SS); which in metazoans 
are GURAGU, YNYURAY and YAG respectively (where R is a purine, Y is a 
pyrimidine, and N is any nucleotide). In metazoans a polypyrimidine tract is 
also present which includes a 10-12 nucleotide sequence rich in pyrimidines, 
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particularly uracil30. The spliceosome catalyses two transesterification 
reactions which lead to intron excision and exon ligation. In the first step, 
known as the branching reaction, the 2' hydroxyl group of the conserved 
adenosine residue at the BPS attacks the 5’SS phosphodiester bond, 
producing a cleaved 5’exon and lariat intron. Secondly, the 3' hydroxyl group 
of the 5' exon attacks the 3’SS phosphodiester bond resulting in cleavage of 
the lariat intron and ligation of the neighbouring exons (Figure 9A).  
The assembly of an active spliceosome starts with recognition of the 5’SS, 
BPS and 3’SS by U1 snRNP, SF1 and U2AF respectively, giving rise to the 
E complex. The U2 snRNP then binds to the BPS, which leads to release of 
SF1 and formation of the A complex30. Next the tri-snRNP, composed of U4, 
U5 and U6 snRNPs, binds to the pre-mRNA forming the catalytically inactive 
B complex67. U6 snRNA displaces U1 snRNA from the 5’SS, which then 
results in the release of the U1 snRNP. BRR2 helicase catalyses the 
separation of the U4/U6 snRNA duplex and the U4 snRNP is released. The 
PRP19-CDC5L and NTR proteins also bind to the spliceosome, leading to 
the formation of the Bact complex. PRP2 catalyses conformational changes of 
the spliceosome which results in the transition to the catalytically active B* 
complex. The spliceosome then catalyses the first transesterification 
reaction, yielding the C spliceosome complex which contains the lariat exon 
and cleaved 5’ exon. Further conformational rearrangements catalysed by 
PRP16 helicase lead to the active C* complex51. The spliceosome then 
catalyses the second transesterification reaction, leading to cleavage of the 
lariat intron and exon ligation (P complex). PRP22 catalyses the dissociation 
of the spliced mRNA product from the P complex. This yields the ILS 
complex, which next dissociates releasing the lariat intron and the 
spliceosome components that are then recycled51.  





Figure 9 Pre-mRNA splicing by the major spliceosome. (A) The spliceosome 
catalyses two transesterification reactions to remove an intron. In the first 
transesterification reaction the 2' hydroxyl group of the conserved branch point 
adenosine attacks the 5' splice site phosphodiester bond, yielding the lariat 
intron and cleaved 5’ exon. In the second reaction, the 3' hydroxyl group of the 
5' exon attacks the 3' splice site phosphodiester bond causing cleavage of the 
lariat intron and ligation of the adjacent exons. The phosphodiester linkages 
(blue oval / diamond) and key hydroxyl groups (green text) are indicated. (B) 
The spliceosome assembles in a stepwise manner on pre-mRNA substrates 
and performs two transesterification reactions (step 1 and step 2) to remove 
an intron. Components include small nuclear ribonucleoproteins (U1, U2, U4, 
U5 and U6) and large protein assemblies called the PRP19-CDC5L complex 
and PRP19 related proteins (NTR). Adapted from 30,67. 
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In addition to the major spliceosome (Figure 9), 700-800 genes in humans 
contain an intron which is spliced by the minor or U12 dependent 
spliceosome. U12 introns show key differences compared to introns spliced 
by the major spliceosome, including lack of a polypyrimidine tract and 
divergent 5’SS and 3’SS. The overall formation of the minor and major 
spliceosomes are related in terms of the components, assembly steps and 
mechanism. However, the minor spliceosome contains unique snRNPs (U11, 
U12, U4atac and U6atac), which are similar in function to snRNPs of the 
major spliceosome (U1, U2, U4 and U6 respectively). The U5 snRNP is 
common to both the minor and major spliceosomes. Unlike assembly of the 
major spliceosome, during assembly of the minor spliceosome the U11 and 
U12 snRNPs bind to the pre-mRNA together as a preformed complex. The 
splicing of U12 introns is also significantly slower than major introns. U12 
introns are found in only a small group of eukaryotes and are absent in yeast 
and nematodes68. Minor introns are enriched in genes with the following 
functions: DNA replication, DNA repair, transcription, RNA processing, 
translation and cell cycle control69,70. 
 
1.3.2 Splicing regulation  
Correct spliceosome assembly requires a large number of additional 
proteins, which are either essential for spliceosome function or play a 
modulatory role. In fact, over 170 proteins have been isolated from different 
stages of the spliceosome, during assembly and catalysis71. Recognition of 
splice sites is complex and cis-acting nucleotide sequences within both the 
exon and intron determine the overall strength of a splice site. In addition, 
trans acting splicing regulatory proteins bind to intronic or exonic sequences 
in the pre-mRNA further enhancing or silencing splicing at a particular site. 
The many proteins involved in recognising a splice site ensures accuracy, 
while the collective effect of the many weak interactions allows flexibility in 
splice site usage. It is this flexibility in splice site usage which makes both 
alternative splicing and spatial or temporal regulation of splicing possible30.  
Alternative splicing (AS) allows the inclusion or exclusion of certain regions in 
the mRNA transcript, which can lead to a range of protein or noncoding RNA 
products for a given gene (see Figure 10). More than 95% of human genes 
are subject to alternative splicing and each gene has on average seven 
alternative mRNA products72. In addition to trans acting splicing factors and 
cis acting pre-mRNA regulatory sequences, further processes within the cell 
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can also influence alternative splicing. Both the speed of pre-mRNA 
elongation by RNA polymerase and the epigenetic signature of the gene 
have been shown to affect splicing. Furthermore, even after spliceosome 
assembly has commenced, splicing may either proceed, pause or be 
discarded73.  
  
Figure 10 Categories of alternative splicing. Light blue boxes represent 
constitutively spliced exons and mid/ dark blue boxes represent alternative 
exons.  
 
1.3.3 Splicing in humans vs yeast 
Despite conservation of pre-mRNA splicing machinery from humans to yeast; 
there are many key differences between splicing in these organisms. In 
humans, the 5’ SS, BP, polypyrimidine tract and 3’ SS sequences are more 
degenerate compared to the highly conserved sequences in the yeast, S. 
cerevisiae; allowing for more flexibility in human splice site usage. Only 5% 
of S. cerevisiae genes contain introns and these are all constitutively spliced; 
whereas >95% of human genes contain introns which are alternative spliced. 
In addition, the average length of introns is approximately 3000 nt in humans 
compared to 270 nt in S. cerevisiae72,74-76. This means that the human 
spliceosome has to overcome many additional challenges, in order to ensure 
splicing fidelity and flexibility for alternative splicing. Many core spliceosome 
proteins are conserved from humans to yeast (S. cerevisiae); however, many 
Constitutive splicing
Exon skipping/ inclusion
Alternative 5’ splice site
Alternative 3’ splice site
Mutually exclusive exons
Intron retention
Constitutive exon Alternatively spliced exon/region
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human spliceosome proteins include extra unstructured regions47,49,77. In 
addition, the composition of human spliceosomes involves many extra 
proteins compared to S. cerevisiae. These proteins include proteins of the 
hPrp19/CDC5L complex (NTC), specific Prp19- related proteins (NTR) and 
further splicing factors49. It is thought that these differences provide further 
flexibility of the spliceosome allowing spatial and temporal regulation of 
splicing and alternative splicing30,47,78.  
 
1.3.4 Current understanding of PPIL1 in the spliceosome 
PPIL1 is present in purified human spliceosomes at stoichiometric levels; as 
analysis of spliceosome components using 2D electrophoresis ranked PPIL1 
as highly abundant and at similar levels to other known core protein 
components71. It has also been shown that PPIL1 remains associated with 
the U5 snRNP in complex C even in 1M NaCl, suggesting that PPIL1 is 
stably bound to the spliceosome rather than engaging in a transient 
interaction with the spliceosome79. PPIL1 belongs to the NTR, a non snRNP 
sub-complex of the spliceosome, which is recruited to the spliceosome prior 
to activation (during formation of the Bact complex), remaining in the 
spliceosome until the intron lariat is released (after ILS complex; see Figure 
9)30,49,50. (Compared to other subcomplexes within the spliceosome, proteins 
of the NTR make few direct contacts with each other in the spliceosome and 
instead interact indirectly through connections with PRP19/CDC5L 
proteins48.)  
PPIL1 was also detected in the 35S U5 complex, a spliceosome dissociation 
complex which contains PRP19/CDC5L and NTR proteins in addition to U5 
snRNP components80,81. This shows that PPIL1 remains associated with 
spliceosome proteins even after initial stages of spliceosome disassembly 
commence. PPIL1 is then released from binding partners in the spliceosome 
before the U5 snRNP is recycled and enters a new spliceosome cycle. This 
is apparent from mass spectrometry analyses of the 20S U5 snRNP and tri-
snRNP which both lack PPIL180. It is unclear what leads to these subsequent 
dissociation steps, and causes proteins such as PPIL1 to be released from 
the U5 snRNP.  
PPIL1 is one of nine cyclophilin proteins found in the spliceosome (Table 2). 
Due to the distribution of cyclophilins across different phases of spliceosome 
activation it is therefore likely that they have distinct roles in this process 
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(Table 2)46. Cyclophilins contain a PPIase active site and it is therefore 
proposed that these proteins may either catalyse proline isomerisation of 
spliceosome proteins or act as chaperones, binding to and stabilising proline 
rich regions of spliceosome components43. It is thought that the presence of 
cyclophilins across the spliceosome may assist with the many conformational 
changes of the spliceosome required for activation and splicing30. However, 
two spliceosome cyclophilins (PPIL2 and CWC27) do not display PPIase 
activity on the model PPIase substrate (suc-AGPF-pNA peptide)39. The 
function of spliceosomal cyclophilins is not limited to the PPIase active site 
and these proteins also interact with spliceosome proteins on surfaces 
distinct to their cyclophilin active site (for example cyclophilins play an 
important role linking various spliceosome subunits)46,51.  
 
1.3.5 Findings from splicing assays 
Splicing assays can be a valuable tool for understanding the role of specific 
proteins in the spliceosome. Techniques used to study splicing include: in 
vitro splicing assays, cellular minigene assays or global splicing analysis. In 
vitro splicing reactions typically use radioactively labelled reporter gene 
constructs, incubated with HeLa nuclear extracts, which are enriched in 
spliceosome components. The products and intermediates of splicing can 
then be visualised by gel electrophoresis and autoradiography82. Transient 
transfections of minigene constructs can also be used to study splicing of 
reporter constructs in cell lines. The resulting mRNA is amplified using RT-
PCR and analysed using agarose gel electrophoresis83. Alternatively, 
analysis of endogenous splicing events can be monitored using RT-PCR with 
primers flanking alternative splice sites84. Splicing can also be studied on a 
global scale in the relevant cell or tissue; this was previously carried out 
using microarrays with probes for splicing junctions but is now usually carried 
out using RNA sequencing. RNA sequencing offers several advantages 
including the ability to detect novel AS events and also provide quantitative 
data85. 
Adams et al. investigated the role of cyclophilins in the spliceosome, by 
adding excess of cyclophilin proteins to in vitro splicing assays. AdML and b-
globin reporter gene constructs were used in the in vitro splicing assays. 
Addition of excess PPIL1 caused significant reduction of splicing in these 
assays with the b-globin reporter gene but no significant effect on splicing 
rates in the AdML (adenovirus major late) splicing reporter assay, suggesting 
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that PPIL1 may modulate splicing in a substrate dependent manner46. 
Experiments in which active site residues of spliceosome cylophilins were 
mutated to inactivate PPIase activity, show varying effects across the nuclear 
cyclophilins in the AdML splicing reporter assay. Inactivation of the PPIL1 
active site caused only a small decrease in splicing for PPIL1.The authors 
concluded that cyclophilin PPIase sites may not be required for function of 
the spliceosome46. However, these conclusions are based on the 
assumption that if cyclophilins have a function in the spliceosome, adding 
excess cyclophilin protein will perturb spliceosome activity; therefore, these 
results may not reflect native conditions.   
In a further study of splicing, genes encoding core spliceosome components 
and splicing factors, but also genes encoding proteins with roles in RNA 
processing or chromatin remodelling were knocked down using siRNA. 
Splicing of 38 alternative splicing events known to be important for cell 
proliferation or apoptosis were monitored in HeLa cells using RT-PCR and 
networks were created based on proteins which elicited similar effects. 
Interestingly PPIL1 is found in a region of the network which is enriched for 
helicases. Specifically, PPIL1 forms connections with DHX57 and DDX31 (or 
PPP1R25), both of which are probable ATP-dependent RNA helicases which 
form part of the mRNA bound proteome (DDX57 is found in spliceosome C 
complexes)53,84. In addition, other cyclophilins (PPIG, PPIL2, PPIE, PPIH) 
are dispersed in the network rather than clustering in a single region; which 
further supports the hypothesis that cyclophilins have specific roles across 
the spliceosome. Specifically, PPIL1 knockdown had a significant effect on 
either inclusion or skipping for 12 out of 40 studied splicing events (FAS, 
PAX6, RAC1, CASP2, MAP4K2, CASP9, DIABLO, H2AFY, BIM (EL), BIRC 
(D3), SMN2, and PHF19). Overall knockdown of splicing factors affects 
splice site selection instead of causing widespread inhibition of splicing, and 
PPIL1 knockdown causes both skipping and retention in different alternative 
splicing events84.  
 
1.3.6 SKIP- PPIL1 interaction 
PPIL1 interacts with the spliceosomal binding partner, SNW domain-
containing protein 1 (SNW1); also known as SKI-interacting protein (SKIP). 
SKIP is an essential spliceosome component which is also part of the NTR 
sub-complex30. GST-pulldown assays demonstrated that the PPIL1 binding 
region of SKIP is between residues 59-12955. PPIL1 binds to SKIP with 
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medium affinity, with a dissociation constant of 125 nM, as determined by 
SPR55. NMR studies show that a disordered region of SKIP (59-79) binds to 
a surface of PPIL1 distant to the active site, forming a hook like structure on 
PPIL1’s surface55,86. The minimal PPIL1 binding fragment (PBF) of SKIP was 
narrowed down to residues 61 to 68, using peptide arrays56. The PBF region 
of SKIP is conserved from human to S. pombe; interestingly S. cerevisiae 
lacks both this region of the SKIP homolog and any PPIL1 homolog86.  
It was suggested that the disorder to order transition of SKIP which takes 
place upon binding to PPIL1 may play a role in the significant structural 
reorganisation required for spliceosome activation86. This interaction also 
leaves the PPIase site of PPIL1 available to potentially act as a PPIase or 
molecular chaperone which may further aid the spliceosome structural 
rearrangement86. SKIP is a predominantly disordered protein, in isolation and 
in the spliceosome it is able to adopt an extended conformation, interacting 
with many spliceosomal components (including PRP17, PPIL1, RBM22, 
SYF3, PRP8, SF3b155, U2 and U6 snRNA)47-50,52,77. Due to the high 
connectivity of SKIP across the spliceosome, it is thought that SKIP may be 
a key player in coordinating many dynamic transitions required for catalytic 
activation of the spliceosome48,50. The presence of SKIP in the spliceosome 
is essential for splicing and it has also been shown that SKIP has a role in 
transcription regulation and may act to couple these events87. PPIL1 does 
not have a clear nuclear localisation signal (NLS)61 and in rice, it has also 
been demonstrated that SKIP enables translocation to the nucleus of the rice 
PPIL1 homolog Cyclophilin 18-288, although this has not been shown in 
mammalian cells. 
 
1.3.7 Insights from cryo-EM structures 
Recent advances in cryo-electron microscopy (cryo-EM) have made it 
possible to determine the structure of intact spliceosomes at various stages 
of assembly, at near atomic level resolution. This was made possible by 
improvements in the sensitivity of electron microscopes, due to the use of 
direct electron detectors in the microscopes, which allowed for increased 
signal to noise ratios in the data collected. In addition, improvements in 
software have improved resolution of structures by allowing for correction of 
beam-induced sample motions and for particles to be grouped according to 
similarities in conformation65.  
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The spliceosome is a highly dynamic complex, with significant changes in 
composition and conformation, and this heterogeneity also meant it was 
previously difficult to obtain high resolution structures. Advances in 
experimental techniques to stall spliceosomes at specific stages of assembly 
have therefore been essential for solving spliceosome structures78,89. Most 
human spliceosome complexes are assembled using in vitro splicing 
reactions (as described above), with model pre-mRNA substrates (such as 
AdML or MINX model substrates) and nuclear cell extract from human cell 
lines (e.g. HeLa cells). A frequently used approach uses pre-mRNA 
substrates fused to an MS2 sequence, to allow affinity purification of the 
complex followed by sucrose gradient sedimentation90. Different methods 
have been used to stall spliceosomes at various stages of assembly, for 
example: reduction of MgCl2 (from 2.5-3.5 mM to 0.3 mM) to obtain the B 
complex91, addition of the splicing inhibitor BN82685 to assemble C 
complexes (by inhibiting exon ligation) and lowering of pH (7.9 to 6.4)52 or 
3’SS mutation (AG to GG)47 to stall the complex at stage C*.  
The first spliceosome cryo-EM structure was determined for S. pombe ILS 
complex48 and since 2015 many further spliceosome structures have been 
deduced for both human and S. cerevisiae complexes. S. cerevisiae does 
not contain a PPIL1 homolog; however, PPIL1 is present in many human 
cryo-EM spliceosome structures47,49,50,52,77 and the S. pombe structure48, 
offering important insights into the role of PPIL1 in the spliceosome. 
Specifically, human spliceosome structures determined by cryo-EM include: 
the pre-B complex92, B complex91, a series of Bact complexes 49,50, the C 
complex52,77, the C* complex47,52 the P complex 93,94 and ILS complexes94. 
PPIL1 is stably integrated in all structures except for the pre-B complex, B 
complex and early Bact complexes. PPIL1 is also stably integrated with S. 
pombe ILS complex48. This data suggests that PPIL1 is recruited between B 
and B* stages, remaining in the spliceosome until after splicing is complete; 
and is consistent with data from previous mass spectrometry analyses 
30,47,49,50,52,77,80,81,91.  
PPIL1 is recruited during the transition to Bact spliceosome along with other 
NTR components49,50. Purification and cryo-EM of Bact complexes shows that 
this complex is dynamic and a series of conformational states have been 
identified49,50. During the data analysis, Zhang et al. divided Bact complex into 
three main conformational states and showed that PPIL1 is present in 
mature and late Bact complexes but not in the early complex49. Haselbach et 
al. also determined the structures of eight major sequential Bact 
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conformations. PPIL1 was shown to be stably integrated at step 2, at a point 
where the PRP19 helical bundle moves upwards in the complex50. PPIL1 is 
also shown stabilising the PRP19 bundle later in assembly at complex C*52. 
Interestingly, the region of the spliceosome into which PPIL1 is recruited has 
been shown to exhibit a large degree of conformational flexibility50. (Further 
insights into PPIL1 function in the spliceosome, gained from modelling of 
these structures is discussed in Chapter 3).  
 
1.3.8 Spliceosome mutations and disease   
Aberrations in splicing are well documented as the cause of many diseases, 
such as cancers and genetic disorders95,96. Cis acting splicing mutations 
currently account for approximately 10% of all known inherited disorders95, a 
number which is expected to increase as more mutations are discovered97,98. 
Trans acting mutations of spliceosome components have also been shown to 
cause disease and cause a wide range of symptoms. For example, 
autosomal dominant retinitis pigmentosa is caused by mutations in numerous 
splicing related proteins (PRPF3, PRPF6, PRPF8, PRPF31, RP9 (PAP1), 
and SNRNP200); interestingly, all proteins are associated with the tri-snRNP 
99. Mutations of SNRPA, a component of the U1 snRNP, causes a syndrome 
of intellectual disability and craniofacial abnormalities 100. Disease causing 
splicing mutations affect a range of components including also those of the 
minor spliceosome 70, snRNA70 and in proteins that allow snRNP maturation 
101,102.  
More recently mutations in spliceosome components have been associated 
with genetic disorders which affect the brain; for example mutations in the 
essential spliceosome helicase (DHX16 and DHX38) cofactor, GPKOW, was 
shown to cause severe X linked microcephaly and intrauterine growth 
restriction103. In addition, haploinsufficiency of EFTUD2, a U5 snRNP 
GTPase, causes mandibulofacial dysostosis with microcephaly104. 
Heterozygous and homozygous mutations in RNU4ATAC, which encodes 
the minor spliceosome snRNA U4atac, have also been shown to cause 
microcephalic osteodysplastic primordial dwarfism type I105. In addition to 
spliceosome defects, mutations in components of further RNA processing 
and regulation complexes have also been implicated in brain developmental 
disorders. Mutations in the tRNA splicing complex (TSEN2, TSEN34, 
TSEN54) and a polynucleotide kinase (CLP1) also involved in tRNA splicing, 
have been shown to cause pontocerebellar hypoplasia and microcephaly106-
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108. The RNA exosome complex is required for RNA processing and 
degradation and mutations in the components (EXOSC3 and EXOSC8) also 
lead to a syndrome of pontocerebellar hypoplasia109,110. 
It is interesting that the pathological phenotype of mutations in ubiquitously 
expressed spliceosome components is often restricted to specific tissues. It 
is suggested that particular splicing defects lead to reduction of mature 
mRNAs for specific groups of genes that are particularly important for 
survival for specific cell types111. This is supported by the observation that 
knockdown of spliceosome components causes specific splicing defects 
rather than a general inhibition of splicing84. Alternatively, incomplete splicing 
may lead to accumulation of products which are toxic to specific cells; such 
as novel transcripts or protein isoforms. Another hypothesis is that certain 
tissues may be more susceptible to splicing defects due to an overall higher 
requirement of the splicing machinery112. For example mutations in 
spliceosome components often affect the retina99, which has a high demand 
for splicing, as is reflected by the highest expression of spliceosome snRNAs 
compared to other tissues112. The brain, which is also affected in a large 
number of splicing disorders, has particularly high levels of alternative 
splicing and contains the highest number of tissue specific alternatively 
spliced transcripts113.  
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1.4 Aims and objectives 
The aim of this thesis is to investigate PPIL1 patient variants as a novel 
cause of microcephaly and pontocerebellar hypoplasia (section 1.1.4). The 
effect of the patient variants on PPIL1 protein function, will be studied in 
order to confirm the deleterious effect of the variants and gain further insights 
into the role of PPIL1. 
 
The main objectives are: 
1. To use in silico techniques to: assess the likely pathogenicity of the 
identified PPIL1 variants and gain a deeper understanding of the role 
of PPIL1 in the spliceosome. 
2. To express and purify PPIL1 WT and mutant proteins to investigate 
the effect of the PPIL1 variants on: protein folding and stability, 
protein-protein interactions and enzyme activity of PPIL1. 
3. To gain an insight into the role of the PPIL1 active site in the 
spliceosome. PRP17 was investigated as a putative PPIase substrate 
of PPIL1. 
 
Due to the limited statistical power to confirm variant pathogenicity in rare 
genetic diseases, use of in silico and experimental approaches are important 
lines of evidence for confirming variant pathogenicity. Further investigating 
the role of PPIL1 will not only shed light on the mechanism of this disease, 
but also the mechanism of the spliceosome. Incorrect splicing is implicated in 
a large range of diseases, including many cancers and a wide range of 
genetic diseases, therefore knowledge of the spliceosome has wide 
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Chapter 2 Methods 
2.1 General molecular biology methods 
2.1.1 Reagents 
All general laboratory reagents were purchased from Sigma or Fisher, unless 
otherwise stated.  
2.1.2 Gel electrophoresis 
2.1.2.1 Agarose gel electrophoresis 
Agarose gels were prepared with 1x TAE buffer (see Ogden et al.116), and 
agarose at a concentration of 0.7-1.5% w/v (depending on the DNA size to 
be resolved; Table 3). The solution was heated to dissolve the agarose and 
allowed to cool slightly before adding ethidium bromide (0.5 µg/ml). The 
solution was poured into a casting tray, with a gel comb and allowed to set. 
Samples were loaded with 6x loading buffer (Thermofisher) and Easyladder 
1 (Bioline) was used to estimate size of separated DNA fragments/ PCR 
products. Gels were run at 80-100 V for 60 to 90 minutes, in TAE buffer, and 
visualised using a UV transilluminator. 
Table 3 Percentage agarose gel required (w/v) for resolution of DNA 
fragments in agarose gel electrophoresis 
Percentage agarose gel DNA size resolution 
0.7 % 800 bp to 12 kb 
1.0 % 500 bp to 10 kb 
1.2 % 400 bp to 7 kb 
1.5 % 200 bp to 3 kb 
(*bp = base pairs, kb = kilo base pair) 
 
2.1.2.2 Polyacrylamide gel electrophoresis 
12% SDS-PAGE gels, with a stacking layer, were made using Protogel 
reagents (National Diagnostics), in the quantities detailed below (Table 4). 
The ammonium persulfate and TEMED were added last to start the cross-
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linking reaction, and the solution was immediately poured between the 
assembled glass gel casting plates. The separating layer was prepared first 
and allowed to set before pouring the stacking layer gel on top; this was left 
to set with the gel comb inserted. Samples were prepared using loading 
buffer (see Laemmli et al. 117) and 50 mM dithiothreitol (DTT) and heated at 
95 oC before use. Gels were run in glycine SDS-PAGE running buffer (see 
Laemmli et al. 117) at 200 V for 50 minutes or until the Bromophenol blue dye 
front reached the bottom of the gel. Gels were stained with coomassie blue 
(Table 5) for 3 hours and placed in de-stain solution (Table 5) for a further 
three hours before imaging.  
 
Table 4 SDS-PAGE gel reagents for 2x gels with 12% separating gel and 
stacking layer 
Reagent Stacking layer 12 % separating layer 
dH2O 4.20 ml 5.25 ml 
30 % w/v acrylamide 
(30 % acrylamide, 0.8 % bisacrylamide) 
0.65 ml 6.00 ml 
4x resolving Tris solution 
(1.5 M Tris.HCl pH 8.8, 0.4 % SDS) 
- 3.75 ml 
4x stacking Tris solution 
(0.5 M Tris.HCl pH 6.8, 0.4 % SDS) 
1.60 ml - 
10 % w/v ammonium 
persulphate 
67 µl 150 µl 
TEMED 6.7 µl 15 µl 
 
Table 5 Reagents required for Coomassie blue or de-stain solution 
Reagent Coomassie blue 
solution 
De-stain solution 
Methanol  500 ml / l  100 ml / l 
Acetic acid 100 ml / l 100 ml / l 
Coomassie blue powder 1 g/ l  - 
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2.1.3 Sequencing  
All sequencing reactions were prepared in 0.2 ml thin walled tubes using 10 
µl volumes, 150 ng DNA, 0.2 µM primer, 0.5 µl big dye 3.1 (Applied 
Biosystems) and 2 µl 5x sequencing buffer (Applied Biosystems). Samples 
were incubated in the thermocycler (Dyad Peltier Thermal Cycler, Bio-Rad) 
for 1 minute 96 °C and 25 cycles of (96 °C 10 seconds, 50 °C 5 seconds and 
60 °C 4 minutes), with a temperature ramp between steps of 1 °C/sec. 
Sequencing products were purified by ethanol precipitation. 10 µl of 
sequencing products was added to 5 µl of 125 mM EDTA and 60 µl 100% 
ethanol in a 96-well plate. Samples were spun at 2900 xg for 30 minutes, 
then inverted on tissue and spun at 10 xg for 15 seconds. 60 µl 70% (v/v) 
ethanol was added to the sample which was placed at 780 xg at 4 °C for 15 
minutes. The plate was again inverted on tissue and spun at 10 xg for 15 
seconds. Residual ethanol was removed by placing the plate on a heated 
block at 95 °C for 1 minute. 10 µl Hi Di Formamide (Applied Biosystems) was 
added to the samples prior to analysis. Samples were analysed using 
fluorescence-based capillary electrophoresis on the ABI 3130xl Genetic 
Analyzer (Applied Biosystems). Sequencing results were analysed using 
4Peaks to visualise the electropherogram traces.  
2.2 E. coli cell culture and cloning 
2.2.1 Growth media 
Transformed E. coli cells were grown on LB agar (Table 6) or in LB broth 
(Table 6); except for large scale expression of recombinant proteins where 
2YT broth (Table 6) was used. Media was made as detailed below (Table 6) 
and sterilised by autoclaving. Ampicillin was added at a final concentration of 
100 µg/ml to all media.  
For expression of 15N labelled protein, M9 media supplemented with 15N 
ammonium chloride was prepared using the reagents in Table 7. 50 ml 10x 
M9-N salts (Table 8) and 2 ml 25% (w/v) 15N NH4Cl (Cambridge Isotope 
Laboratories) were added 430.55 ml dH2O. The pH of the solution was 
adjusted to 7.4 and autoclaved. All other components were sterilised 
individually and subsequently added separately to the media in the quantities 
detailed in Table 7. 
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Table 6 Media details 
Reagent LB broth LB agar 2YT broth* 
NaCl 10 g/l 10 g/l 5 g/l 
Yeast Extract 5 g/l 5 g/l 10 g/l 
Tryptone 10 g/l 10 g/l 16 g/l 
Agar - 12 g/l - 
 * The pH of the final solution was adjusted to 7.5 
using NaOH. 
Table 7 Full list of reagents used for 500 ml M9 media 





10x M9-N salts See Table 8   50 ml 





  2 ml 
1M MgSO4     1 ml  
1M CaCl2     50 µl 
20% w/v 
Glucose 
   10 ml 
5% (w/v) 
FeCl(III) 
   400 µl  
MEM vitamins 
(100x) 




See Table 9   0.5 ml  
Ampicillin  
(100 mg/ml) 
   0.5 ml 
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Table 8 10x M9-N salts composition 
Reagent 10x M9-N salts 
Na2HPO4 (anhydrous) 6 g/l 
KH2PO4 3 g/l 
NaCl  0.5 g/l 
  
Table 9 Reagents required for 50 ml 1000x trace elements solution 
Reagent 
1 X 10-5 M ZnSO4 3 X 10-5 M CoCl2 
8 X 10-5 M MnCl2 4 X 10-4 M H3BO3 
1 X 10-5 M CuSO4 3 X 10-6 M (NH4)6(Mo7) 
** 1000x trace elements solution was a gift from Gary Thomson, (previously University of 
Leeds). 
 
2.2.2  Plasmids 
PPIL1 pET22b+ expression vectors were a gift from Guoliang Chai, UCSD. 
(Full length human PPIL1 cDNA was inserted into the vector, in frame with 
the C terminal His tag, using NdeI/XhoI restriction sites). Four vectors were 
received which contained WT and mutant PPIL1 (A99T, T107A and R131Q) 
open reading frames (ORF). In addition, a pDONR221 plasmid containing 
the full length SKIP ORF was also received.  
 
2.2.3 In fusion cloning 
A DNA fragment coding for amino acid residues 59-129 of SKIP (the PPIL1 
binding region) was cloned into a pGEX-6P1 vector using the In-Fusion HD 
Cloning Kit (Clontech), as per manufacturer’s instructions (Figure 11). For 
PCR amplification of SKIP 59-129 coding sequence, primers were designed, 
using the on-line In-Fusion Primer design tool 
[http://www.clontech.com/US/Products/Cloning_and_Competent_Cells/Selec
tion_Guides/Online_In- Fusion_Tools] (forward: 
GAATTCCCGGGTCGAGGAGATGGAGGTGCTTTTC, reverse: 
AGTCACGATGCGGCCTTAATCATCTGCATTCATAACCTC). Primers 
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contain a gene specific 3’ region (black) and a 5’ region (blue) containing 15 
bases with homology to the pGEX-6P1; a stop codon (underlined) was also 
included in the reverse primer. SKIP 59-129 was amplified from SKIP 
pDONR221 vector, using CloneAmp HiFi PCR Premix (Clontech) and the 
following conditions: 98 °C 30 seconds, 25 cycles: (98 °C 30 seconds, 55 °C 
30 seconds, 72 °C 25 seconds) and 72 °C 7 minutes. The vector was 
digested with SalI and NotI restriction enzymes and the linearised vector was 
gel purified using a MinElute gel extraction kit (Qiagen). Insertion of the PCR 
product into the linearised vector was carried out as described in the in-
fusion kit protocol. The resulting plasmids were then transformed into E. coli 
and validated as below (section 2.2.5). 
 
   
Figure 11 In-fusion cloning protocol, Clontech Laboratories. The gene region of 
interest is amplified using primers with a gene specific 3’ region of 18-25 bp 
and a 5’ 15 bp region complementary to the ends of the linearised vector 
(red/green). The (cloning enhancer treated) PCR product is inserted into the 
linearised vector using homologous recombination. 
 
2.2.4 Site directed mutagenesis (SDM) 
The Q5 Site-Directed Mutagenesis Kit (NEB) was used, as described in the 
kit protocol, to introduce the new patient mutation, c.301_318dup 
Linearised
vector
PCR amplify gene 
region of interest
PCR product, with 15 
bp homology arms, 
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p.(A101_D106dup); c.325G>T p.(G109C), into the pET22b+ PPIL1 
expression vector. The first round of SDM was carried out using the primers 
AGATACCAATtGCAGCCAGTTCTTTGTGAC, GGCCCCGCATTGGCCATT 
to introduce c.325G>T p.(G109C): and the second round of SDM was carried 
out using the primers gggccagatACCAATTGCAGCCAGTTCTTTGTG, 
cgcattggcATCTGGCCCCGCATTGGC to introduce the second mutation 
c.301_318dup p.(A101_D106dup); (lowercase letters in primers represent 
the position of the mismatch or additional nucleotides required to insert the 
relevant mutation). (The primers were designed using NEBaseChanger 
online tool [https://nebasechanger.neb.com/], Figure 12) The exponential 
amplification step was carried out with the following conditions: initial 
denaturation 98°C 30 seconds, 25 cycles (98 °C 10 seconds, 69 °C 30 
seconds, 72 °C 3 minutes), final extension 72 °C 2 minutes. All other steps 
were as described in the kit protocol. Site-directed mutagenesis plasmid 
products were transformed into E. coli, amplified and sequenced as below 
(sections 2.2.5, 2.1.3). 
 
Figure 12 Site directed mutagenesis, using Q5 Site-Directed Mutagenesis 
Kit. Mutations are created in plasmid DNA, using exponential 
amplification, with forward (black) and reverse (red) primers. To create 
base substitutions, the desired nucleotide change (cross) is included in 
the forward primer. To create deletions, primers are designed which 
flank the target region to be deleted. For insertions, half of the desired 
insertion sequence is included at the 5’ end of each primer.  
 
2.2.5 Validation of constructs 
For cloning, plasmids were transformed into chemically competent cells 
(Stellar competent cells- Clontech), using heat shock. 1 - 5 μl of DNA (10 pg 
- 100 ng) was added to 50 μl cells and incubated on ice for 30 minutes, at 42 
Substitutions Deletions Insertions
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°C for 45 seconds and on ice for a further 2 minutes. The cells were then 
incubated at 37 °C, 200 rpm, with 200-1000 µl SOC broth (New England 
Biolabs) for 1 hour, spread onto LB agar plates (100 µg/mL ampicillin) and 
incubated at 37 °C overnight. Bacteria from a single colony were inoculated 
into 5 ml LB cultures (100 µg/mL ampicillin) and grown at 37 °C overnight. 
Plasmid DNA was isolated using a Miniprep kit (Qiagen; using kit protocols) 
and constructs were verified by sequencing (see section 2.1.3), using 
primers in Table 10. If higher DNA yields were required, 200 ml LB cultures 
were grown at 37 °C overnight (100 µg/mL ampicillin) and DNA was 
extracted using a Maxiprep kit (Qiagen, using kit protocols); the vectors were 
again verified by sequencing. Samples were aligned to the predicted vector 
sequence using EMBOSS needle, pairwise sequence alignment (nucleotide) 
online algorithm 
(https://www.ebi.ac.uk/Tools/psa/emboss_needle/nucleotide.html), to verify 
that genes were cloned in the correct orientation in frame with the relevant 
tag, mutations were in the correct location, where applicable, and that no 
additional mutations had been introduced.   
Table 10 Primers used to sequence plasmids 
Primer Primer sequence Plasmids 
sequenced 
T7 forward TAATACGACTCACTATAGGG pET22b plasmids 
T7 terminator GCTAGTTATTGCTCAGCGG pET22b plasmids 
pGEX forward GCAAGCTACCTGAAATGCTG pGEX-6P1 
pGEX reverse GGCAGATCGTCAGTCAGTCA pGEX-6P1 
 
2.3 Protein methods 
2.3.1 Protein expression 
Expression vectors were transformed into chemically competent BL21(DE3) 
E. coli cells (Agilent/Stratagene) for protein expression, using the method 
described above (see section 2.2.5). For expression of unlabelled protein 
cells were grown in 400 ml 2YT broth (see 2.2.1) and for 15N labelled protein 
cells were grown in 500 ml minimal media supplemented with 15N ammonium 
chloride (see section 2.2.1); all media contained 100 µg/ml ampicillin. 
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Samples were inoculated with 5 ml overnight starter cultures and grown at 
37°C, 200 rpm in 2 l flasks. Protein expression was induced at OD600 0.5-0.8 
by adding IPTG (Isopropyl β-D-1-thiogalactopyranoside) to a final 
concentration of 1 mM and incubation was continued at 18 °C overnight for 
PPIL1 proteins, or for 3 hours 37 °C for GST tagged proteins. Cells were 
harvested by centrifugation at 4000 xg for 30 minutes, at 5 °C.  
 
2.3.2 Protein purification 
Protein purification was carried out using the following steps; with specific 
buffers, columns and elution conditions appropriate for the protein (Table 
11). Cell pellets were resuspended in 30 ml resuspension buffer (Table 11). 
PMSF, lysozyme (Sigma #62970) and triton X-100 were added to final 
concentrations of 1 mM, 0.4 mg/ml and 0.2 % (v/v) respectively and 
incubated at room temperature for 10 minutes. 2 ng/µl DNaseI (Sigma 
#D5025) and 3 mM MgSO4 were added and the samples were incubated at 
room temperature for a further 10 minutes3. Insoluble material was pelleted 
by centrifugation at 7500 xg, 5 °C, for 30 minutes and the supernatant was 
loaded onto an affinity column using a peristaltic pump, at 4 oC. Columns 
were washed and protein was eluted using an ÄKTA explorer system 
(Amersham pharmacia biotech) (Table 11), at room temperature. The purity 
of protein solutions was assessed using SDS-PAGE and the molecular 
weight of purified proteins was confirmed using time-of-flight mass 
spectrometry (Astbury Centre Mass Spectrometry facility). 
  
                                            
3 Stock solutions were prepared as follows: PMSF, 100 mM solution in isopropanol; 
lysozyme, 20 mg/ml in deionised water; triton X-100, 10% v/v in deionised 
water; MgSO4, 1M in deionised water; DNase I, 1 mg/ml in 10 mM Tris.HCl pH 
7.9 150 mM NaCl. Lysozyme and DNase solutions were filtered (0.22 µm filter) 
and stored at -20 oC as 300 µl and 50 µl aliquots respectively. 
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Table 11 His-tagged PPIL1 and GST tagged protein purification conditions 
 His-tagged PPIL1 proteins GST-tagged proteins 
Column 1 ml HisTrap HP columns 
(GE Healthcare) 
Glutathione sepharose 




20 mM NaH2PO4, 0.3 M 
NaCl, 10 mM imidazole, pH 
8.0 
PBS (pH 7.4) 
Elution conditions imidazole gradient (20 mM 
NaH2PO4, 0.5 M NaCl, 10 
mM to 500 mM imidazole, pH 
8.0) over 25 column volumes 
5-10 ml injection of 50 
mM Tris-HCl, 10 mM L-
glutathione reduced, pH 
8.0 
Column flow rate 1 ml/minute 0.5 ml/ minute 
Elution fraction 
size 
2 ml 1 ml 
 
2.3.3 Calculation of protein concentration 
Protein concentration was calculated by measuring absorbance at 280 nm 
(A280) using a 1 cm pathlength quartz cuvette in a Genesys 6 
spectrophotometer (Thermo Spectronic). A baseline reading was taken with 
the relevant buffer and samples were diluted so that the A280 reading was 
between 0.1 and 1. Protein concentration was then calculated using the 
Beer-Lambert law (Equation 1). The molar extinction coefficient (ε) was 
calculated using ExPASY ProtParam online tool118, which uses Equation 2 to 
calculate the A280 molar extinction coefficient (M-1 cm-1), assuming that all 
cysteine residues are reduced118.  
Equation 1 
 $ = 	'	(	)  
(where A is absorbance, ε is the molar extinction coefficient, l is pathlength (cm) and c is 
concentration of solution (M).  
Equation 2 
 ε = (number of tyrosine residues x 1490) + (number of tryptophan 
residues x 5500). 
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2.3.4 Buffer exchange and protein concentration 
Protein solutions were exchanged into the relevant buffer using Spectra/Por 
1 dialysis membrane, molecular weight cut off (MWCO) 6-8 kDa (Spectrum 
Laboratories). Experiments were carried out in 1x PBS (made from 10 x PBS 
stocks; Fisher), unless otherwise stated (for techniques where specific buffer 
components must be avoided or optimised to improve signal to noise ratios 
(e.g. CD, NMR)). 
For experiments which required high concentrations of PPIL1 protein, the 
protein was concentrated using Vivaspin 500 concentrator columns (GE 
healthcare), with MWCO 3,000 Da.  
 
2.3.5 Size exclusion chromatography (SEC) 
Analytical SEC was carried out using a Superdex 75 10/300 gel filtration 
column (GE healthcare; which is suitable for analysis of 3–70 kDa globular 
proteins), connected to the ÄKTA pump system (as before). PBS buffer was 
used for both dialysis and running buffers; buffer was degassed and filtered 
using a vacuum pump and 0.45 µm filter prior to use on the ÄKTA. 0.25 
mg/ml protein samples were loaded onto the column using a 250 µl sample 
loop and flow rate of 0.6 ml/minute. 
A calibration curve was used to estimate protein molecular weight by 
injecting globular monomeric standards of known molecular weight, from the 
low molecular weight calibration kit (GE healthcare; #28-4038-41), at the 
recommended concentration. The curve was plotted using normalised Kav 
values calculated using the equation below (where V0 is column void volume, 
Ve is elution volume and Vc is geometric column volume). The void volume 
was calculated using injections of blue dextran (1 mg/ml) from the low 




-) − -0 
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2.3.6 Circular dichroism (CD) 
Protein secondary structure content was assessed using far-UV CD spectra 
(190 - 240 nm). Samples were dialysed extensively against 10 mM sodium 
phosphate buffer, 50 mM NaF, pH 7.4 and diluted to 0.2 mg/ml, 200 µl total 
volume for analysis. Spectra were recorded using a 1 mm quartz cuvette in a 
Chirascan CD spectrometer (Applied Photophysics) at 20 oC. The following 
parameters were used: 1 nm increments, scan speed = 1 nm/second and 
bandwidth = 2.5 nm. Results are the average of two consecutive spectra and 
were subtracted from the spectra of buffer alone. Data was collected in 
millidegrees (mdeg) and converted to mean residue ellipticity (θ MRW) for 
analysis using Equation 4 (where θ is the observed ellipticity [mdeg], MRW = 
mean residue weight, c = concentration [mg/ml], l is the pathlength [cm]. 
Secondary structure content was calculated using CDSSTR on the 
Dichroweb online tool using reference set 7, which is optimised for 
wavelengths of 190-240 nm. CDSSTR estimates secondary structure using a 
variable selection method, in which reference proteins which do not fit the 
data are removed and secondary structure content is determined by singular 
value decomposition. CDSSTR is recognised as a tool which gives better fits 
of globular proteins119. 
Equation 4 
[θ] MRW = θ x MRW* /10 x c x l 
(*MRW = molecular mass, Da / number of residues -1) 
 
2.3.7 Protein unfolding and aggregation screen 
Protein aggregation and unfolding were measured simultaneously over a 16-
90 °C temperature gradient using an Optim machine (Unchained Labs). 
Protein samples (9 µl) were loaded into 16-well Optim microcuvette arrays. 
Protein stability was measured using the barycentric mean wavelength of 
intrinsic protein fluorescence, to assess protein unfolding. Fluorescence was 
excited using a laser at 266 nm and emission monitored from 280 nm to 450 
nm. Protein aggregation was detected by measuring static light scattering at 
266 nm. During the assay, the temperature was increased from 16-90 °C in 
1°C steps and the temperature was held constant for 30 seconds before 
recording fluorescence or static light scattering data. Analysis was performed 
with Optim Analysis Software (Avacta Analytical). Assays conducted to 
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compare stability and aggregation of WT and mutant PPIL1 proteins were 
carried out using protein at 1 mg/ml, in PBS. 
Optim protein unfolding assays were also used as a screen, to determine 
optimal buffer compositions for future experiments. The buffer screen was 
designed and provided by Iain Manfield, University of Leeds. For the buffer 
screen PPIL1 WT protein (4 mg/ml), was diluted with the following reagents 
to give the range of buffer conditions. 1 M buffer stocks were added to stock 
PPIL1 protein (9 µl protein :1 µl buffer) to give 0.1 M buffer concentrations at 
a range of pH values (Table 12). For NaCl and glycerol concentration 
screens PPIL1 protein was diluted 1:1 in 2x stock reagents of NaCl (100-
3000 mM) and glycerol (5-60 % v/v) solutions to give 50 -1500 mM NaCl and 
2.5-30 % v/v conditions. An additive screen was also carried out using the 
following reagents: ammonium sulphate, potassium acetate, potassium 
glutamate, potassium chloride, sodium sulphate, sodium chloride, lithium 
chloride, magnesium chloride, magnesium nitrate, calcium chloride, lithium 
nitrate, sodium thiocyanate, lithium perchlorate, arginine. Protein was diluted 
(9:1) in 1 M additive solutions to give a final additive concentration of 0.1 M. 
As controls two further samples were monitored: an undiluted stock protein 
sample in PBS (pH 7.4) and protein samples diluted in water (1:1 or 9:1; to 
control for the effects of protein dilution). 
 
Table 12 Optim pH screen for protein stability 
Condition Details 
Water control Water only 
pH 3.0 0.1M citric acid: sodium citrate pH 3.0 
pH 3.5 0.1M citric acid: sodium citrate pH 3.5 
pH 4.0 0.1M acetic acid: sodium acetate pH 4.0 
pH 4.5 0.1M acetic acid: sodium acetate pH 4.5 
pH 5.0 0.1M acetic acid: sodium acetate pH 5.0 
pH 5.5 0.1M MES.NaOH pH 5.5 
pH 6.0 0.1M MES.NaOH pH 6.0 
pH 6.5 0.1M MES.NaOH pH 6. 
pH 7.0 0.1M HEPES.NaOH pH 7.0 
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pH 7.5 0.1M HEPES.NaOH pH 7.5 
pH 8.0 0.1M HEPES.NaOH pH 8.0 
pH 8.5 0.1M bicine.NaOH pH 8.5 
pH 9.0 0.1M CHES.NaOH pH 9.0 
pH 9.5 0.1M CHES.NaOH pH 9.5 
  
2.4 Protein interaction assays 
2.4.1 Surface plasmon resonance (SPR) 
SPR binding experiments were performed on a Biacore 3000 system with a 
CM5 chip (GE healthcare) at 25 oC. 
 
2.4.1.1 Amine coupling 
Anti-GST antibodies were captured on the chip surface (flow cells two and 
three) using the amine coupling and GST Capture kits (GE Healthcare). The 
system was primed with 100 mM sodium acetate running buffer (pH 5.6) and 
the surface was activated using a 35 µl 1:1 injection of 0.1 M N-
hydroxysuccinimide (NHS) and 0.4 M N-ethyl-N’-(dimethylaminopropyl) 
carbodiimide (EDC; both from GE Healthcare amine coupling kit) for 7 
minutes. 30 µg/ml anti-GST antibody (immunosorbent-purified polyclonal 
goat antibody, GST capture kit) solution was injected over the chip surface at 
5 µl/minute for 4 minutes. Unreacted material was eluted using 2x 20 µl, 1 
minute injections of 1M NaCl, 75 mM sodium acetate (pH 5.6). Unreacted 
sites were capped using 35 µl, 7 minute injection of 1 M ethanolamine.HCl 
(pH 8.5; GE healthcare). Flow cell 1 was used as a reference surface and 
was treated as above, without protein injections.  
 
2.4.1.2 Experiment design 
GST-SKIP 59-129 and GST (control) proteins were immobilised on the anti-
GST antibodies by injecting the protein solutions across the surface of the 
chip in separate flow cells. GST-SKIP 59-129 was immobilised at a density of 
700 RU (response units) and GST at a density of 560 RU. PPIL1-SKIP 
binding was measured by injecting the three PPIL1 proteins across the chip 
- 48 - 
surface at varying concentrations (15.6 – 2000 nM), using a flow rate of 50 
µl/min and injection time of 2.5 minutes. Buffer was washed across the chip 
for at least 20 minutes after the protein injection was complete and before 
any subsequent injections. All proteins used were dialysed extensively in 
PBS prior to use. Running buffer used for injections of GST tagged protein 
and PPIL1 proteins was PBS with 0.05 % v/v IGEPAL detergent. Data was 
analysed using Biacore BiaEvaluation software. All experimental data was 
overlaid, aligned and subsequently subtracted from reference flow cell data 
to account for any bulk refractive index changes between the running and 
sample buffer.  
 
2.4.2 Isothermal titration calorimetry (ITC) 
A peptide was designed which corresponds to residues 89-101 of PRP17 
(Bio-FAPEFGPENPFRT-NH2. Peptide modifications (N-terminal biotinylation 
and C-terminal amidation) were used to increase peptide stability and the 
biotin modification allowed use in other assays (such as SPR). The peptide 
was synthesised and purified by Peptide Synthetics to a purity of >98 % (as 
judged by HPLC analysis). ITC was used to measure binding between 
PRP17 peptide and PPIL1. ITC experiments were performed on Microcal ITC 
200, at 25 oC. PPIL1 protein was extensively dialysed against PBS and the 
cell was filled with 40 µM protein (200 µl cell volume). Lyophilised PRP17 
peptide was dissolved in PBS buffer from the final dialysis step. 2 mM 
PRP17 peptide was titrated into the cell, using 2 µl 4 second injections, 
spaced 2 minutes apart. The calorimetric signal was calculated by integration 
of the heat signal generated after each injection. The data point from the first 
injection, which is affected by diffusion of the syringe solution during 
equilibration, was removed (as is standard practice). The resulting binding 
isotherms were analysed using Microcal Origin 7 software and fit to a one-
site binding model, with a fixed stoichiometry of 1 (as is necessary for low 
affinity interactions120).  
2.5 NMR methods 
2.5.1 NMR theory 
Atomic nuclei with odd numbers of neutrons and protons have the property of 
spin which makes them possible to study by NMR (e.g. 1H, 13C, 15N, 31P, 
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19F). When a magnetic field is introduced (B0) these spins rotate around the 
field (around the z axis), in a process known as Larmor precession. The 
alignment of spins is either in the same direction of the magnetic field (the 
low energy state) or in the reverse direction to the field (the high energy 
state; Figure 13). Overall, the majority of spins will be in the low energy state 
(although the difference is small), and this creates bulk magnetisation along 
the Z axis.  A radiofrequency (r.f.) pulse is used to rotate magnetisation by a 
defined angle (e.g. 90 o). The resulting magnetisation creates a current in the 
receiver coil which can be detected. This creates a signal which decays with 
time called the free induction decay (FID). An FID signal is a function of time 
and this can be converted to a function of frequency by Fourier 
Transformation, yielding an NMR spectrum.  
Not all nuclei in a sample experience the same magnetic field due to a 
process known as shielding; this results in different chemical shifts for each 
nucleus in an NMR spectrum. Shielding is caused by electrons surrounding 
the nucleus. Therefore, larger atoms with more electrons typically exhibit 
larger chemical shifts. Nuclei of a specific type e.g. (1H) can also exhibit 
different chemical shifts due to a process known as deshielding, where 
electrons are pulled away from the nucleus by bonding to electronegative 
atoms or by hydrogen bonding. This means that each nucleus has a specific 
position in the spectrum, as a result of the local electron distribution121. 
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Figure 13 Energy levels for spin ½ nuclei (such as 1H 13C and 15N). These nuclei 
are charged and have the property of spin which means they behave like a 
magnet. When exposed to an external magnetic field (B0) nuclei have two 
possible orientations. Nuclei with higher energy create a magnetic field in the 
opposite direction to the external magnetic field, while nuclei with lower energy 
create a magnetic field in the same direction as the external magnetic field. 
The difference between the two energy levels depends on the strength of B0 
(the external magnetic field) and the gyromagnetic ratio of a nucleus (which is 
different for each isotope and is a ratio of its magnetic moment to its angular 
momentum). (The energy difference between higher and lower energy states 
also corresponds to the radio wave frequency required to rotate the 
magnetisation.) 
 
In a simple one dimensional NMR experiment, during the preparation phase, 
r.f. pulses are applied to excite specific nuclei (e.g. 1H); this is followed by a 
detection phase during which the resulting FID is measured for a specific 
time (t1). The result is a spectrum with a peak for each nucleus occupying a 
different chemical environment, at different chemical shift frequencies. In 
peptides and proteins, amide and aromatic protons typically show the highest 
chemical shift, while aliphatic and methyl groups typically show lower 
chemical shifts. In two dimensional (2D) NMR experiments, specific pulse 
sequences are used to transfer magnetisation between nuclei; to detect 
correlations of nuclei that are connected through bonds (i.e. via J coupling) 
or through space (using the nuclear overhauser effect ;NOE). 2D 
experiments can be used to correlate nuclei of the same type (homonuclear 
experiments) or different types of nuclei (heteronuclear experiments). In 2D 
heteronuclear experiments magnetisation is typically transferred from more 
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proportional to both the magnetic field strength (B0) and the gyromagnetic 
ratio of the nucleus121.  
 
2.5.2 General NMR methods 
NMR experiments were carried out in collaboration with Dr Arnout Kalverda, 
Dr Lars Kuhn and Dr Rhys Thomas in the NMR facility (University of Leeds). 
NMR spectra were acquired on 600 MHz, 750 MHz or 950 MHz 
spectrometers operating at 600.13, 747.98 and 950.13 MHz resonance 
frequencies respectively. NMR samples were loaded into standard Wilmad 
5mm tubes, 3 mm tubes or susceptibility matched 5 mm Shigemi tubes 
depending on the experiment. Each spectrometer was equipped with a cryo-
probe, Bruker Avance III HD console and pulsed field gradient along Z. Cryo 
probes used were as follows: triple resonance TXO cryo probe (TXO-CP), 
triple resonance TCI cryo-probe (TCI-CP) and quadruple resonance QCI-P 
cryo-probe (QCI-CP) for the 950 MHz, 750 MHz and 600 MHz spectrometers 
respectively. D2O was added to all samples at 5% v/v, resulting in a 5% 
dilution of buffer components and peptide/protein samples. All experiments 
were conducted at 25 oC. Results were processed using NMRPipe122 and 
analysed using CCPNMR Analysis123; except for 1D 1H experiments which 
were analysed using Topspin 3.2 software (Bruker).  
 
2.5.3 Binding experiments 
2.5.3.1 PPIL1 and PRP17 peptide 
The interaction of PPIL1 and PRP17 was monitored using 15N uniformly 
labelled PPIL1 protein and unlabelled PRP17 peptide (Bio-
FAPEFGPENPFRT-NH2; as above). 1H 15N heteronuclear single quantum 
coherence (HSQC) spectra of 15N PPIL1 were acquired with PRP17 peptide 
titrations. Samples contained 80 µM 15N PPIL1 and 0 - 400 µM PRP17 
peptide, in 10 mM sodium phosphate, 100 mM NaCl, 5% v/v D2O pH 6.5. 
Sample volumes of 550 µl were used in a standard Wilmad tube and spectra 
were acquired using a 600 MHz spectrometer. Spectra were acquired using: 
Hsqcfpf3gpphwg pulse sequence (Topspin 3.2, Bruker), 2048 data points, 8 
scans and spectral widths of 9578.544 and 2066.565 Hz for 1H and 15N 
respectively.  
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The published assignment of PPIL1124 was used to identify the region of 
PPIL1 involved in binding to PRP17. Chemical shift perturbations were 
determined using Equation 5 (from Hewitt et al. 2017125), which calculates 
the average distance moved by each peak. Shifts in the proton dimension 
were multiplied by the gyromagnetic ratio of 15N and 1H nuclei (gH/gN) to 
account for the different magnitudes of chemical shifts in the proton and 
nitrogen dimensions. ∆δ represents the total shift from the free state and ∆δN 
and ∆δH represent the shift in the nitrogen and proton dimensions 
respectively. Residues with significant chemical shift perturbations were 
defined as those which: a) broadened beyond detection or b) shifted more 
than one or two corrected standard deviations above the mean (as 
recommended and detailed by Schumann et al.126). 
Equation 5 
∆2 = 	3(∆25)7 + (∆29)7(:9/:5)7 
 
2.5.3.2 PRP17 1-172 and PPIL1 
15N uniformly labelled protein corresponding to a larger region of PRP17, 
residues 1-172, was a gift from Guoliang Chai (UCSD). The interaction 
between PRP17 1-172 and full length PPIL1 was monitored by acquiring 1H 
15N transverse relaxation optimized spectroscopy (TROSY) spectra of 15N 
PRP17 1-172 in the presence and absence of  PPIL1. Samples consisted of 
30 µM PRP17 1-172 and 0-90 µM PPIL1 in 25 mM sodium phosphate buffer, 
100 mM NaCl, 1 mM DTT, 5% v/v D2O pH 7.0 in a Shigemi tube (300 µl total 
volume). Spectra were acquired using a 750 MHz spectrometer, 1272 data 
points, 32 scans and spectral widths of 8971.292 and 1895.006 Hz in 1H and 
15N dimensions respectively. 
 
2.5.4 Monitoring PPIase activity 
2.5.4.1 Model substrate 
The PPIase model substrate, N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide 
peptide (Sigma #S7388), was used to monitor PPIase activity of PPIL1 
proteins. One-dimensional 1H spectra were recorded to measure proline cis-
trans isomerization of this peptide, using a gradient excitation sculpting 
sequence for water suppression. The peptide 1H chemical shifts were 
previously assigned in the literature127 and Ala2 methyl proton peaks were 
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used to monitor proline cis-trans isomerisation. Samples consisted of 550 µl, 
500 µM peptide, dissolved in PBS (pH 7.4), 5% D2O and where indicated 
sub-stochiometric concentrations of PPIL1 protein (0-10 µM). As a control, 
the active site inhibitor CsA (Cyclosporin A; #9973 Cell Signalling 
Technology), was also added to samples at equimolar ratios to PPIL1. 
Spectra were acquired using standard 5 mm Wilmad tubes and the 600 MHz 
spectrometer. The zgesgp pulse sequence (Topspin 3.2, Bruker) was used 
with 32768 data points, 128 scans and a 1H spectra width of 9578.44 Hz. 
Exchange rates of proline isomerisation were determined using NMR signal 
lineshape analysis, on the Dynamic NMR (DNMR) module of the TopSpin 
3.2 acquisition and processing software (Bruker). Exchange rates were 
determined iteratively, using fixed nuclei positions and coupling constants for 
Ala2 methyl cis- and trans- signals (N-succinyl-Ala-Ala-Pro-Phe-p-
nitroanilide).  
 
2.5.4.2 PRP17 substrate 
PPIase activity of PPIL1 was monitored on a putative substrate of PPIL1, 
PRP17. For identification of cis and trans conformations of PRP17 Gly94-
Pro95 peptide bond, a peptide corresponding to residues 89-101 of PRP17 
(sequence as above; Ac-FAPEFGPENPFRT-NH2) was purchased with a 15N 
and 13C labelled proline, from Peptide Synthetics. The peptide had N-
terminal acetylation and C-terminal amidation modifications (to mimic a 
peptide bond at the ends of the peptide, which increases stability to 
peptidases). PRP17 peptide was dissolved to 500 µM in 550 µl PBS (pH 
7.4), 5 % v/v D2O and placed in a standard 5 mm Wilmad tube. Cis and trans 
states were assigned using a constant time 1H 13C HSQC spectrum, 
recorded on a 750 MHz spectrometer. Spectra were collected using: 
hsqcctetgpsisp pulse sequence (Topspin 3.2, Bruker), 1024 data points, 4 
scans and spectral widths of 11961.723 and 8839.628 Hz in 1H and 13C 
dimensions. Cis and trans peptide bond assignment was based on 13C 
chemical shift for C: and Cβ proton resonances, as shown by Shen and Bax 
201037.	 
1H,15N - H(C!)N ZZ exchange experiments (based on those used by 
Dujardin et al. 2015128) were conducted, to detect proline isomerisation of 
PRP17 Gly94-Pro95 peptide bond. Spectra were recorded using 550 µl 500 
µM PRP17 peptide (with labelled proline, as described above) in the 
absence and presence of catalytic concentrations of PPIL1 (5 µM). The 
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sample buffer was PBS (pH 7.4), 5 % v/v D2O, as above, and spectra were 
acquired using a standard 5 mm Wilmad tube and 950 MHz spectrometer. 
The spectra were acquired using 2048 data points, 1664 scans and spectral 
widths of 15243.902 and 192.577 Hz (2 ppm) for 1H and 15N dimensions 
respectively. The 15N carrier was set to 134 ppm to centre on the proline 15N 
resonance frequency and 10 complex increments were acquired for a total 
experiment time of 22.5 hours. 
 
2.5.4.3 Identifying rates of proline isomerisation on PRP17 
1H-15N ZZ exchange experiments were used to determine rates of proline 
isomerisation on PRP17. 15N universally labelled PRP17 peptide was a gift 
from Guoliang Chai (UCSD). In brief this peptide was expressed in E. coli 
with a SUMO tag and purified firstly using affinity purification. After cleavage 
of the tag, the peptide was purified using HPLC and lyophilised for storage. 
PRP17 peptide corresponded to residues 84-101 of PRP17, 
TYETMFAPEFGPENPFRT, (the peptide was five residues longer than 
PRP17 peptide used above, for optimal stability during expression and 
purification steps). 
To assign the PRP17 peptide 1H 15N HSQC-TOCSY  and 1H 15N HSQC-
ROESY experiments were used. (1H 15N HSQC-TOCSY  and 1H 15N HSQC-
ROESY spectra contain HSQC pulse sequences at the start of the pulse 
sequence to help separate the large number of signals [which result from the 
multiple conformations of PRP17 peptide]). Spectra were recorded on the 
600 MHz spectrometer using 300 µl sample volumes in a 5 mm Shigemi 
tube. Sample conditions were as follows: 400 µM peptide, 25 mM sodium 
phosphate buffer, 100 mM NaCl, 1mM DTT, 5% D2O pH 7.0. 1H 15N HSQC-
TOCSY spectrum (80 ms mixing time) was recorded using: 2048 data points, 
80 scans and spectral width of 9578.544 and 1276.404 Hz for 1H and 15N 
respectively. 1H 15N HSQC-ROESY spectra (mixing times 200 and 300 ms) 
were acquired with: 2048 data points, 288 scans, and spectral widths of: 
6893.382 and 1276.404 Hz for 1H and 15N respectively. 200 complex 
increments were acquired in 15N for a total acquisition time of 65 hours.  
1H-15N ZZ exchange experiments, to monitor proline isomerisation, were 
carried out using the uniformly 15N labelled PRP17 peptide (details as 
above). Sample and buffer conditions were as above and spectra of PRP17 
peptide (400 µM) were recorded in the absence and presence of 4 µM 
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PPIL1. Spectra were acquired on the 950 MHz spectrometer, using 3 mm 
NMR tubes (200 µl volume). The experiment was repeated using mixing 
times of 40, 80, 120, 200, 250, 350, 450, 600, 750 ms. The order of 
experiments was randomised and contained two technical repeats. The 
experiment was based on the Hsqcexf3gpwgph pulse sequence (Topspin 
3.2, Bruker) and included: 4096 data points, 8 scans and spectral widths of 
15243.902 and 2022.029 Hz for 1H and 15N dimensions. 
In order to determine rates of proline isomerisation, auto and exchange peak 
intensities were measured for each experiment. Exchange peak intensities 
were normalised to the relevant exchange peak intensity at t=0. All peak 
intensities were then expressed as a fraction of total cis and trans auto peak 
intensity at t=0. The data was fit to the two state exchange equations, based 
on equations by Kleckner et al. 2011129 (Equation 6, Equation 7, Equation 8), 
using GraphPad (Prism7). I refers to the peak intensity, at a given mixing 
time, for cis (AA), trans (BB), and exchange (AB and BA) peaks. T 
represents time in seconds, P is the population of cis or trans conformations, 
R1 is the longitudinal relaxation rate constant and kex is the overall cis ↔ 
trans exchange rate per second.  
Equation 6 
=>>(?) = @>(@> + @A exp(−EFG?))exp	(−HI?) 
 
Equation 7 
=AA(?) = @A(@A + @> exp(−EFG?))exp	(−HI?) 
 
Equation 8 
=>A(?) = =A>(?) = @>@A(1 − exp(−EFG?))exp	(−HI?) 
 
2.6 Other methods 
2.6.1 Variant pathogenicity predictions and protein modelling  
Polyphen (Polymorphism Phenotyping v2)130, SIFT (Sorting Intolerant From 
Tolerant)131, PROVEAN (Protein Variation Effect Analyzer)132 and CADD 
(Combined Annotation Dependent Depletion v.1.4)133 online software tools 
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were used to predict the effect of patient PPIL1 variants. Software was 
available on the following links: http://genetics.bwh.harvard.edu/pph2/, 
http://sift.bii.a-star.edu.sg/, http://provean.jcvi.org and 
https://cadd.gs.washington.edu/score respectively. Prediction of variant 
pathogenicity was made using default parameters for all tools used.  
Allele frequencies of patient variants were taken from gnomAD (Genome 
Aggregation Database; http://gnomad.broadinstitute.org/)134. 
Protein alignments were made using Clustal omega software 
(https://www.ebi.ac.uk/Tools/msa/clustalo/)32 and annotated using ESPript 
(‘Easy Sequencing in PostScript’) 3.0 online software 
(http://espript.ibcp.fr/ESPript/ESPript/)33 
UCSF Chimera software (downloaded from 
http://www.rbvi.ucsf.edu/chimera)57 was used to model protein structures and 
produce images displayed in this thesis. The published data used (Table 13) 
was downloaded from the relevant entry in the protein data bank (PDB; 
www.rcsb.org)135. 
Table 13 PDB data used in this thesis 
Structure PDB ID Reference 
PPIL1 crystal structure 2X7K 56 
PPIL1 NMR structure 1XWN 55 
PPIL1 and SKIP NMR structure 2K7N 86 
S. pombe ILS spliceosome 3JB9 48 
Human C spliceosome 5YZG 77 
Human C spliceosome 5O9Z 52 
Human C* spliceosome  5XJC 47 
Human Bact spliceosome (late) 5Z57 49 
Human Bact spliceosome (mature) 5Z56 49 
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Human Bact spliceosome (core) 6FF7 50 
Human P spliceosome 6QDV 93 
Human P spliceosome 6ICZ 94 
human ILS spliceosome [before 
prp43 loaded],  
6ID0 94 
Human ILS spliceosome [after 
prp43 loaded] 
6ID1 94 




2.6.2 Ethical approval 
The families provided signed informed consent to participate in studies 
approved by the Leeds East Research Ethics Committee (07/H1306/113), 
see Appendix.
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Chapter 3 In silico modelling 
3.1 Introduction 
Identification of causative gene variants in autosomal recessive disease has 
increased rapidly following the development of whole exome sequencing137. 
However, finding the correct disease causing variant in a background of 
many variants across the genome remains challenging. As a result, further 
lines of evidence are required to confirm if an identified variant causes the 
disease in question. In silico tools are frequently used to assess if an 
identified variant is likely to be pathogenic and may also be used to further 
investigate the mechanism behind a disease138. 
PPIL1 variants were previously detected as the cause of microcephaly and 
pontocerebellar hypoplasia, using whole exome sequencing and 
autozygosity mapping (unpublished data, University of Leeds and University 
of California San Diego; discussed in Chapter 1). Although many variants 
were detected in the patients’ DNA, variants in PPIL1 were determined to be 
the most likely pathogenic variants using the following methods. Firstly 
common variants in dbSNP (2014 version), the Exome Sequencing Project 
(ESP) project, and in locally sequenced samples from individuals of Pakistani 
origin were excluded. Only variants that were present in biallelic state in both 
individuals and that were missense, splice site, frameshift or stop variants 
were called. After filtering variants as above, two missense variants 
remained: in RAB44 and PPIL1. The RAB44 variant had a very low CADD 
score (4.476), whereas the PPIL1 variant had a CADD score of 29.7 
suggesting the PPIL1 variant is highly likely to be pathogenic and the RAB44 
variant likely benign. Therefore mutations in PPIL1 were considered most 
likely to be the pathogenic variants (unpublished data, University of Leeds). 
Sanger sequencing of the patient’s and parents DNA confirmed segregation 
of PPIL1 variant with disease. Independently, a laboratory at University of 
California San Diego also mapped the pathogenic variant in a case of 
microcephaly and pontocerebellar hypoplasia to be located in PPIL1 
(unpublished data, UCSD). 
Combined, the data from the University of Leeds and UCSD provided strong 
evidence that mutations in PPIL1 cause microcephaly and pontocerebellar 
hypoplasia in the patients discussed. However, additional work was required 
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to provide further support for this hypothesis and in silico work was first 
carried out to investigate the consequences of the patient mutations in 
PPIL1. All PPIL1 variants were homozygous and cause the following PPIL1 
protein changes: A99T, T107A, R131Q and G109C;101_106dup. In this 
chapter, the consequences of the protein changes were assessed using 
pathogenicity prediction tools. In addition, the conservation of PPIL1 was 
assessed directly using a protein sequence species alignment. Structural 
analyses were also used to understand the functional consequences of the 
protein changes caused by the patient variants.  
The pathogenicity prediction tools used to assess the likely pathogenicity of 
PPIL1 patient variants included: Polymorphism Phenotyping v2 (Polyphen), 
Sorting Intolerant From Tolerant (SIFT), CADD (Combined Annotation 
Dependent Depletion) and Protein Variation Effect Analyzer (PROVEAN). 
These tools are frequently used to help assess the likely pathogenicity of 
missense variants, (or in the case of PROVEAN missense or INDEL 
variants)20. The SIFT algorithm makes predictions based on amino acid 
conservation among species and also the properties of the amino acids in 
question131. Polyphen2 also uses sequence conservation data but also takes 
into account structural information (for example whether the mutation will 
perturb the hydrophobic core or further relevant features of the protein)130. 
SIFT and Polyphen2 are limited to predicting the effect of amino acid 
substitutions only. PROVEAN was developed to predict the effect of all types 
of protein sequence changes, including duplications. PROVEAN also uses 
amino acid conservation between species to predict pathogenicity, but also 
considers conservation of flanking sequences132. CADD is a tool which 
integrates many different methods of pathogenicity prediction including: 
conservation, sequence context of variant, gene annotations, epigenetic data 
and functional predictions from tools including PolyPhen and SIFT139. 
In addition, very little is currently known about the function of PPIL1. PPIL1 is 
a component of the spliceosome and many spliceosome cryo-EM 
spliceosome structures have recently been published. This was made 
possible, by both advances in cryo-EM and also in techniques to stall 
spliceosomes at specific stages of assembly (as discussed in Chapter 1). 
The advances in cryo-EM were made possible by increased sensitivity of 
microscopes and improvements in processing software. Various techniques 
have been employed to stall the spliceosome at specific phases of assembly 
(e.g. change of pH or addition of splicing inhibitors), allowing more 
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homogenous complexes to be analysed and thus increasing the resolution of 
spliceosome structures. 
In this chapter, in silico modelling of published spliceosome cryo-EM data 
was used to gain novel insights into the role of PPIL1 in the spliceosome. 
Data was analysed for each stage of the spliceosome which contains PPIL1 
and for which data was available (Bact to ILS spliceosome stages). This 
analysis suggests PPIL1 interacts with several proteins in the spliceosome 
and has led to the identification of a putative PPIL1 PPIase substrate.  
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3.2 Results 
3.2.1 In silico prediction of variant pathogenicity 
3.2.1.1 Pathogenicity prediction tools 
The effect of the PPIL1 variants identified in the patients was assessed using 
CADD139, PolyPhen2130, SIFT131 and PROVEAN132 (Table 14); this is 
standard practice after discovery of novel candidate variants. Overall, variant 
pathogenicity prediction tools suggest a likely pathogenic interpretation of 
PPIL1 variants. CADD scores for all variants are greater than 15 suggesting 
a pathogenic interpretation of the variants and the SIFT algorithm also ranks 
all PPIL1 variants as ‘damaging’. For family 3 and 4 PPIL1 variants (p. 
R131Q, p.G109C;A101_D106dup) are predicted to negatively affect protein 
function across all 4 prediction tools used. Family 1 variant (p.T107A) is also 
predicted to affect protein function in SIFT, PROVEAN and CADD tools, and 
is classed as ‘possibly damaging’ by Polyphen2. However, predictions for the 
PPIL1 variant in family two (p.A99T) are most variable across the prediction 
tools, being classed as ‘benign’ or ‘neutral’ by PolyPhen2 and PROVEAN but 
‘damaging’ or ‘pathogenic’ by SIFT and CADD. This indicates one of the 
drawbacks of using this approach. 
Due to the rare occurrence of autosomal recessive genetic diseases it is 
predicted that disease causing variants must be relatively rare in the general 
population138. The occurrence of all patient single nucleotide variants in 
PPIL1 was therefore investigated using the Gnomad database (Table 14). 
For all patient single nucleotide variants, the PPIL1 variants are either not 
present in the Gnomad database or are found at less than 0.01 % in the 
general population (Table 14). The Gnomad database also provides allele 
frequencies for specific ethnic populations and shows that none of the single 
nucleotide variants in PPIL1 were found in the relevant ethnic population 
(Table 14). None of the patient variants were homozygous in any of the 
populations in the Gnomad database. The Gnomad database only reports 
two biallelic missense variants in PPIL1 p.Cys36Ser (79 individuals) and 
p.Gly46Asp (2 individuals; out of 141,456 individuals in the database), with 
allele frequencies of 0.01970 and 0.00007651 respectively. This indicates 
that PPIL1 exhibits a low tolerance to biallelic missense variants across the 
gene. These results support the hypothesis that the identified PPIL1 variants 
are likely to be deleterious.  
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Table 14 Pathogenicity prediction of PPIL1 variants. All patients were homozygous for missense variants, except family 4 (*) which was 
homozygous for a complex allele consisting of a missense variant and duplication (*). Pathogenicity was predicted using CADD 
(https://cadd.gs.washington.edu/)139, Polyphen2 (http://genetics.bwh.harvard.edu/pph2/)130, SIFT (http://sift.bii.a-star.edu.sg/)131 and 
PROVEAN (http://provean.jcvi.org)132 and used the default cut off scores: CADD >15 predicted pathogenic; Polyphen >0.15 possibly 
damaging, >0.85 probably damaging; SIFT <0.05 predicted deleterious PROVEAN <-2.5 predicted deleterious. Allele frequencies in the 
general population were taken from Gnomad database and are shown for both the global population and specific populations.  
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(-8.512) Variant not present in Gnomad
*Chr.6:36855996_368
56013dup
c.301_318dup p.A101_D106dup 22.5 N.A. N.A.
Deleterious
(-14.714) N.A.
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3.2.1.2 Protein conservation 
Conservation of specific residues across species may suggest an 
evolutionary constraint and functional importance of a particular residue in a 
protein140. Residue conservation is therefore a useful predictor of variant 
pathogenicity and was assessed directly using a protein sequence alignment 
for PPIL1 homologs (Figure 14). Both T107 and R131 residues are strictly 
conserved across species, suggesting the functional importance of these 
residues (Figure 14). A99 is also highly conserved across species, with 
serine being the only other residue found at this position (Figure 14); a 
residue which is equivalent to alanine except for a hydroxyl group in place of 
one methyl group protons. The patient variant affecting residue 99 of PPIL1 
results in an alanine to threonine substitution. Although threonine is similar in 
structure to serine, a residue tolerated at this position in many species, 
threonine is larger than serine and contains a methyl group in place of a beta 
proton in serine.  Threonine is not found at this position in any other species 
(Figure 14) (or in other human cyclophilins, Appendix Figure 59), suggesting 
that threonine may not be tolerated at this position. G109 is also highly 
conserved, with only S. pombe containing a different amino acid at this 
position (serine). The duplicated region (A101_D106dup) also contains four 
strictly conserved amino acids between species. The high degree of 
conservation of residues affected by patient variants in PPIL1 suggests that 
PPIL1 is intolerant of the variation observed at  these residues.





Figure 14 Alignment of PPIL1 amino acid sequence, showing conservation 
across species:  Homo sapiens (NP_057143.1), Mus musculus 
(NP_081121.1), Danio rerio (NP_001029350.1), Drosophila melanogaster 
(NP_523874.1), Caenorhabditis elegans (NP_501118.1), 
Schizosaccharomyces pombe (NP_593308.1) and Arabidopsis thaliana 
(NP_181157.1). Conserved residues are shown with red letters and strictly 
conserved amino acids are highlighted in red with white letters. Positions of 
the patient mutations are indicated with green boxes for amino acid 
substitutions and a cyan box for the duplication region (A101_D106dup). 
Sequences were aligned using Clustal Omega32 and rendered for sequence 
similarities using ESPript33.   
- 65 - 
3.2.1.3 PPIL1 protein structural analysis 
In order to gain an understanding of the region of PPIL1 affected by the 
patient variants, the relevant residues were highlighted on the published 
structure of PPIL156 (Figure 15). PPIL1 is a single domain globular protein 
with a PPIase active site and on the opposite side of the protein a SKIP 
interaction site (Figure 15)55,56. All mutations affect residues on the surface of 
the protein, except for A99T which is a buried residue in the hydrophobic 
core of the protein (Figure 15; Appendix Figure 56). G109, T107, A99 and 
the duplicated region (A101_D106dup) are found next to the PPIase active 
site (Figure 15). Specifically G109, T107 and A101_D106 are found in a loop 
between beta strands 5 and 6. This loop forms the S2 pocket, an adjacent 
pocket to the active site which is thought to confer PPIase substrate bind 
specificity39. It is also thought that flexibility of this loop is crucial for PPIase 
substrate turnover55. R131 is found on the SKIP binding surface and this 
residue is known specifically to be required for interaction with SKIP56,86, 
other variants at this residue abolish the interaction with SKIP86.  
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Figure 15 Location of residues affected by PPIL1 patient variants (A99T, 
T107A, R131Q, G109C; 101_106 dup). Light blue represents residues 
affected by missense mutations and purple represents residues affected by  
in-frame duplication mutations. All patients were homozygous for the PPIL1 
variants, including G109C; 101_106 dup where patients were homozygous for 
both mutations. Most mutations cluster around the active site (left); however, 
the R131Q mutation affects a residue on the SKIP binding surface of the 
protein (right). The SKIP binding surface, as defined by Wang et al. 2010, is 
shown in yellow on the surface representation86. Images were created using 
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3.2.2 Insights from cryo-EM structures 
3.2.2.1 PPIL1 interactions 
Little is known about the role of PPIL1 in the spliceosome; therefore, 
spliceosome cryo-EM data was analysed to uncover novel insights about 
PPIL1. Data for spliceosome structures containing PPIL1 was available for: 
human Bact mature (5.1 Å)49, human Bact late (6.5 Å)49, human Bact 
[composite] (4.5 Å)50, human C (4.1 Å)77, human C (5.9 Å)52, human C* (3.6 
Å)47, human P (3.3 Å)93, human P (3.0 Å)94, human ILS [before prp43 loaded] 
(2.9 Å)94, human ILS [after prp43 loaded] (2.9 Å)94 and S. pombe ILS (3.6 Å) 
spliceosome complexes (Table 15). The published data was imported from 
the protein data bank (www.rcsb.org) and modelled using Chimera software. 
Analysis of the spliceosome structures confirms that as shown previously, 
PPIL1 binds to SKIP (Figure 16)55,56,86. SKIP is a predominantly disordered 
protein in solution86, but these structures show that SKIP adopts an ordered 
conformation in the spliceosome. Analysis also shows previously unknown 
interaction partners binding to PPIL1 in the spliceosome structures, 
including: PRP17 N terminus, RBM22 C terminus, CRNKL1, SYF2 and 
SPF27 of the PRP19 helical bundle (Figure 16).  
 
Table 15 Spliceosome cryo-EM structures, which include PPIL1 protein 
Spliceosome complex PDB code Resolution 
human Bact mature 5Z56 5.1 Å 
human Bact late 5Z57 6.5 Å 
human Bact [composite] 6FF7 4.5 Å 
human C 5YZG 4.1 Å 
human C 5O9Z 5.9 Å 
human C* 5XJC 3.6 Å 
human P 6QDV 3.3 Å 
human P 6ICZ 3.0 Å 
human ILS [before 
prp43 loaded] 
6ID0 2.9 Å 
human ILS [after prp43 6ID1 2.9 Å 
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loaded] 
S. pombe ILS 3JB9 3.6 Å 
 
All interactions observed, occur on surfaces of PPIL1 outside of the active 
site, except for the interaction with PRP17 (Figure 16). A loop of PRP17 
protein interacts with PPIL1 active site. PPIL1 is a peptidyl prolyl isomerase 
enzyme, whose substrate is a prolyl peptide bond55. Interestingly, Gly94-
Pro95 peptide bond of PRP17 occupies the centre of the active site (Figure 
17). Gly94-Pro95 is strictly conserved between all species which contain this 
N-terminal region of PRP17 (Figure 18). S. cerevisiae PRP17 homolog does 
not contain an equivalent region corresponding to hPRP17 N-terminal region 
(1-135); however, S. cerevisiae also does not have a PPIL1 homolog (Figure 
18; Appendix Figure 65). The PRP17-PPIL1 interaction is shown across all 
human spliceosome structures which contain PPIL1 and PRP17 (Bact to ILS 
complexes) and in the S. pombe ILS spliceosome structure (Figure 16). 
PPIL1 is a member of the cyclophilin family of PPIases, which contain an 
adjacent pocket to the active site called the S2 pocket; this region binds to 
substrate i-2 residues and this interaction is proposed to influence substrate 
binding specificity39. PRP17 Phe93 (i-2) sidechain binds to the S2 pocket in 
human spliceosome structures (Figure 17). 
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Figure 16 Cryo-electron microscopy structures of spliceosome complexes: 
human Bact mature (A)49, human Bact late (B)49, human Bact composite (C)50, 
human C (D)77, human C (E)52, human C* (F)47, human P (G)93, human P 
(H)94, human ILS [before prp43 loaded] (I)94, human ILS [after prp43 loaded] 
(J)94, S. pombe ILS (K). PPIL1 is shown as a grey surface fill model and 
interacting proteins are highlighted (PRP17 [red], SKIP [green], RBM22 
[yellow], CRNKL1 [blue], SYF2 [orange] and the PRP19 helical bundle 
[purple/pink] in the human model and the corresponding homologs in S. 
pombe). Other components of the spliceosome are shown in brown. Images 
were created using published data from the protein data bank 
(www.rcsb.org135; 5Z5649, 5Z5749, 6FF750, 5YZG77, 5O9Z52, 5XJC47,  6QDV93, 
6ICZ94, 6ID094, 6ID194, 3JB948) and Chimera software 
(http://www.rbvi.ucsf.edu/chimera)57. Regions of proteins without sufficient 
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Figure 17 PRP17 (89-101) and PPIL1 interaction in the spliceosome. The 
published cryo-EM structure of the C* human spliceosome47 shows a loop of 
PRP17 (residues 89-101; yellow) is positioned in the PPIase active site of 
PPIL1 (grey). This loop contains a conserved proline residue which sits at the 
centre of the PPIL1 proline isomerase active site. (Phe93 sidechain occupies 
the S2 pocket, a region thought to confer binding specificity for substrates of 
the PPIase active site39). This region of the model was rebuilt and refined by 
Chuangye Yan and  Yigong Shi, Tsinghua University, to confirm conformation 
and interaction of PPIL1 and PRP17. 
 
Figure 18 Amino acid alignment of PRP17 (77-120) showing conservation 
across species: Homo sapiens (NP_056975.1), Mus musculus 
(NP_082155.1), Danio rerio (NP_001009990.1), Drosophila melanogaster 
(NP_651005.1), Caenorhabditis elegans (NP_492851.1), Arabidopsis thaliana 
(NP_172528.2), Schizosaccharomyces pombe (NP_596089.1) and 
Saccharomyces cerevisiae (NP_010652.3). The loop of PRP17 (residues 89-
101) which interacts with PPIL1 in the cryo-EM structures 47,48 is indicated. 
The critical proline residue which occupies the PPIL1 active site in cryo-EM 
data (highlighted in yellow; Pro95 human PRP17, Pro69 S. pombe PRP17) is 
conserved across species; from human to S. pombe. (See appendix for full 
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3.3 Discussion 
Overall pathogenicity prediction tools, sequence conservation and structural 
analysis of PPIL1 support the hypothesis that the PPIL1 variants are likely to 
be deleterious to function. However, despite most results supporting this 
conclusion some of the pathogenicity prediction tools gave different results 
for A99T depending on the tool used. This similarity in properties of serine, a 
residue tolerated at residue 99 and threonine (the substitution caused by a 
PPIL1 patient variant, A99T) might be the reason for this disparity. These 
prediction tools have a high error rate (e.g. SIFT and PolyPhen have an 
estimated sensitivity of 69% and 68% and specificity of 13% and 16% 
respectively)22. A significant proportion of human proteins do not have full 
domain annotations meaning algorithms using annotation data, such as 
Polyphen, may not provide the full picture. Analysis of sequence 
conservation and structural analysis coupled with the literature is also 
required in order to best predict effects of patient variants. The findings 
presented here also highlight the importance of directly investigating variant 
pathogenicity in the laboratory. 
In addition to suggesting the identified PPIL1 variants are deleterious, the in 
silico results were also valuable for informing the design of further 
experiments. Structural analysis shows that one patient variant affects 
residue 99 in the hydrophobic core of PPIL1. In proteins, the arrangement 
and composition of the hydrophobic core is crucial for structure and stability. 
Substitutions at residue 99 may therefore affect PPIL1 stability and the 
folding and stability of PPIL1 proteins is investigated in Chapter 4. Structural 
analysis also shows that most of the PPIL1 patient variants affect residues 
around the PPIase active site and the effect of the variants on PPIase activity 
was monitored (Chapter 5). A further patient variant affects residue 131 at 
the SKIP binding interface; it was therefore also tested whether patient 
variants perturb this interaction (Chapter 5).   
Previously only SKIP was a known binding partner of PPIL155, therefore the 
analysis of spliceosome structures provides important insights into the role of 
PPIL1 in the spliceosome. Interestingly the region of PPIL1 which binds to 
the PRP19 helical bundle, was suggested as a putative additional binding 
site in PPIL1 due to the presence of several positively charged residues55. 
The observation that a proline residue of PRP17 occupies the PPIL1 active 
site, in the spliceosome structures raises the questions of whether PRP17 
may be a substrate of PPIL1 in the spliceosome. The high conservation of 
- 73 - 
PRP17 Pro95 across species suggests a functionally important role of this 
residue (see Chapter 6).  
Many of the proteins PPIL1 binds to form long range interactions across the 
spliceosome, from peripheral regions to the spliceosome core. The PPIL1 
interacting proteins include PRP17 which has an N-terminal region spanning 
over 100 Å and a WD40 domain adjacent to the spliceosome catalytic 
centre47. In addition, PPIL1 binds to the PRP19 helical bundle, of which 
CDC5L spans a large distance across the spliceosome. CDC5L Myb 
domains also contact the catalytic centre of the spliceosome, where they 
stabilise the catalytic U2/U6 structure and interact with PRP8; while the C-
terminus of CDC5L forms part of the PRP19 helical bundle at the 
spliceosome periphery47. SKIP has an extended conformation interacting 
with more than 10 proteins across the spliceosome, contacting proteins such 
as PPIL1 at the periphery and also the catalytic RNA centre of the 
spliceosome51. These long range interactions may play a role in transferring 
information from regulatory factors to the catalytic core47,77.  
Overall this work suggests the identified PPIL1 variants are likely pathogenic 
and informs the design of laboratory experiments to test this hypothesis 
(Chapter 4-5). In addition, analysis of spliceosome structures has given 
important insights into the role of PPIL1, which will aid the understanding of 







- 74 - 
Chapter 4 Protein purification, folding and stability 
4.1 Introduction 
In silico work (Chapter 3), suggests that patient variants in PPIL1 are 
pathogenic and likely to have a significant impact on PPIL1 protein function. 
In order to confirm these findings and further understand the effect of these 
variants on PPIL1 protein function, PPIL1 proteins corresponding to WT and 
mutant PPIL1 protein were made. PPIL1 proteins were expressed and 
purified from BL21(DE3) strain of E. coli, with a C-terminal His tag for 
purification purposes, as this strategy has previously been shown to yield 
soluble folded PPIL1 WT protein55. The identity, purity and homogeneity of 
these proteins was first assessed using SDS-PAGE, mass spectrometry and 
size exclusion chromatography. In order to inform experimental design and 
buffer choice for future experiments a protein stability screen was also 
carried out using a range of different buffer conditions (pH range, salt 
concentrations, glycerol concentrations and additives).  
PPIL1 interacts with SKIP in the spliceosome47,55,56,77,86 and therefore SKIP 
was also expressed and purified to study this interaction. SKIP is 
predominantly disordered and interacts with PPIL1 via a linear epitope 56,86. 
The PPIL1 binding region of SKIP (residues 59-129)55,56,86, which contains 
this epitope, was expressed and purified from E. coli. This protein was 
expressed using a GST tag for purification purposes and also to allow 
immobilization during binding experiments with PPIL1. SKIP identity and 
purity were similarly assessed using SDS-PAGE and mass spectrometry as 
for PPIL1. 
PPIL1 patient variants result in amino acid substitutions or amino acid 
duplications in the encoded PPIL1 protein (A99T, T107A, R131Q, 
101_106dup; G109C; Figure 19). PPIL1 is a small globular protein (19 kDa) 
consisting of a compact eight-stranded beta barrel capped by two alpha 
helices55,56. A99T substitution affects a residue on the beta 5 strand of PPIL1 
which is a buried residue in the hydrophobic core of PPIL1. The T107A 
substitution affects a solvent-exposed residue which is in a loop connecting 
beta strands 5 and 6. The R131Q substitution also affects a solvent-exposed 
residue, which is on beta 7 strand of PPIL1. The final patient was 
homozygous for variants that resulted in both a duplication and amino acid 
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substitution (101_106dup; G109C) and affects residues of the loop between 
beta 5 and 6 strands, which are also solvent exposed. (See Chapter 3 for an 
in depth analysis). 
 
  
Figure 19 PPIL1 substitutions (light blue) and duplications (purple), caused by 
PPIL1 patient variants. Affected residues are highlighted on the published 
crystal structure of PPIL156.  
 
Both amino acid substitutions and duplications can have a significant effect 
on protein folding and stability. Stability and folding of PPIL1 proteins were 
assessed using circular dichroism, aggregation and unfolding assays. Far 
UV circular dichroism was first used to determine whether any of the patient 
variants significantly perturbed PPIL1 protein secondary structure content. 
The overall stability of PPIL1 proteins was also assessed using a protein 
unfolding screen. Finally, the impact of patient variants on protein 
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4.2 Results 
4.2.1 Protein expression and purification 
4.2.1.1 PPIL1 protein expression and purification 
PPIL1 pET22b+ protein expression plasmids (WT, T107A, A99T and R131Q) 
were a gift from Guoliang Chai, UCSD. A further PPIL1 G109C 101_106dup 
pET22b+ plasmid was created using site directed mutagenesis. pET22b+ 
plasmids contain a C-terminal His tag to allow protein purification using 
affinity chromatography. All plasmids were sequenced to confirm the 
plasmids contained the correct coding sequence, inserted in the correct 
orientation, in-frame with the his tag and that no additional mutations were 
present (Appendix Figure 66).  
Recombinant PPIL1 proteins were expressed in BL21(DE3) E. coli cells, 
transformed with the PPIL1 pET22b+ plasmids. Expression was induced with 
the addition of IPTG and expression trials confirm that this induced protein 
production of the correct size, 19 kDa (Figure 20A). PPIL1 protein was 
purified on Ni-NTA columns and eluted using an imidazole gradient. A 
significant proportion of each expressed protein was soluble, bound to and 
could be purified from the Ni-NTA columns (Figure 20B), with the exception 
of PPIL1 A99T and G109C;101_106dup. Both G109C;101_106dup and 
PPIL1 A99T proteins were insoluble when expressed at 37 oC (data not 
shown). Reducing the culture temperature after IPTG induction to 18 oC, 
resulted in a proportion of the expressed protein becoming soluble and 
purifiable. Elution chromatograms show a clear peak in absorbance at 280 
nm, as the imidazole gradient is raised, showing PPIL1 proteins were eluted 
from the columns (Figure 20C). SDS-PAGE gels confirm PPIL1 proteins are 
of high purity (Figure 20D). Both A99T and 101_106dup; G109C PPIL1 
proteins could only be purified at much lower yields compared to PPIL1 WT 
and exhibit very low solubility (Figure 20D).  
 


















































Figure 20 Protein expression and affinity 
purification of recombinant PPIL1 
proteins (19 kDa). Representative 
Coomassie stained SDS-PAGE gels and 
purification chromatograms are shown.   
A) Protein expression was induced with 
IPTG and samples were taken from 
uninduced (U) and induced (I) cultures. The 
expected 19 kDa band corresponding to 
PPIL1 is seen in all the induced cultures 
B) Example protein purification gel for PPIL1 
WT. Protein was purified using affinity 
chromatography and samples were taken 
during the procedure: total protein (T), 
insoluble protein in pellet (P), soluble protein 
(S), flow through from column (F), column 
wash (W) and elution fractions. The elution 
fractions which were analysed correspond to 
the peak in absorbance at 280 nm in the 
elution chromatogram, and fractions from 
either side of the peak.  
C) Example chromatogram of PPIL1 WT 
protein purification, showing absorbance at 
280 nm (blue) and 260 nm (cyan) and the 
imidazole gradient (red) used to elute the 
protein. A single sharp peak in absorbance 
at 280 nm indicates elution of PPIL1 protein. 
D) SDS-PAGE gel of purified PPIL1 
proteins, showing that all PPIL1 proteins are 
of high purity.  
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4.2.1.2 SKIP protein expression and purification 
A sequence encoding SKIP residues 59-129 was cloned into pGEX-6P1 
plasmid, to allow protein expression and purification (Appendix Figure 66). 
Recombinant SKIP 59-129 protein was expressed in BL21(DE3) E. coli cells, 
with an N-terminal GST tag for purification purposes and to allow 
immobilisation in binding experiments. GST tag alone was also expressed 
and purified alongside GST:SKIP 59-129 to act as a control reagent in 
binding experiments. Expression trials were carried out, as for PPIL1 
proteins, and showed that induction with IPTG resulted in protein expression 
of approximately the expected protein size, 35 and 28 kDa for GST:SKIP 59-
129 and GST tag respectively (Figure 21A). GST tagged proteins were 
purified on columns containing glutathione sepharose, which has a strong 
affinity for GST. A large fraction of expressed GST proteins were soluble, 
bound to and were subsequently purified from the columns (Figure 21B). 
GST proteins were eluted using a glutathione injection and the resulting 
chromatogram shows a single sharp peak in absorbance at 280 nm 
indicating GST-tagged proteins were eluted from the column (Figure 21C). 
GST-SKIP and GST purification yielded proteins that migrated at 
approximately the expected molecular weight in SDS-PAGE. However, an 
additional band is present on SDS-PAGE gels for GST-SKIP which 
corresponds to cleaved GST tag (as also shown by Stegmann et al.56; Figure 
21D). Apart from the extra band representing a small proportion of cleaved 
GST in the GST:SKIP 59-129 sample, purified GST tagged proteins are also 
of high purity (Figure 21D). There is a small discrepancy in expected 
molecular weight of GST-tagged proteins and the apparent molecular weight 
from SDS-PAGE; likely caused by specific properties of the protein. For 
example, different residues vary in their charge and affinity for SDS which 
therefore affects migration through the gel.  



























Elution buffer volume (ml)
Absorbance at 280nm Absorbance at 260nm
Figure 21 GST (28 kDa) and GST:SKIP 59-
129 (35 kDa) protein expression and 
purification. Example SDS-PAGE gels 
(Coomassie stained) and purification 
chromatograms are displayed.   
A) Samples were taken from uninduced (U) 
and induced (I) cultures to confirm protein 
expression had been induced by IPTG.  
B) Representative protein purification gel for 
GST:SKIP 59-129. Protein was purified from E. 
coli lysates using a glutathione sepharose 
column. Total protein (T) represents all protein 
in the cell lysate. After centrifugation to remove 
insoluble protein, samples from the insoluble 
protein pellet (P) and remaining soluble protein 
(S) were collected. The soluble protein was 
loaded onto the column and the flow through 
(F), column wash (W) and elution fractions 
were collected.  
C) Representative chromatogram of GST:SKIP 
59-129 protein purification. GST tagged 
proteins were eluted using a single glutathione 
injection (10 mM) and a single sharp peak in 
absorbance can be seen at 280 nm (blue) and 
260 nm (cyan) as the protein was eluted.  
D) SDS-PAGE gel showing purity of proteins. 
(GST:SKIP 59-129 sample also contains a 
small proportion of cleaved GST.) 
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4.2.1.3 Validation of purified proteins 
Soluble purified proteins were verified using time of flight mass spectrometry 
analysis (by Dr James Ault, Astbury Mass Spectrometry facility). All 
determined molecular weights were equal or within 1 Da of the expected 
molecular weight (Table 16), confirming the identity of the purified proteins. 
PPIL1 mutant proteins A99T and G109C; 101_106 dup could not be 
analysed due to a high propensity to aggregate (see section 4.2.2.1). These 
results also confirms that any small differences in expected and apparent 
molecular weight determined by SDS-PAGE is a result of altered migration 
rather than any other factor, such as degradation or incorrect product.  
 
 
Sample Predicted molecular 
weight (Da) 
MS results (Da) 
PPIL1 WT 19170.7 19170.58 ±	1.54 
PPIL1 T107A 19140.7 19140.32	 ± 1.13 
PPIL1 R131Q 19142.6 19142.67	 ± 0.24 
GST-SKIP 35352.8 35352.76	 ± 	0.40 
GST (control) 28429.9 28429.24 ± 0.11 
Table 16 Confirmation of the molecular masses of purified proteins. Protein 
molecular weight was determined by time of flight mass spectrometry and 
compared to the predicted molecular weight (calculated using ExPASy 
ProtParam tool). The predicted molecular weight for PPIL1 proteins is shown 
for removal of N-terminal methionine, as is often seen for recombinant 
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Size exclusion chromatography (SEC), using a Superdex 75 column, was 
used to confirm the purified PPIL1 proteins were homogenous, monomeric 
and of the expected size. All three soluble PPIL1 proteins (WT, T107A, 
R131Q) elute at a single elution volume and show a single sharp 
symmetrical peak in the elution chromatogram, confirming the purified PPIL1 
protein solutions are homogenous and of high purity (Figure 22A). A 
calibration curve was plotted with protein standards, which are globular 
proteins of known molecular weight (Figure 22B), to calculate the apparent 
molecular weight of PPIL1 based on the elution volume. All three PPIL1 
proteins elute at a volume consistent with a molecular weight of 15 kDa, 
which is close to the actual molecular weight of PPIL1 of 19 kDa (Figure 
22C), suggesting that PPIL1 is monomeric. The small difference between the 
apparent and actual molecular weight of PPIL1 is likely due to the 
heterogenous shape of proteins, which make it difficult to predict molecular 
weights with high accuracy using this technique (see discussion)141. 
Increasing salt concentrations (from 137 mM to 300 or 500 mM NaCl) in the 
elution buffer to disrupt any interactions with the column that could lead to 
this difference, did not cause PPIL1 proteins to elute at a different volume 
(data not shown).  

















Figure 22 Analytical size exclusion chromatography (SEC) of PPIL1 proteins 
using a Superdex 75 column.  
A) Representative SEC elution chromatograms of PPIL1 proteins (WT, T107A 
and R131Q), showing absorbance at 220 nm (black), 280 nm (blue) and 260 
nm (red).  
B) A calibration curve was made using globular proteins of known molecular 
weight (Aprotinin, 6.5 kDa; Ribonuclease A, 13.7 kDa; Carbonic Anhydrase, 
29.0 kDa and Ovalbumin 43.0 kDa). To create the calibration curve, relative 
molecular mass (Mr) was plotted on a logarithmic scale against the partition 
coefficient, Kav. Kav was calculated, as shown above, using the elution volume 
(the volume between sample injection and elution from the column), void 
volume (the buffer volume that does not enter the pores; determined using 
blue dextran injections) and geometric column volume (the total volume of the 
column).  
C) Using the calibration curve, the apparent molecular weights of PPIL1 
proteins were calculated. 
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4.2.1.4 Buffer screen  
In order to determine optimal buffer conditions for stability of PPIL1 protein, a 
protein stability screen was carried out using a range of: pH conditions, NaCl 
concentrations, glycerol concentrations and different additives. To measure 
protein stability, protein unfolding was monitored over a temperature gradient 
using the different buffer conditions. The high-throughput Optim system 
(Unchained Labs) was used, which can simultaneously measure protein 
unfolding in 48 samples. The degree of protein unfolding was measured 
using the barycentric mean wavelength of intrinsic protein fluorescence. 
Proteins fluoresce due to the presence of aromatic amino acids (tryptophan, 
phenylalanine and tyrosine) which are able to absorb and subsequently 
release light. Intrinsic fluorescence emission was analysed between 280 and 
450 nm, which is primarily due to fluorescence emission of tryptophan. The 
emission wavelength of tryptophan is particularly sensitive to changes in 
environment and increases as a protein is unfolded due an increase in 
solvent exposure142. 
As the temperature was raised, PPIL1 protein transitions from folded to 
unfolded protein, which is represented by an increase in the barycentric 
mean wavelength of intrinsic protein fluorescence (Figure 23). PPIL1 WT 
shows a single transition from folded to unfolded protein as temperature is 
increased (Figure 23). This is consistent with the single domain structure of 
PPIL155. Small, globular, single domain proteins typically show a single 
transition from folded to unfolded protein. (Multiple transitions may represent 
unfolding of multiple protein domains or several intermediate unfolding 
steps)143. 
Buffer pH can have a large effect on protein stability by altering charges on 
ionizable groups in amino acid sidechains, as a result of protonation or 
deprotonation144. A range of pH conditions (pH 3.0 - 9.5) were tested for 
impact on PPIL1 stability. The pH range 6.5-8.5 appears to be optimal for 
PPIL1 stability, as PPIL1 remains folded at higher temperatures, compared 
to other pH conditions tested (Figure 23A). A pH above or below this range is 
detrimental to PPIL1 stability.  
Salt concentration may also have a significant effect on protein stability145 
and the effect of NaCl concentration (50-1500 mM) on PPIL1 stability was 
tested. All NaCl conditions tested, give rise to PPIL1 unfolding curves which 
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closely overlay (Figure 23B). This suggests that NaCl concentration, within 
this range, does not have a significant effect on protein stability.  
Glycerol is commonly used to enhance protein stability due to the ability to 
promote compact protein conformations and also reduce aggregation146. 
Therefore, the presence of glycerol in sample buffers was also tested for 
impact on PPIL1 protein stability. Increasing glycerol concentrations, caused 
PPIL1 to unfold at higher temperatures, indicating increased PPIL1 protein 
stability (Figure 23C). However, the contribution towards PPIL1 protein 
stability is relatively small, compared to other factors such as pH. 
It is widely known that protein stability may be improved with the inclusion of 
chemical additives in the sample buffer145. A range of chemical additives 
were tested for their effect on PPIL1 protein stability. However, none of the 
tested reagents caused any significant improvement in PPIL1 protein 
stability. All unfolding curves either overlay closely with the no additive 
control, or are shifted to lower temperatures, suggesting these the reagents 
tested may have a neutral or detrimental effect on PPIL1 protein stability, at 
the concentrations tested (Figure 23D).  
Overall these results show that PBS (pH 7.4) is suitable as a general buffer 
for PPIL1 protein. Altering pH or salt concentration or presence of additives 
does not significantly improve PPIL1 stability. Although glycerol improves 
PPIL1 stability, the impact is only small. High concentrations of glycerol that 
are required to significantly improve PPIL1 stability may not be optimal for 
future experiments, such as SPR. In addition, specific types of experiments 
may also require different buffer conditions, such as NMR where a low pH is 
advantageous. These results show that, if required, the pH can be reduced 
to 6.5 without significantly perturbing protein stability.  
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Figure 23 PPIL1 WT Optim 
buffer screen. Different buffer 
conditions were tested (pH 
range, glycerol concentrations, 
NaCl concentrations and use of 
additives) to determine optimal 
conditions for PPIL1 WT protein 
stability. Protein stability was 
measured over a temperature 
gradient using the barycentric 
mean (BCM) of intrinsic protein 
fluorescence as a measure of 
protein folding. Stock PPIL1 
protein was in PBS, pH 7.4 (137 
mM NaCl, 2.7 mM KCl, 11.9 mM 
phosphate buffer; no glycerol or 
additives). 
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4.2.2 Comparison of PPIL1 WT and mutant protein folding and 
stability 
4.2.2.1 Protein solubility 
Both PPIL1 A99T and G109C; 101_106 dup proteins were highly unstable 
when expressed and purified from E. coli. Although small amounts could be 
purified, the protein rapidly aggregated and precipitated in solution. Due to 
these results, these mutant proteins could not be taken forward for further 
analysis. However, these results suggest that both PPIL1 A99T and G109C; 
101_106 dup have a pathogenic effect on PPIL1 protein function by 
perturbing PPIL1 protein structure. All other proteins (WT, T107A and 
R131Q) were highly soluble and could be used for further analysis.  
 
4.2.2.2 Circular dichroism (CD) 
In order to determine whether any of the other patient variants had more 
subtle effects on PPIL1 protein structure, secondary structure content was 
compared between WT and mutant proteins. Circular dichroism 
spectroscopy (CD) at far UV wavelengths (190-240 nm) allows the rapid 
determination of protein secondary structure content and was therefore used 
to compare the secondary structure content of WT and mutant proteins. CD 
signals arise as a result of different absorption of right and left-handed 
circularly-polarised light. The peptide bond absorbs light below 240 nm and 
yields CD spectra with maxima and minima peaks at characteristic 
wavelengths, based on secondary structure content119. The spectra recorded 
for PPIL1 proteins show negative peaks at 223 nm and 208 nm consistent 
with alpha helical content, as expected for PPIL1 proteins (Figure 24A). Beta 
sheets have a less well-defined predicted maxima (from 190 nm to over 200 
nm) due to the variation in possible conformations beta sheets can take. The 
CD spectra also contain a positive peak at 198 nm consistent with a 
significant beta sheet content, as expected (Figure 24A). 
Spectra for WT and mutant proteins overlay, suggesting that the T107A and 
R131Q substitutions do not significantly perturb secondary structure in PPIL1 
(Figure 24A). The secondary structure content was deconvoluted using 
Dichroweb online tool147. CDSSTR was the only analysis programme in 
Dichroweb which was able to fit the data (see Figure 24B for representative 
fit). This programme carries out a large number of calculations compared to 
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other programmes and often produces results where other analysis 
programmes fail148. NRMSD (normalized root-mean-square deviation) scores 
were below 0.05 for all proteins tested, suggesting a good fit to the data 
(Figure 24C). The predicted proportion of residues found in helices, beta 
strand or other conformation does not differ significantly between PPIL1 WT 
and mutant proteins and is in line with the published PPIL1 structures (Figure 
24C). These results therefore suggest that the patient variants do not  
significantly perturb secondary structure content of PPIL1. 
 
  
Figure 24 Far UV circular dichroism (CD) of PPIL1 wild type and mutant 
proteins. (A) Overlaid far UV CD spectra of PPIL1 proteins (WT, T107A and 
R131Q) at 20 oC. Spectra were acquired using wavelengths 190-240 nm and 
CD signal is shown as mean residue ellipticity [θ]. Samples consisted of 0.2 
mg/ml protein in 10 mM sodium phosphate buffer, 50 mM NaF, pH 7.4. (B) 
Secondary structure content was estimated using CDSSTR on the Dichroweb 
online tool (http://www.cryst.bbk.ac.uk/cdweb)147, using reference set 7, which is 
optimised for wavelengths of 190-240 nm. The reconstructed fit of the data 
calculated by CDSSTR is shown for PPIL1 WT CD spectrum. (C) Table of 
estimated secondary structure content of PPIL1 proteins, calculated by 
CDSSTR. Secondary structure content of PPIL1 in published crystal (PDB: 
2X7K)56 and NMR (PDB: 1XWN)55 structures is shown for reference. (Helix 

































Protein Helix Stand Other NRMSD score
WT 0.18 0.28 0.55 0.04
T107A 0.18 0.26 0.56 0.04
R131Q 0.19 0.27 0.55 0.03
NMR structure 0.15 0.27 0.58
Crystal structure 0.16 0.30 0.55
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4.2.2.3 Optim: protein unfolding and aggregation assays 
To establish whether the patient variants had any effect on the overall 
structure and stability of PPIL1, unfolding and aggregation screens were 
carried out, using an Optim machine. Protein unfolding was measured over a 
temperature gradient, as described previously (section 4.2.1.4). Intrinsic 
protein fluorescence was used to measure protein unfolding, as before. All 
PPIL1 proteins show a single transition from folded to unfolded proteins ( 
Figure 25A, B), as is expected for small, globular, single domain proteins. 
The unfolding curves for PPIL1 T107A and R131Q proteins are shifted to the 
left, compared to PPIL1 WT, showing that PPIL1 T107A and R131Q begin to 
unfold at lower temperatures than PPIL1 WT ( Figure 25A). The midpoint of 
the unfolding curve, called the transition temperature ( Figure 25B), was 
determined using three separate preparations of protein. These results show 
that the unfolding transition temperature of PPIL1 WT is 46.8 oC, under the 
conditions tested. PPIL1 T107A and R131Q unfold at 3.0 and 3.4 oC lower 
temperatures, respectively, compared to PPIL1 WT.  
In addition to the protein unfolding screen, protein aggregation was 
measured simultaneously across the same temperature gradient. Protein 
aggregation was measured as an increase in static light scattering at 266 
nm. Comparison of the temperatures at which the static light scattering 
signals begin to increase, shows that PPIL1 T107A and R131Q are also 
more prone to aggregation than PPIL1 WT ( Figure 25D). This trend was 
consistent across three experimental replicates with different preparations of 
protein.  
 
- 89 - 































































































Sample Transition Temperature (°C)
WT 46.8 ± 0.46
T107A 43.8 ± 0.29






 Figure 25 Protein 
unfolding and aggregation 
screen of PPIL1 wild type 
and mutant proteins. (A) 
Shift in the barycentric mean 
wavelength of intrinsic 
protein fluorescence was 
used to measure PPIL1 
protein unfolding over a 
temperature gradient. (B) 
The transition temperature of 
folded to unfolded protein 
was calculated as the 
steepest point of the 
unfolding curve, which was 
determined by plotting the 
differential of the unfolding 
curve. (C) Mean transition 
temperatures of three 
experimental replicates, 
using different preparations 
of protein, are shown with 
standard deviation error. (D) 
Static light scattering was 
used to measure aggregation 
over a temperature gradient.  
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4.3 Discussion 
PPIL1 WT protein and mutant proteins were successfully expressed and 
purified from E. coli. However, both PPIL1 A99T and G109C;101_106dup 
mutations disrupt the structure of PPIL1, causing significant aggregation and 
precipitation out of solution. The crystal structure of PPIL1 shows that A99 is 
a buried residue in PPIL1 protein core56, so this may explain why substitution 
of this residue has such a profound effect on protein stability and 
aggregation. G109C;101_106dup causes both a six amino acid duplication 
and amino acid substitution in the loop between β5 and 6 strands of PPIL1. 
This loop shows no variation in size across human cyclophilins or between 
PPIL1 homologs in different species and may be critical to PPIL1 stability 
(Chapter 3). 
SEC results suggest that all soluble PPIL1 proteins are monomeric. 
However, there was a small discrepancy in calculated apparent molecular 
weight of PPIL1 proteins (15 kDa), compared to the predicted molecular 
weight of PPIL1 proteins (19 kDa). Increasing the buffer salt concentration to 
reduce any non-specific binding to the column, which may cause this 
difference, did not cause PPIL1 proteins to elute at a different volume. Mass 
spectrometry results confirmed that the actual protein molecular weight is 19 
kDa, as expected. The heterogenous shape of proteins mean that small 
deviations from theoretical protein molecular weight are often observed when 
molecular weight is deduced from SEC elution volumes141. PPIL1 WT protein 
has previously been characterized as monomeric using dynamic light 
scattering experiments149. Here it was shown that soluble WT and mutant 
PPIL1 proteins elute at similar volumes in SEC experiments. Taken together, 
the work by Xu et al. and our SEC experiments, indicate that all soluble 
PPIL1 proteins are monomeric (WT, T107A and R131Q)56. 
Characterisation of all soluble PPIL1 proteins, using SDS-PAGE, MS and 
SEC, has shown that these protein are of high purity and homogenous. 
These properties mean that further characterisation of these proteins was 
possible. PPIL1 T107A and R131Q mutant proteins exhibit reduced thermal 
stability and increased aggregation compared to PPIL1 WT, suggesting that 
these substitutions perturb the structure of PPIL1. Both T107A and R131Q 
substitutions affect solvent exposed residues, unlike A99T which is buried in 
the core of PPIL1. This likely explains why these substitutions have a more 
subtle impact on PPIL1 protein stability and aggregation compared to A99T. 
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However, it is clear that all patient PPIL1 variants have some impact on 
PPIL1 protein stability.  
The availability of PPIL1 proteins will allow further investigation of the impact 
of PPIL1 patient variants on PPIL1 protein function. Little is understood about 
PPIL1 function, but it is known that PPIL1 interacts with another protein, 
SKIP, in the spliceosome55. Expression and purification of GST-SKIP 59-129 
and GST was also successful and will therefore allow the interaction 
between SKIP 59-129 and PPIL1 to be studied (see Chapter 5). PPIL1 is 
also a PPIase enzyme55 and the effect of the patient variants on this activity 
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Chapter 5 Effect of PPIL1 patient variants on protein 
function: interaction with SKIP and PPIase activity 
 
5.1 Introduction 
Biallelic variants at the PPIL1 locus cause a novel form of microcephaly and 
cortical dysplasia, together with cerebellar and brainstem hypoplasia 
(unpublished data: University of Leeds, UCSD). The variants result in the 
following PPIL1 protein changes: A99T, T107A, R131Q, 
G109C;101_106dup. In this chapter, the effect of PPIL1 patient variants on 
PPIL1 protein function was investigated. Little is known about the function of 
PPIL1; however, it is known that PPIL1 binds to SKIP and also exhibits 
peptidyl prolyl isomerase (PPIase) enzyme activity55,56,86. PPIL1 WT and 
mutant proteins that correspond to the PPIL1 patient variants have 
previously been expressed and purified (Chapter 4). PPIL1 A99T and 
G109C;101_106dup destabilise PPIL1 protein and cause significant 
aggregation and precipitation out of solution (Chapter 4). These results show 
a clear consequence of these variants; however, this also meant that these 
proteins were not suitable for further analysis. PPIL1 WT, T107A and R131Q 
proteins are soluble (Chapter 4) and were assessed for their interaction with 
SKIP and PPIase enzyme activity.  
The PPIL1-SKIP interaction takes place in the spliceosome, a complex and 
dynamic ribonucleoprotein enzyme which splices introns from pre-
mRNA30,47,77. SKIP is a 61.5 kDa, predominantly disordered protein, which 
spans a large region of the spliceosome47,48,77. SKIP is able to interact with 
many proteins throughout the spliceosome and it is thought that SKIP may 
play a key role in coordinating dynamics across the spliceosome48,50. SKIP 
binds to PPIL1 via a surface of PPIL1 distinct from the active site; which 
includes residue R131, a residue affected by a PPIL1 patient mutation 
(R131Q; see Chapter 3). The PPIL1 binding region of SKIP is found between 
residues 59-129 of SKIP, which is a disordered region55. It is known that a 
linear epitope of SKIP (residues 61-68) is essential for the interaction with 
PPIL156,86. The PPIL1-SKIP interaction induces a disorder to order transition 
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of SKIP, and residues 59-79 of SKIP form a hook like structure on the 
surface of PPIL1 upon binding56,86.  
The impact of PPIL1 patient variants on the interaction with SKIP was 
investigated using surface plasmon resonance (SPR), a technique which has 
been successfully used previously, to study this interaction55,86. SPR 
monitors changes in the refractive index at a chip surface. Changes in mass 
near the chip surface, from processes such as binding, result in detectable 
shifts in the refractive index which are measured in arbitrary response units 
(RU)150. This technique offers many advantages over other protein-protein 
interaction methodologies, including the ability to use unlabeled protein, the 
potential to derive kinetic and affinity values from the data, and the 
requirement for relatively small quantities of protein interaction partners 
compared to other techniques150. GST:SKIP 59-129 and PPIL1 proteins were 
successfully expressed and purified from E. coli (see Chapter 4) and were 
used in SPR experiments to study this interaction. 
PPIL1 also exhibits PPIase activity55, the ability to catalyse the transition 
between a cis and trans peptide bond, before a proline residue. The type of 
peptide bond, cis or trans, may have important consequences for the local 
structure of the polypeptide chain. The peptide bond isomer may therefore 
be important for protein folding or protein conformational changes34. Proline 
isomerization is an intrinsically slow process and PPIase enzymes are 
ubiquitous in eukaryotes and prokaryotes in order to accelerate this 
interconversion (see Chapter 1 for more information)35. PPIL1 has previously 
been shown to exhibit PPIase activity on the model substrate N-succinyl-Ala-
Ala-Pro-Phe-p-nitroanilide (suc-AAPF-pNA)55. 
NMR was used to investigate the effect of PPIL1 patient variants on the 
PPIase enzyme activity of PPIL1. This analytical technique can be used to 
monitor proline isomerisation and is not subject to the same limitations of 
alternative assays151. The first published PPIase assay monitors proline 
isomerization on the tetrapeptide substrate suc-AAPF-pNA and uses 
chymotrypsin to cleave p-nitroanilide (pNA) from the peptide. Chymotrypsin 
can only cleave pNA from the peptide in the trans conformation of the Ala-
Pro peptide bond and therefore cleavage of pNA is limited by the rate of 
proline isomerization. Accumulation of pNA can be used to monitor the rate 
of proline isomerization and is measured as increase in absorbance at 390 
nm over time152,153. Although this has been a useful assay to identify PPIase 
enzymes55,154, it has many limitations including susceptibility of some PPIase 
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enzymes to chymotrypsin cleavage155-157. This has previously led to some 
PPIase proteins incorrectly being labelled as inactive or having reduced 
activity155-157. A modified version of this assay, without chymotrypsin, has 
also been used157. This assay can also use the same substrate (suc-AAPF-
pNA) and uses the difference in absorption coefficients of the peptide in the 
cis and trans isomers to monitor proline isomerization157. However, both of 
these assays are limited by low sensitivity and also use non-equilibrium 
conditions which may not be biologically relevant. NMR is sensitive to 
changes in the chemical environment of nuclei and can therefore be used to 
investigate proline isomerisation. This technique allows proline isomerisation 
to be monitored under equilibrium conditions151. In addition, there is greater 
flexibility in the buffers which can be used for NMR, allowing experiments to 
be performed in more physiologically relevant buffers. 
In this chapter, PPIase enzyme activity of PPIL1 was monitored on the model 
substrate, suc-AAPF-pNA, using NMR. Specifically 1D 1H NMR was used to 
monitor proline isomerization (as used by Hubner et al.151), which has high 
sensitivity to the changes in the chemical environment of nuclei that occur 
during proline isomerisation. In addition, 1D 1H spectra can be acquired 
rapidly in minutes. Lineshape analysis of the spectra was used to measure 
rates of proline isomerisation, as the degree of line broadening can be used 
to measure chemical exchange such as proline cis-trans isomerisation. NMR 
lineshape is sensitive to slow-intermediate exchange (ms timescale), which 
is the timescale under which PPIase catalysed proline isomerisation typically 
takes place151. This technique allowed proline isomerization to be measured 
under equilibrium conditions without the use of chymotrypsin and enabled 
comparison of PPIL1 WT and mutant activity on suc-AAPF-pNA. 
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5.2 Results 
5.2.1 PPIL1 interaction with SKIP 
The impact of PPIL1 patient variants on the interaction between PPIL1 and 
SKIP was investigated using Biacore surface plasmon resonance (SPR). In 
order to measure the interaction, one component, the ligand, is immobilised 
on the chip surface and the interaction partner, or analyte, is then injected 
over the chip surface. GST:SKIP 59-129 (ligand) was immobilised on a 
sensor chip surface using an affinity capture system of anti-GST antibodies 
(Figure 26A). GST tag alone was also immobilised on anti-GST antibodies, in 
a separate flow cell, to confirm PPIL1 proteins did not bind to the GST tag. 
The anti-GST antibodies were first immobilised on the chip surface using 
amine coupling. This technique covalently links primary amine groups on the 
protein of interest (protein N-terminus or lysine sidechains) with the dextran 
matrix. This technique allowed immobilisation of approximately 10 000 RU of 
anti-GST protein on each flow cell and an example amine coupling 
sensorgram is shown (Figure 26B). After this procedure was complete, 
GST:SKIP 59-129 or GST (control) proteins were immobilised on the anti-
GST antibodies using injections of protein into the relevant flow cell (e.g. 
Figure 26C). GST:SKIP 59-129 was immobilised at a density of 
approximately 700 RU and GST at a density of approximately 560 RU (e.g. 
Figure 26C). 
All soluble PPIL1 proteins (WT, T107A, R131Q) were subsequently injected 
across the SPR chip surface to detect binding with SKIP 59-129 (Figure 26A, 
Figure 27A). Clear binding curves can be observed upon injection of PPIL1 
WT protein across the flow cell containing SKIP 59-129, confirming binding 
between PPIL1 WT and SKIP 59-129 (Figure 27A), as shown previously55,86. 
PPIL1 T107A also interacts with SKIP 59-129, as shown by the binding curve 
generated upon PPIL1 T107A protein injection across SKIP 59-129 surface 
(Figure 27A). However, no response could be detected after injection of 
PPIL1 R131Q across SKIP 59-129 (Figure 27A), suggesting this amino acid 
substitution disrupts the interaction with SKIP. These results are consistent 
across three repeat experiments with separate preparations of PPIL1 and 
SKIP proteins. Control titrations against GST tag alone confirm PPIL1 
proteins do not bind to GST tag (or anti-GST antibodies), (Figure 27B). The 
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Biacore software was unable to fit a 1:1 Langmuir binding model to any of 
the data which closely followed the binding curves obtained; therefore, 
kinetic or affinity values for the interaction were not determined (Appendix 
Figure 58). This was despite efforts to optimise and verify experimental 
conditions which might otherwise prevent 1:1 binding, including: ensuring 
purity and homogeneity of ligand and analyte protein, minimising mass 
transport effects, minimising non-specific binding, minimising bulk refractive 
index changes and use of appropriate reference and control flow cells (see 
discussion). Therefore, presented here are qualitative SPR data only (Figure 
27A); however, these results demonstrate a clear pathogenic effect of the 
R131Q patient mutation on PPIL1 function.  






     
Figure 26 Experimental design and ligand immobilisation for PPIL1 and SKIP 
59 -129 surface plasmon resonance (SPR) binding experiments. (A) SPR 
experimental design. Anti-GST antibodies were immobilised on a CM5 chip 
surface using amine coupling. GST:SKIP 59-129 protein or GST protein 
(control) was captured on the anti-GST antibodies and PPIL1 protein was 
injected across the surface to measure binding.  
(B) Representative sensorgram for amine coupling of anti-GST antibodies to 
the CM5 chip. Amine coupling was carried out using 0.1 M sodium acetate 
running buffer, pH 5.6, at 5 µl/min. The surface was activated with a 7 minute 
injection of NHS/EDC (step 1). Anti-GST antibodies were injected across the 
activated matrix at 30 µg/ml for 4 minutes (step 2). Unreacted material was 
eluted with two, one-minute injections of 1 M NaCl at increased flow rate (20 
µl/min; step 3). The surface was deactivated with a 7 minute injection of 1 M 
ethanolamine.HCl, pH 8.5 (step 4). More than 10 000 RU of anti-GST 
antibodies were immobilised on the chip surface, in each flow cell, using this 
method. 
(C) Representative sensorgram of GST protein capture on anti-GST 
antibodies. GST and GST:SKIP 59-129 proteins (20 µg/ml) were injected 






























Figure 27 Surface plasmon resonance (SPR) binding and control experiments 
to analyse the interaction between PPIL1 proteins and SKIP 59-129. (A) 
PPIL1 protein injections (1 µM) across GST:SKIP 59-129. (B) GST was 
immobilised on the surface of a separate flow cell and PPIL1 proteins were also 
injected across the surface, to ensure PPIL1 proteins do not bind to the GST 
tag. The response is measured in arbitrary response units (RU), which is 
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5.2.2 PPIL1 PPIase activity 
The effect of the PPIL1 patient variants on peptidyl prolyl cis trans isomerase 
(PPIase) enzyme activity of PPIL1 was determined on a model peptide 
substrate suc-AAPF-pNA. 1D 1H NMR was used to measure proline 
isomerisation of the Ala-Pro peptide bond. NMR is highly sensitive to 
chemical exchange processes, such as proline isomerisation, and results in 
line broadening of signals for affected residues151. The degree of line 
broadening is proportional to the rate of proline isomerisation (relative to the 
chemical shift difference [Hz] between the cis and trans resonances)151 and 
could be quantified using the mathematical technique, lineshape analysis. 
1D 1H spectra of the substrate were recorded, firstly in the absence of PPIL1 
enzyme (Figure 28A). 1D 1H experiments were suitable to monitor proline 
isomerisation in this instance, as the substrate suc-AAPF-pNA is a small 
molecule (four resides in length), meaning that there are relatively few 
signals in the spectrum and therefore signals were sufficiently dispersed for 
analysis (Figure 28A). Using the published assignment of this peptide127, 
signals corresponding to the Ala2 methyl protons of suc-AAPF-pNA were 
identified (Figure 28B). Ala2 methyl proton signals are well-resolved in the 
spectrum and show distinct, well-separated signals for the cis and trans 
peptide bond conformations (Figure 28B) and were therefore suitable to 
monitor proline isomerisation. The relative area under the cis and trans 
signals, corresponds to the populations of the peptide found in each 
conformation. Integration of these signals shows that cis and trans 
conformations of the peptide are present at 10 % and 90 % respectively, 
under the conditions used. This is in line with previous studies of suc-AAPF-
pNA127. 
- 100 - 
 
Figure 28 1D 1H NMR spectrum of the model PPIase peptide substrate: N-
succinyl-Ala-Ala-Pro-Phe-p-nitroanilide. Spectra were recorded in PBS at 
25 oC. (A) Whole spectrum and (B) enlarged region of spectrum showing the region 
of the alanine 2 methyl proton resonances. The Ala-Pro peptide bond is found in 
both cis and trans conformations and gives rise to distinct signals in the spectrum. 
(Ala2 methyl proton signals appear as doublets due to coupling with Ala2 Hα.) 
 
 
Spectra were recorded in the presence and absence of sub-stoichiometric 
concentrations of PPIL1 WT (Figure 29). Upon addition of PPIL1, cis and 
trans signals broaden, which is indicative of exchange (kex) between two 
states and thus here corresponds to increase in exchange between cis and 
trans conformations151. This confirms that as shown previously55, PPIL1 is an 
active PPIase and can catalyse proline isomerisation on the model substrate. 
The PPIase activity is concentration dependent, as expected; demonstrated 
by increased line broadening upon addition of increasing concentrations of 
PPIL1 (Figure 29). It should be noted that addition of PPIL1 causes such a 
large degree of line broadening that the cis signals disappear into the noise; 
this is due to the low fraction of the cis conformation, (approximately 10 %). 
To further confirm that PPIase activity is the cause of line broadening, the 
PPIase competitive active site inhibitor CsA (Cyclosporin A), was added to 
the sample at equimolar ratios to PPIL1. (CsA has been reported to interact 
with PPIL1 at nanomolar affinity [9.8 nM]158 and equimolar ratios of CsA have 
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been shown to be sufficient to inhibit PPIase activity of cyclophilins151). Upon 
addition of CsA, line broadening is reduced and the spectra closely 
resembles that of peptide alone. This confirms that the observed activity is 
due to the action of the PPIL1 PPIase active site. 
 
 
Figure 29 PPIase activity of PPIL1 WT. Spectra of the model peptide (N-succinyl-
Ala-Ala-Pro-Phe-p-nitroanilide) were recorded in the presence and absence of 
PPIL1. The region of the spectra containing Ala2 methyl proton signals that 
was used to monitor proline isomerization is shown. PPIL1 concentration was 
varied from 0-10 µM and the peptide concentration was held constant at 500 
µM. Exchange between cis and trans Ala-Pro peptide bond conformations (i.e. 
proline isomerization) is indicated by line broadening. The PPIL1 competitive 
active site inhibitor CsA (cyclosporin A) was further added to samples, at an 
equimolar ratio to PPIL1, to confirm the observed activity is due to the active 
site of PPIL1 (purple spectrum). 
 
 
The NMR assay was repeated to compare activity of PPIL1 WT and T107A 
and R131Q mutant proteins. Upon addition of catalytic concentrations of 
PPIL1 proteins (10 µM; WT, T107A and R131Q) to the peptide substrate, cis 
and trans Ala2 methyl proton signals broaden, indicating increased proline 
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isomerisation of the model substrate. This confirms that all three PPIL1 
proteins tested (WT, T107A and R131Q) have PPIase activity. (Figure 30A). 
As before for PPIL1 WT (Figure 29), a control experiment was carried out in 
which the active site inhibitor (CsA) was added to the substrate and PPIL1 
samples (Figure 30A). Addition of CsA reduces line broadening in all 
samples, confirming the activity observed is due to the PPIase active site 
(Figure 30A). Although all three proteins have PPIase activity on this 
substrate, T107A causes a smaller degree of line broadening compared to 
PPIL1 WT (Figure 30A). This suggests that PPIL1 T107A is a less active 
PPIase.  
The rate of proline isomerisation was calculated from the spectra using the 
mathematical technique, lineshape analysis (Figure 30B). The analysis 
confirms that all PPIL1 proteins significantly accelerate proline isomerisation 
on the model substrate (Figure 30B). PPIL1 R131Q catalyses proline 
isomerisation to similar levels as PPIL1 WT (Figure 30B). However, addition 
of PPIL1 T107A results in a reduced rate of proline isomerisation, by twofold, 
compared to PPIL1 WT (Figure 30B).  
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A 
 
B Experimental condition Rate of proline cis-trans 
isomerisation  
Peptide alone < 0.1  s-1 
Peptide + PPIL1 WT 9.6 ± 1.0 s-1 
Peptide + PPIL1 T107A 5.3 ± 0.2 s-1 
Peptide + PPIL1 R131Q 10.2 ± 1.5 s-1 
 
Figure 30 Comparison of PPIL1 WT and mutant PPIase activity on N-succinyl-
Ala-Ala-Pro-Phe-p-nitroanilide peptide substrate. Proline isomerisation 
was measured by monitoring NMR lineshape of cis and trans signals (Ala2 
methyl proton signals). (A) 1D 1H NMR spectra were recorded of the peptide 
substrate alone (black) and with catalytic concentrations of PPIL1 protein (10 
µM; red). Line broadening is indicative of exchange between cis and trans Ala-
Pro peptide bond conformations (i.e. proline cis-trans isomerisation). As a 
control, CsA was subsequently added to the sample to block PPIase activity 
(purple). (B) Lineshape analysis was used to determine rates of cis-trans 
exchange in the substrate. The assay was repeated three times with 
independent preparations of protein and the mean and standard deviation of 
these results are shown. PPIL1 T107A shows reduced PPIase activity on this 
substrate compared to WT PPIL1. 
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5.3 Discussion 
In this chapter, it has been shown that PPIL1 patient variants impact both 
binding to SKIP and PPIase activity of PPIL1. SPR results confirm that PPIL1 
R131Q substitution completely abolishes binding with SKIP. This is 
consistent with previous reports which show that residue 131 is highly 
important for the interaction56,86. Specifically, R131 together with I97 of PPIL1 
forms a hydrophobic groove of PPIL1 into which SKIP P65 binds. In addition, 
the sidechain of R131 also forms a hydrogen bond with the sidechain of 
Glu66 in SKIP56. SKIP is an essential splicing factor and is required for 
splicing to occur at the correct splice site159. Binding between PPIL1 and 
SKIP induces a disorder to order transition of SKIP and it is thought that this 
transition may contribute towards the large structural rearrangement of the 
spliceosome during assembly and catalytic activation86. In addition, it is 
proposed that this interaction is required to recruit PPIL1 PPIase active site 
to the correct location in the spliceosome, where it may bind to a target 
substrate55,86. 
It was not possible to achieve a good fit of the SPR data to a 1:1 Langmuir 
binding model and thus derive affinity and kinetic data for the interaction of 
PPIL1 proteins and SKIP. Previous SPR studies of this interaction55,86  
reported affinity values derived from 1:1 Langmuir binding model fits of the 
data. However, neither study showed the fits of the data55,86. Efforts were 
made to improve experimental design in order to rule out experimental 
conditions as the cause of deviations from a 1:1 interaction. PPIL1 analyte 
samples were confirmed to be of high purity and homogenous, as verified by 
SDS-PAGE, MS and SEC (Chapter 3). A low ligand immobilization density 
and high experimental flow rate were used to minimise the effects of mass 
transport. Any bulk refractive index changes were minimised by matching 
sample and running buffers, by extensive dialysis of PPIL1 proteins, and 
using a reference cell. Ligand homogeneity was ensured by confirming 
sample purity using SDS-PAGE and MS and also immobilising SKIP using 
an affinity capture system which results in a more uniform orientation of 
immobilised ligands. Non-specific binding was minimized by using a 
carboxymethyl dextran sodium salt in the sample buffer and was also 
controlled for with use of a reference cell. However, none of the above 
generated data that could be fitted to a 1:1 Langmuir binding model.  
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It is possible that the PPIL1-SKIP interaction is more complex than a 1:1 
interaction. Cryo-EM data suggests that a second region of SKIP may also 
bind to PPIL1 (Appendix Figure 57)47. However, investigating this was 
beyond the scope of this project. Therefore, after the above efforts, further 
optimization was halted and it was decided that data would only be analysed 
qualitatively. Qualitative analysis, even in the absence of kinetic or affinity 
data was highly informative in this project and clearly demonstrated PPIL1 
R131Q substitution abolished binding to SKIP. 
NMR results also showed that T107A substitution reduced PPIase activity of 
PPIL1 on the model substrate suc-AAPF-pNA. This is unsurprising as  
residue T107 is positioned close to the active site (see Chapter 3). 
Specifically, T107 is part of the S2 pocket, a hydrophobic pocket which is 
thought to confer binding specificity for substrates of the neighbouring 
PPIase active site (see Chapter 1)39. T107 has been defined as one of the 
‘gatekeeper residues’ of the S2 pocket, which may regulate binding of the 
substrate to the pocket as a result of the orientation and properties of the 
sidechain39. In addition, T107 is positioned in a flexible loop between beta 5 
and beta 6 strands of PPIL155. In the PPIL1 homolog, CypA, this loop 
becomes more flexible upon binding to a model substrate and it is thought 
that this flexibility may be crucial for substrate turnover, specifically by 
allowing Asn102 to form a hydrogen bond with the substrate58. It is clear that 
T107 and the surrounding loop have an important role in PPIase activity and 
therefore it is not surprising that T107A substitution affects PPIase activity of 
PPIL1. R131Q substitution does not significantly alter PPIase activity of 
PPIL1; however, this residue is found on a surface of PPIL1 distant to the 
active site55,56.  
All patient variants clearly perturb PPIL1 protein function either by affecting 
protein stability (Chapter 4), interaction with SKIP or PPIase enzyme activity. 
All characterized effects of the patient mutations on PPIL1 function, result in 
reduction or loss of PPIL1 function rather than any gain of function.  Taken 
together, these results confirm the deleterious effect of PPIL1 patient 
variants on PPIL1 function. 
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Chapter 6 The role of PPIL1 active site in the spliceosome  
6.1 Introduction 
In this thesis it has been shown that PPIL1 patient variants, which cause a 
novel syndrome of pontocerebellar hypoplasia, clearly perturb known 
functions of PPIL1 protein (Chapter 3-5). However, the precise role of PPIL1 
in the spliceosome remains unclear. In Chapter 5, NMR data demonstrated 
that a protein substitution caused by a patient variant (PPIL1 T107A), results 
in reduced PPIase activity of PPIL1 on a model substrate. However, it is not 
known what the role of the PPIL1 PPIase active site is in the spliceosome. 
The role of the PPIL1 active site in the spliceosome was investigated, to aid 
understanding of this disease. Advances in spliceosome biology also have 
implications for the understanding of many further diseases, as aberrant 
splicing activity is also implicated in a wide range of genetic diseases and 
cancers96.  
Cyclophilins, such as PPIL1, possess a PPIase active site, which can 
catalyse proline isomerisation - the transition between a cis and trans peptide 
bond preceding a proline residue (see Chapter 1). The type of peptide bond 
(cis or trans) affects the local conformation of the peptide chain, and the 
transition may be required for protein folding or protein conformational 
changes34. Several studies have shown that spliceosome cyclophilins, such 
as PPIL1, bind to other spliceosome components via surfaces outside the 
active site55,160; however the role of cyclophilin active sites in the 
spliceosome is unclear43. Cyclophilins that are associated with the 
spliceosome demonstrate a range of PPIase activity rates on a model 
substrate; and some spliceosome cyclophilins lack PPIase activity 
altogether39,43. Therefore, it is not clear whether PPIase activity is displayed 
by cyclophilins in the spliceosome. 
Splicing reporter gene assays by Adams et al. suggests that PPIase activity 
may not be important in the spliceosome and instead the function of 
cyclophilins in the spliceosome may be to interact with other components on 
surfaces outside the active site46. However these conclusions are based on 
observations from in vitro splicing assays with a specific reporter gene, which 
also relies on addition of excess cyclophilin protein46. Therefore, these 
assays may not be biologically representative. It is now becoming clear that 
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even core components of the spliceosome, may have a modulatory role in 
the spliceosome, and the function of spliceosome components may be gene 
or intron specific; therefore, studies on reporter genes may not reveal the full 
function of spliceosome components84.  
Recent advances in both cryo-electron microscopy and spliceosome 
purification have meant that a large number of spliceosome structures have 
recently been released65. Due to the spliceosome’s dynamic nature, it was 
previously difficult to determine spliceosome structures at high resolution. 
However, techniques to stall the spliceosome at various stages have now 
made it possible to determine the structure of a large part of the core 
spliceosome at near atomic level resolution78,89. Both the S. pombe ILS48 and 
human C* spliceosome47 structures have significant resolution for part of pre-
mRNA-processing factor 17 (PRP17) N-terminal region. Detailed 
interrogation of the structures indicated that a loop of PRP17 (human PRP17 
residues 89-101) interacts with PPIL1 in both structures (Chapter 3;Figure 
17)47,48. Analysis of these structures showed that a highly conserved proline 
of PRP17 (human Pro95) is positioned directly in the PPIL1 active site 
(Figure 17; Figure 18). The sidechain of Phe93 also occupies the 
neighbouring S2 pocket of PPIL1, a region thought to influence binding 
specificity of PPIase substrates by interacting with sidechains of residues N-
terminal to the prolyl peptide bond39. A phenylalanine residue at position i-2 
(i.e. Phe93), has previously been shown to be favourable for PPIase 
substrate binding for a different cyclophilin, Cyclophilin A161. The N-terminal 
region of PRP17, including the putative PPIL1 interaction site (human PRP17 
residues 89-101), is conserved in PRP17 from human to S. pombe; but is 
absent from S. cerevisiae which also lacks a PPIL1 homologue (Figure 18). 
(As this work was being completed further human spliceosome structures 
have been published which also indicate this interaction, [human Bact, C, P, 
ILS spliceosome complexes13,35,36,49,50,77] Chapter 3.) 
PRP17 (also known as CDC40) is a core component of the spliceosome30 
and, like PPIL1, is recruited to the spliceosome during Bact stage of 
spliceosome assembly49,50. PRP17 consists of a C-terminal WD40 domain 
and N-terminal region of extended conformation47,162. The PRP17 WD40 
domain is positioned close to the spliceosome catalytic centre and 
participates in the second catalytic step of the spliceosome47,52,162. The N-
terminal region of PRP17 forms a large number of connections spanning 
over 100 Å of the spliceosome, including an interaction with PPIL1, which is 
positioned close to the periphery of the spliceosome47. The interactions of 
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spliceosome components with PRP17 N-terminus are proposed to be 
important for ensuring fidelity of the spliceosome catalytic centre47,52. It is 
also suggested that PRP17 coordinates conformational changes across the 
spliceosome, as many conformational changes coincide with stable 
integration of PRP17 into the spliceosome50. 
Given the evidence above, the hypothesis that PRP17 could act as the 
substrate of PPIL1 in the spliceosome, was tested. It was first confirmed that 
hPPIL1 and hPRP17 (residues 89-101) interact and that this interaction 
occurred at the PPIL1 active site. It was assessed whether the interaction 
had any impact on the conformation of PRP17. Patient variants in PPIL1 
cause a novel syndrome of microcephaly and pontocerebellar hypoplasia 
(Chapters 1, 3, 4 and 5). The effect of the PPIL1 amino acid substitutions 
(T107A and R131Q) caused by the patient variants, on the PPIL1:PRP17 
interaction was also investigated. Given that the interaction with PRP17 
occurs at the PPIL1 active site and the cryo-EM data shows the 
PPIL1:PRP17 interaction involves a conserved proline residue of PRP17, it  
was also assessed whether PPIL1 has PPIase activity on PRP17. These 
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6.2 Results 
A peptide was synthesized (Peptide Synthetics) which corresponds to the 
putative PPIL1 binding region of PRP17 (residues 89-101 of PRP17; Figure 
17 and Figure 18). This peptide was used in binding studies and an 
equivalent peptide with 13C and 15N labelled proline (Pro95) was used in 
initial proline isomerisation studies. 
 
6.2.1 PPIL1 – PRP17 peptide interaction 
6.2.1.1 NMR analysis 
The interaction between PPIL1 and PRP17 was confirmed using 1H 15N 
heteronuclear single quantum coherence (HSQC) NMR. 1H 15N HSQC NMR 
is a highly valuable method to analyse protein interactions, as in addition to 
detecting an interaction, this technique can also provide information about 
the interaction site and affinity of the interaction163. 1H 15N HSQC spectra 
show H-N correlations of nuclei directly linked through covalent bonds, (by 
passing magnetisation between 1H and 15N nuclei; Figure 31). This spectrum 
yields a ‘protein fingerprint’ where specific signals for the amide group of 
each amino acid (except for proline and N-terminal residues) can be 
observed at specific chemical shifts. (Correlations in the following sidechain 
groups may also be seen in the spectrum: asparagine Nδ-Hδ2, glutamine Nε-
Hε2, Trp Nε-Hε and (at low pH) Arg Ne-He.) 
PPIL1 was 15N labelled using standard methods. A 1H 15N HSQC spectrum 
was first recorded of 15N labelled PPIL1 alone, to evaluate suitability for NMR 
(Figure 32). The dispersion of signals in the 1H dimension can be used to 
assess if a protein is folded, as 1H nuclei are particularly sensitive to their 
environment164,165. In the 1H 15N HSQC spectrum of PPIL1, resonances are 
well dispersed in the 1H dimension suggesting PPIL1 protein was folded 
(Figure 32). In addition, most signals are well resolved and of roughly 
uniform intensity, suggesting that PPIL1 protein is soluble and also suitable 
for further analysis (Figure 32). 
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Figure 31 1H 15N HSQC schematic, showing magnetisation pathway on two 
neighbouring amino acid residues. Magnetisation is first transferred from 1H 
to 15N (e.g. amide proton to nitrogen), chemical shift is then evolved on 15N 
and magnetisation is finally passed back to 1H for detection. 
 
1H 15N  HSQC spectra of PPIL1 were acquired with titrations of PRP17 
peptide (0-5 molar equivalents), to measure binding. Upon addition of PRP17 
peptide to PPIL1, resonances for certain residues of PPIL1 broaden beyond 
detection or shift, indicating PRP17 binds to PPIL1 (Figure 33). The chemical 
shift perturbations are indicative of specific binding rather than a non-specific 
effect; as only specific PPIL1 resonances broadened or shifted during the 
PRP17 titration and these shifts occur in different directions. Resonances 
which shift, move smoothly, from free to bound states suggesting a fast rate 
of exchangeiv. (Exchange detected by these experiments may result from 
either exchange between bound and unbound states of PPIL1 or a 
conformational change in PPIL1 induced by PRP17 binding.) Several 
resonances also broaden beyond detection and this is likely indicative of 
exchange on the intermediate timescale (Figure 33). 
The interaction site of PRP17 on PPIL1 was identified using the published 
assignment of PPIL1124 and HSQC data described above. Weighted 
chemical shift changes were calculated for each residue (Figure 34). 
Resonances which shifted more than 1 or 2 corrected standard deviations 
above the mean or broadened beyond detection were considered to be 
significant (Figure 34) and were mapped onto the published crystal structure 
of PPIL1 (Figure 35)56. The significantly perturbed residues cluster around 
                                            
iv Fast exchange is defined as kex (s-1) >> Δδ, intermediate exchange as kex (s-1) ≈ 
Δδ and slow exchange as kex (s-1) << Δδ, where Δδ is the chemical shift 
difference in Hz between the interconverting states (e.g. free & bound forms) 
and kex is the overall exchange rate in seconds. 
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the active site surface of PPIL1 confirming that, as predicted from the cryo-
EM structures, PRP17 binds to the PPIL1 active site (Figure 17; Figure 35). 
In addition, significantly perturbed residues also cluster around a 
neighbouring pocket to the active site, the S2 pocket (Figure 35). The S2 
pocket binds residues N-terminal to the prolyl peptide bond and is thought to 
confer substrate binding specificity for the PPIase active site39. Significantly 
perturbed residues include those which have been specifically defined as 
either active site (R55, F60, N102 and W121) or S2 pocket ‘gatekeeper’ 
(T107, S110 and Q111) residues39. (Active site residues were defined as 
those which create the hydrophobic proline binding pocket or are within 4Å of 
the prolyl peptide bond in model structures of the PPIL1 homologue 
CypA39,58. S2 pocket gatekeeper residues include PPIL1 residues which 
have sidechains positioned around the entrance to the pocket and are 
proposed to control access to the pocket39). These results are therefore 
consistent with the published cryo-EM data, which suggests that PRP17 
interacts with the active site and S2 pocket of PPIL147,48,77. 
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Figure 32 1H 15N HSQC spectrum of 15N  labelled PPIL1 WT protein alone. 
Spectra were recorded using 80 µM PPIL1 protein in 10 mM sodium 
phosphate buffer, 100 mM NaCl, pH 6.5 in a 600 MHz NMR spectrometer at 
25 oC Assignments were identified using the published assignments of PPIL1 
by Xu et al.124. 
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Figure 33 Overlaid 1H 15N HSQC spectra of PPIL1 WT protein before and after 
titrations with PRP17 peptide (0-5 molar equivalents). Concentration of 
PPIL1 protein used was 80 µM and PRP17 peptide was added at the relevant 
molar ratios. Specific resonances shift or broaden beyond detection indicating 
specific binding of PRP17 peptide to PPIL1. An example region of the spectra 
is enlarged to show resonances which shift (bottom), broaden beyond 
detection (centre) or are unaffected by the titration (top).
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Figure 34 Histogram showing average chemical shift perturbations (Δδ) of 
PPIL1 residues upon addition of PRP17 peptide. PRP17 peptide was added to 
PPIL1 at a 5:1 molar ratio. Grey lines show the chemical shift differences (for 
residues which were visible in the NMR spectrum before and after addition of 
PRP17 peptide). Solid and dashed lines indicate the cut-off values for resonances 
which shift greater than 1 or 2 corrected standard deviations above the mean, 
respectively (as recommended by Schumann et al.126). Red lines show residues at 
which the signal disappears as a result of significant resonance broadening. Spaces 
are present at proline and unassigned residues. (Weighted chemical shift changes 
were calculated using the following equation:	∆# = 	%(∆#')) + (∆#+))(,+/,')) from 
Hewitt et al. 2017125, see Chapter 2) 
 
Figure 35 Identification of PRP17 interaction site on PPIL1, using chemical 
shift perturbation mapping. PPIL1 WT residues which showed significant 
chemical shift perturbations after titration with PRP17 peptide in 1H 15N HSQC 
spectra were mapped on the published structure of PPIL1. Residues at which the 
signal disappears as a result of significant resonance broadening are shown in red. 
Residues which shift > 2 or >1 corrected standard deviations above the mean are 
shown in orange and yellow respectively. Residues which broaden or shift 
significantly include residues which have been described previously39 to define the 
active site (R55, F60, N102 and W121) and S2 pocket (T107, S110 and Q111). 
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PPIL1 PRP17 binding curves were plotted for all PPIL1 residues which 
shifted significantly in the HSQC spectra upon addition of PRP17 (Figure 36). 
The affinity of the PPIL1 PRP17 interaction was calculated using a global fit 
of the binding curves. The PPIL1 PRP17 interaction is low affinity (231.4 
µM), which is consistent with the resonance shift patterns in the spectra, 
which move smoothly from an unbound to a bound state. However, this 
analysis does not consider residues which broaden beyond detection, as it 
was not possible to follow these resonances throughout the titration. (These 
resonances likely represent those for which the difference between free & 
bound chemical shifts [∆#] are much larger and therefore of the same order 
of magnitude as the exchange rate [kex].) ITC has also been used to confirm 
the interaction and determine the overall affinity of the interaction (see 
section 6.2.1.2).  
 
Figure 36 Global fitting of NMR 1H 15N HSQC titration curves. PRP17 peptide 
was titrated into 15N PPIL1 protein (0-400 µM). For significantly shifting 
resonances (> 1 corrected standard deviation above the mean), chemical shift 
changes (∆#) are plotted against PRP17 concentration. The KD was calculated 
with a global fit of the binding curves in Prism 7. (All datasets could be 
described by a single best fit KD value; however, the Bmax parameter was 
allowed to vary between curves due to the different magnitudes of ∆# between 
residues.) Any residues which were not possible to track throughout the 
titration were removed from the analysis (residues 114 and 127).  
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Given that variants in PPIL1 cause a novel syndrome of microcephaly and 
pontocerebellar hypoplasia (Chapters 1, 3, 4, 5), it was investigated whether 
the resulting PPIL1 residue substitutions (T107A and R131Q) affect the 
interaction with PPIL1. 1H 15N HSQC titration experiments of PPIL1 protein 
with PRP17 peptide were repeated for PPIL1 mutant proteins (T107A and 
R131Q), to determine if the amino acid substitutions had any impact on the 
PPIL1 PRP17 interaction. As shown for PPIL1 WT (Figure 33), specific 
resonances of mutant PPIL1 (T107A and R131Q) shift or broaden beyond 
detection upon addition of PRP17 peptide (Figure 37); indicating specific 
binding. Resonances which broaden or shift significantly in PPIL1 WT upon 
binding to PRP17 peptide, also broaden or shift in mutant PPIL1 (T107A and 
R131Q) upon binding to the PRP17 peptide (for resonances which could be 
assigned; Figure 38). This indicates that PRP17 peptide binds to the same 
site in all three PPIL1 proteins. 
R131Q PPIL1 1H 15N HSQC spectra closely resemble that of PPIL1 WT 
(Figure 33; Figure 37). However, for PPIL1 T107A, specific resonances show 
an unusual chemical shift pattern upon titration with PRP17 peptide. Unlike 
PPIL1 WT resonances which shift smoothly in a linear pattern, specific 
resonances for PPIL1 T107A residues move in a nonlinear fashion (Figure 
37; Figure 39). This is only the case for resonances corresponding to specific 
residues of PPIL1 T107A and other resonances show smooth linear 
chemical shift patterns or do not shift (Figure 39). The affected residues are 
found in a loop connecting β strands 4 and 5, which lies below the S2 pocket 
in PPIL1 (Figure 40). These unusual shift changes are not simply 
representative of slow exchange, as resonances do not simply reduce in 
intensity and grow in intensity at a shifted location. Nonlinear chemical shift 
patterns indicate that something more complex than simple two state binding 
may be occurring (see discussion). 
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Figure 37 Overlaid 1H 15N HSQC spectra of PPIL1 T107A (top) and R131Q 
(bottom) protein before and after titrations with PRP17 peptide. Specific 
resonances shift or broaden beyond detection in the spectra, while other 
resonances are unaffected by the titration, indicating specific binding between 





 0:1, 0.5:1, 1:1, 2:1, 3:1, 4:1, 5:1
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Figure 38 Chemical shift perturbation histograms of PPIL1 proteins (WT, 
T107A and R131Q) after addition of PRP17 peptide (5:1 molar ratio). 
PPIL1 residues which shift in the 1H 15N HSQC spectra, upon addition of 
PRP17 peptide, are represented by grey histogram bars; residues which 
broaden beyond detection are represented by red histogram bars. (* marks 
the position of the PPIL1 amino acid substitutions). Residues which broaden 
beyond detection or more than two corrected standard deviations above the 
mean for PPIL1 WT are labelled on the histograms. 
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Figure 39 Addition of PRP17 peptide to PPIL1 T107A caused unusual chemical 
shift perturbation patterns for specific residues of PPIL1 T107A (74, 75, 
79, 82, 83 and 87). 1H 15N HSQC spectra of 15N PPIL1 T107A were recorded, 
with increasing titrations of PRP17 peptide, to measure binding. Specific 
resonances shifted significantly upon titrations with PRP17 peptide; however, 
some of these resonances shifted in a nonlinear manner (residues 74, 75, 79, 
82, 83 and 87). Chemical shift perturbation (Δδ) is plotted against PRP17 
peptide concentration (left). An example residue which shows an unusual 
nonlinear chemical shift perturbation (residue 74) and a residue which shifts in 
a smooth linear manner (residue 151) are shown (right). 
 
 
Figure 40 Surface and ribbon models of PPIL1 protein, showing residues of 
PPIL1 T107A which exhibit a nonlinear relationship between chemical 
shift and PRP17 concentration in HSQC spectra (cyan). Active site 
residues (yellow), S2 pocket residues (brown) and shared S2 pocket and 
active site residues (orange) are also highlighted. Residues with non-linear 
shift patterns in the HSQC are found in the β4-β5 loop. The β4- β5 loop is 
adjacent to the β5-β6 loop which forms the base of the S2 pocket.
Active site
S2 pocket












β5 – β6 loop 
T107
T107
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6.2.1.2 ITC analysis 
Isothermal titration calorimetry (ITC) was used to confirm binding between 
PPIL1 and PRP17 peptide. ITC is an accurate and sensitive method which 
can be used to measure molecular interactions in solution, without the need 
to label any interaction partner. This technique monitors binding by 
measuring the heat which is released or absorbed during an interaction. 
Titrations of binding partners are used to obtain binding curves, from which 
information such as binding affinity can be determined150. Weak affinity 
interactions are often difficult to characterise; however, Turnbull et al. 
showed that ITC produces reliable KD values for such interactions given that 
sufficient ligand titrations are used and a fixed stoichiometry is applied120. 
(However, it is recommended not to derive further parameters such as ∆H° 
and ∆S°, as these parameters can be less reliably determined using low 
affinity data120.) 
PRP17 peptide was titrated against PPIL1 protein to measure the interaction. 
Given the low affinity of the interaction, over 10 molar equivalents of ligand 
(PRP17) were titrated into the cell and KD values were calculated with a fixed 
stoichiometry (n=1)120. Clear binding curves were observed between PPIL1 
WT and PRP17 peptide with a calculated KD of 111.9 µM (Figure 41). These 
results therefore confirm that PPIL1 interacts with PRP17 with weak affinity, 
on a similar order of magnitude to the binding detected by NMR (section 
6.2.1.1). These results are therefore consistent with previous experimental 
observations. It was also investigated whether T107A and R131Q 
substitutions affect this interaction. ITC results also show that PPIL1 T107A 
and R131Q bind to PRP17 peptide with similar affinities to PPIL1 WT; 109.5 
µM and 107.9 µM respectively, compared to 111.9 µM (Figure 41). This 
indicates that PPIL1 T107A and R131Q patient mutations do not significantly 
affect the overall binding affinity of the PPIL1 PRP17 interaction.
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Figure 41 Isothermal titration calorimetry (ITC) analysis of the interaction between PPIL1 proteins (WT, T107A and R131Q) and PRP17 
peptide (PRP17 residues 89-101). PRP17 peptide (2 mM) was titrated into PPIL1 WT (40 µM) at 25 oC in PBS (pH 7.4). A control 
titration of PRP17 peptide into buffer, was carried out to determine the heat of PRP17 peptide dilution (top). Sequential heat pulse data 
(µcal/sec) for the titration of PRP17 peptide into PPIL1 proteins (WT, T107A, R131Q) is shown (middle panels). The heat changes upon 
binding were integrated to give binding curves for the interaction of each PPIL1 protein (WT, T107A, R131Q) with PRP17 peptide (bottom 
panels). Curve fitting with a fixed stoichiometry of 1.0 was used to calculate the KD of each interaction.
KD: 111.9 µM ± 4.0 KD: 109.5 µM ± 4.9 KD: 107.9 µM ± 4.4
Control titration of PRP17 peptide into buffer
Titration of PRP17 peptide into PPIL1 protein
WT T107A R131Q
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6.2.2 PRP17 1-172 and PPIL1 interaction 
It is possible that the PPIL1:PRP17 interaction induces a conformational 
change in PRP17. To test this hypothesis 15N labelled PRP17 1-172 was 
expressed and purified (this was a gift from Guoliang Chai, UCSD) and 1H 
15N transverse relaxation optimized spectroscopy (TROSY) NMR was used 
to analyse PRP17 1-172. 1H 15N TROSY experiments are equivalent to 1H 
15N HSQC (Figure 31) but show increased resolution and sensitivity for 
larger proteins163. The spectrum of the protein alone shows sharp well 
resolved resonances (Figure 42), suggesting the protein was suitable for 
further analysis. In addition, all resonances are found in a narrow 1H spectral 
range, suggesting that this protein is predominantly disordered in solution. A 
few resonances are shifted slightly upfield in the 1H dimension, suggesting 
that a small number of residues may have alpha helical tendencies (Figure 
42).  
PRP17 1-172 is mostly disordered in solution, it is possible that the 
interaction with PPIL1 stabilises a region of PRP17 1-172 and promotes a 
disorder to order transition. To investigate this further, unlabelled PPIL1 WT 
protein was titrated against 15N labelled PRP17 1-172 protein and 1H 15N 
TROSY spectra were acquired (Figure 43). Upon titration of PPIL1 into 
PRP17, a small number of specific PRP17 resonances broaden significantly, 
in a concentration dependent manner. At molar ratios above 0.5:1 
PPIL1:PRP17 these resonances broaden beyond detection (and do not 
reappear at another position in the spectrum). The observation that only 
specific resonances are affected by the PPIL1 titrations suggests that 
specific binding occurs between PRP17 1-172 and PPIL1; this is consistent 
with previous observations of the interactions between the PRP17 peptide 
and PPIL1 (sections 6.2.1.1 and 6.2.1.2). Resonance broadening is likely 
indicative of intermediate exchange, either between bound and unbound 
states of PRP17 or conformational exchange of PRP17 caused by binding. 
Resonance broadening here closely mirrors that of key active site PPIL1 
residues during PRP17 peptide titration, discussed above (section 6.2.1.1; 
Figure 33; e.g. R55, W121). The small number of resonances affected 
suggests that the interaction involves a localised region of PRP17 1-172. The 
data suggests that there is no large disorder to order transition of PRP17 1-
172 upon binding as there is absence of a significant number of resonances 
which shift in the spectra.  
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To confirm that the PPIL1 PRP17 1-172 interaction observed occurs via the 
PPIL1 active site, the PPIL1 active site competitive inhibitor, cyclosporin A 
(CsA) was used. 1H 15N TROSY experiments were repeated with PRP17 1-
172 alone (30 µM), with addition of PPIL1 (15 µM) and upon subsequent 
addition of CsA to the same sample (30 µM; Figure 44). The spectra with 
PRP17 1-172 alone and with PPIL1 are identical to those in Figure 43 and 
show that specific resonances of PRP17 1-172 broaden beyond detection, 
upon addition of PPIL1 (Figure 43; Figure 44). Upon addition of CsA to the 
sample containing PRP17 1-172 and PPIL1, the resonances which 
broadened beyond detection upon addition of PPIL1, sharpen and can be 
resolved (Figure 44). These results show that CsA can block the PPIL1 
PRP17 1-172 interaction and therefore confirm that the interaction occurs at 
the active site of PPIL1. In addition, these results further confirm that the 
observed resonance broadening is a result of specific binding rather than any 
other non-specific effect. The results of these experiments show that there is 
no large conformational change of PRP17 1-172 upon binding to PPIL1.  




Figure 42 1H 15N TROSY spectrum of PRP17 1-172 protein alone, in 25 mM 
sodium phosphate, 100 mM NaCl, 1 mM DTT, 5% D2O pH 7.0. Spectra 
were recorded using a 750 MHz NMR spectrometer at 25 oC. 




Figure 43 Overlay of PRP17 1-172  1H 15N TROSY spectra before and after 
PPIL1 WT titrations. Spectra were recorded using 30 µM PRP17 and PPIL1 
was titrated in from a 450 µM stock to give the following molar ratios. 
Resonances which broaden beyond detection are indicated by boxes. (There 
are currently no assignments for PRP17). The enlarged region of the spectra 
shows: an example resonance which broadens beyond the limit of detection 
upon titration of PPIL1 (top) and an example resonance which remains 
unaffected during the titration (bottom). 
 
 




Figure 44 Overlay of PRP17 1-172  1H 15N TROSY spectra: PRP17 1-172 alone 
(black), after addition of PPIL1 (green) and after addition of both PPIL1 
and the PPIL1 active site inhibitor, CsA (blue). The resonances which 
broaden beyond detection upon addition of PPIL1, reappear upon addition of 
the PPIL1 active site inhibitor CsA (indicated with boxes; e.g. top resonance of 
inlay). All other resonances are unaffected by addition of CsA (e.g. bottom 
resonance of inlay). The concentrations of molecules used were: 30 µM 
PRP17, 15 µM PPIL1, 30 µM CsA.
- 127 - 
6.2.3 PPIL1 PPIase activity on PRP17 (Gly94-Pro95) 
6.2.3.1 NMR Gly94-Pro95 cis and trans isomer assignment 
The data above suggests that binding between PRP17 and PPIL1 occurs at 
the PPIL1 PPIase active site. This raises the hypothesis that PRP17 is a 
substrate for the PPIase activity of PPIL1. Therefore, it was investigated 
whether addition of PPIL1 to PRP17 increases cis/trans proline isomerisation 
of the Gly94-Pro95 peptide bond; the prolyl peptide bond which occupies the 
PPIL1 active site in cryo-EM spliceosome structures (Figure 17; Figure 18). 
A peptide was synthesised (Peptide Synthetics) with an identical amino acid 
sequence to PRP17 peptide used for binding studies, but with the central 
proline (Pro95) uniformly 15N and 13C labelled. 
13C chemical shifts can be used to assign cis and trans peptide bond 
isomers37; therefore a 1H 13C HSQC of PRP17 peptide was acquired. 1H 13C 
HSQC spectra show all correlations between protons and 13C labelled 
carbons in a sample which are one bond coupled (i.e. linked directly by a 
covalent bond; Figure 45). The 1H 13C HSQC spectra recorded for PRP17 
peptide shows major resonances for each carbon of proline’s pyrrolidine ring 
(α, β, γ, δ; Figure 46), as these are all linked to at least one proton. These 
signals show two 1H shift values for β, γ, δ carbons as each carbon has 
covalent bonds with two protons; with the exception of Cγ trans resonances 
which are degenerate (i.e. the two resonances overlay and appear as a 
single resonance). There is a single major resonance for Cα as this atom has 
a covalent bond with a single 1H. In addition to the major resonances, a set 
of adjacent minor resonances can also be observed, suggesting that 
significant populations of both cis and trans isomers of this peptide may exist 
under the conditions tested.  
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Figure 45 1H 13C HSQC magnetisation pathway. 13C labelled proline and i-1 
residues are shown for a trans and cis peptide bond. Magnetisation is passed 
from 1H to 13C nuclei, where the chemical shift is evolved, and back to 1H for 
detection (shown with red arrows). All 1H-13C correlations are detected in the 
spectrum. (Only proline carbon atoms are 13C labelled). 
 
The 13Cβ and 13C! chemical shift differences (Δβγ) were used to determine 
whether the major and minor states correspond to trans and cis peptide bond 
isomers. Shen and Bax showed that Δβγ is higher when a proline peptide 
bond is in the cis conformation compared to the trans conformation and can 
be used to discriminate between cis and trans peptide bonds37. Δβγ is larger 
for the minor resonances (9.87 ppm) than major resonances (5.00 ppm) in 
the PRP17 peptide 1H 13C HSQC spectrum (Figure 46, right); consistent with 
minor resonances corresponding to the cis conformation and the major 
resonances corresponding to the trans conformation of the peptide bond. 
The major and minor resonances also fall within the expected 13Cβ and 13C! 
chemical shift ranges for trans and cis conformations (Figure 46), further 
confirming the assignment. Other possible causes of the minor resonances, 
such as low sample purity, were excluded as mass spectrometry and HPLC 
data shows that the peptide has a single molecular weight and is of >98 % 
purity (see appendix). 
The ratios of cis and trans populations were determined by comparing the 
relative peak volumes of the cis and trans 1H 13C HSQC resonances. This 
analysis shows that the ratio of cis and trans populations are 12 % and 88 % 
respectively. This finding is consistent with data for unstructured peptides 
where the cis conformation is found at a lower population than the trans 
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peptide, which is likely a result of the preceding glycine residue, which is 
favourable for the cis conformation37.  
 
 
Figure 46 1H 13C HSQC PRP17 peptide spectrum, showing resonances of the 
central proline residue (corresponding to Pro95 of PRP17). PRP17 
peptide (corresponding to residues 89-101 of PRP17), was synthesised with a 
13C and 15N labelled proline (corresponding to Pro95 of PRP17). The 1H 13C 
HSQC spectrum of PRP17 peptide was used to assign proline cis and trans 
peptide bond isomers based on Δβγ (the difference between 13Cβ and 13C! 
shifts). Expected 13Cβ and 13C! shifts for trans (pink) and cis (grey) isomers are 
shaded on the enlarged 13Cβ and 13C!  region of the spectrum (mean ± one 
standard deviation; Shen and Bax 201037). Spectra were acquired at 25 oC, in 
PBS (pH 7.4), on a 750 MHz spectrometer. 
 
6.2.3.2 ZZ exchange NMR experiments 
To determine whether PPIL1 has PPIase activity on PRP17, NMR 
experiments were used to monitor exchange between the cis and trans 
states of the Gly94-Pro95 peptide bond. ZZ exchange experiments were 
chosen as these experiments can measure slow exchange (≈ 0.2 – 100 s-1), 
which is the timescale proline isomerisation typically falls under129. During 
the 1H 15N,  H(C")N ZZ exchange experiments, magnetisation is passed 
from the 1H" to 15N amide via C". A mixing period follows where 
magnetisation is stored along the Z axis and during which exchange can 
occur (between proline peptide bond cis and trans conformations). The 
magnetisation is then transferred back to the H"	for detection, via C" (Figure 
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47). Therefore, if there is significant interconversion between states (cis and 
trans) during the mixing time, exchange signals appear in the spectrum128.  
 
Figure 47 Magnetisation pathway of 1H 15N, H(C")N ZZ exchange experiments, 
showing proline and a preceding residue (cis and trans peptide bond 
conformations are shown). Magnetisation is transferred from 1H" to 13C"	
and then to 15N amide, where it is labelled with 15N chemical shift. The 
magnetisation is then stored as NZ magnetisation (i.e. along the Z axis), for a 
defined period of time, during which exchange (e.g. proline isomerisation) may 
take place. Finally, magnetisation is passed back to 1H" for detection, via 
13C".  
 
1H 15N,  H(C")N ZZ exchange spectra were first recorded in the absence of 
PPIL1. Distinct major and minor signals were observed for the labelled 
proline (corresponding to Pro95 of PRP17; Figure 48). The minor and major 
signals correspond to the cis and trans conformations of the Gly94-Pro95 
peptide bond, as assigned in section 6.2.3.1. Levels of proline isomerisation 
were too low to detect in the absence of PPIL1, as no exchange crosspeaks 
are detected between the cis and trans conformations (Figure 48A). On 
addition of sub-stoichiometric concentrations of PPIL1, exchange cross 
peaks appear between the cis and trans resonances (Figure 48B). These 
results indicate that PPIL1 can significantly increase the rate of proline 
isomerisation on PRP17 (Gly94-Pro95 peptide bond) and therefore supports 
the conclusion that PRP17 is a substrate of PPIL1.  
There is also a further minor signal adjacent to the trans signal (Figure 48). 
Since Pro95 is the only 15N labelled residue the extra signal must also arise 
from this residue. (MS and HPLC analysis provided by the company confirm 
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Figure 61, Figure 62) Since there are two further prolines in this peptide (89-
FAPEFGPENPFRT-101), it is likely that this reflects a minor cis conformation 
of another proline. Cis and trans peptide bond isomers also cause resonance 
doubling for neighbouring residues166. The extra resonance is only seen for 
Cα in the 1H 13C HSQC (Figure 46); suggesting that this resonance appears 
as a result of a minor conformation of the proline N-terminal to Pro95, Pro91. 
 
 
Figure 48 PPIL1 catalysed proline isomerisation of PRP17 peptide (Gly94-
Pro95). PRP17 peptide was synthesised with 15N (and 13C) labelled proline 
(residues 89-101 and Pro95 of PRP17) to monitor proline isomerisation of 
PRP17 Gly94-Pro95 peptide bond. 2D 1H 15N, H(C")N ZZ exchange NMR 
spectra were acquired of PRP17 peptide alone (A) and with sub-stoichiometric 
concentrations of PPIL1 (5 µM; B). Dashed circles represent the region of the 
spectra in which exchange peaks should appear if there is significant 
interconversion between cis and trans proline peptide bond isomers during the 
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6.2.4 Further analysis of PPIL1 PPIase activity on PRP17  
6.2.4.1 Assignment of PRP17 84 - 101 peptide 
To measure rates of proline isomerisation in PRP17, alternative shorter ZZ 
exchange experiments were used, to allow acquisition of the many spectra 
required for such calculations (see section 6.2.4.2). This required use of a 
peptide with 15N labelled amide groups, therefore a uniformly labelled PRP17 
peptide was made (gift from Guoliang Chai, UCSD). This peptide 
corresponds to residues 84-101 of PRP17 (further residues of PRP17 
sequence were included for expression and purification purposes) and all 
residues were uniformly 15N labelled.  
A 1H 15N HSQC spectrum was recorded of the peptide alone, which shows 
clear well resolved resonances (Figure 51). Resonances are found in a 
narrow 1H spectral window, showing that the peptide is predominantly 
disordered under the conditions tested. As shown for PRP17 peptide with 
labelled Pro95 (section 6.2.3; Figure 46), the spectrum of uniformly labelled 
PRP17 peptide also contains major and minor resonances (Figure 51). In 
section 6.2.3 it was demonstrated that PRP17 peptide minor and major 
resonances correspond to cis and trans conformations respectively. The 
displayed assignment of major resonances (Figure 51; Table 17) were 
determined using 1H 15N HSQC, 1H 15N HSQC ROESY and 15N HSQC-
TOCSY spectra.  
TOCSY (TOtal Correlated SpectroscopY) spectra were acquired to gain a 
‘fingerprint’ for each amino acid, where the pattern and chemical shifts of 
resonances were used to help identify the type of amino acid residue. 
ROESY (Rotating frame nuclear Overhauser effect spectroscopy) spectra 
were also acquired to determine sequential connections between residues. 
Despite the small size of the peptide, the spectrum was complicated by the 
presence of many minor signals. Therefore, in order to assign the 
resonances 1H 15N HSQC-TOCSY and 1H 15N HSQC ROESY spectra were 
used which give better separations of signals, than standard 1H-1H TOCSY 
and ROESY spectra (Figure 50). 1H 15N HSQC-TOCSY results in a 
resonance for all 1H-15N direct couplings and corresponding 1H chemical 
shifts for all protons linked by covalent bonds in that spin system (i.e. all 
protons in that residue); see Figure 49. 1H 15N HSQC-ROESY also shows 
resonances for all 1H-15N direct couplings but subsequent connections for all 
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protons linked in space (rather than through bonds). The precise correlations 
depend on factors such as the mixing time used and size of the molecule. 
The 1H 15N HSQC ROESY used here gave good correlations between 1H" of 




Figure 49 2D 1H 15N HSQC-TOCSY magnetisation pathway. An initial HSQC 
pulse sequence transfers magnetisation between 15N and 1H (shown in grey, 
with red arrow). The signal is then propagated via covalent bonds through the 
whole spin system and magnetisation is evolved on all 1H nuclei (blue and 
grey). This results in correlations between 15N amide and all protons in that 
residue.  
 
Assignments were recorded for all major HSQC resonances and also all 
major proton resonances visible in the 1H 15N HSQC-TOCSY (Table 17). The 
N-terminal residue was absent in the spectrum, as is often the case, due to 
proton exchange with the solvent. Proline residues do not give a resonance 
in a 1H 15N HSQC, as they lack an amide proton; therefore, no assignment 
was determined for the three proline residues. The second residue of the 
peptide is also absent from the spectra, presumably due to high flexibility of 
the N-terminal region or accelerated amide proton exchange. The 
assignment was confirmed using sequential connections shown in the 1H 15N 
HSQC-ROESY spectra (Figure 50, Figure 52, Appendix Figure 63). The 
HSQC-ROESY spectrum showed near complete sequential HN-HN and HN-
Ha crosspeaks for the trans state signals but could not detect the much 
weaker sequential crosspeaks from the cis state signals. HSQC-ROESY 
resonances allowed connections between all residues to be confirmed; 
except for interruptions by proline residues (which do not give any signals in 
these experiments due to lack of an amide proton). Figure 52 shows an 
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example sequential connection pathway for residues 3-7 (residues one and 
two were not visible and the sequential connection was interrupted at residue 
8, as this residue is a proline residue). 
The minor states could not be assigned using these methods, due to the low 
population of the minor states. This meant that any corresponding TOCSY or 
ROESY resonances were too low in intensity to detect. However, the data 
presented in section 6.2.3.1,  indicates that the minor states correspond to 
the cis conformation and the major states correspond to the trans 
conformation. 
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Figure 50 Overlay of 1H 15N  HSQC (black), 1H 15N HSQC-TOCSY (blue) and 1H 15N HSQC-ROESY (red) spectra of PRP17 peptide (84-
101) used for assignment. Assignments are shown for amide resonances (left), Hα resonances (centre) and sidechain resonances 
(right). 14Asn sidechain also contains 1H-15N  connections, and the corresponding resonances are also found in the left region of the 
spectra. (The region of the spectra between 5.0 and 6.25 ppm (1H) is omitted as no resonances were found here). Resonances are 
numbered according to their position in the peptide (i.e. residue 1, corresponds to residue 84 of full length PRP17).  
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Figure 51 1H 15N HSQC spectrum of PRP17 peptide (84-101), showing 
assignment of amide resonances and 14Asn sidechain (H2Nδ) 
resonance. Resonances are numbered according to their position in the 
peptide (i.e. residue 1, corresponds to residue 84 of full length PRP17). 
Spectra were acquired at 25 oC, in 25 mM sodium phosphate buffer, 100 
mM NaCl, 1mM DTT, 5% D2O pH 7.0, using a 600 MHz spectrometer.




Acid N H Hα Hβ Hɣ Hδ Other 
1 Thr  * 
      
2 Tyr * 
      
3 Glu 122.70 8.52 4.26 2.01, 1.98 2.21, 2.21 
  
4 Thr 114.80 8.07 4.23 4.13 1.14, 1.11 
  
5 Met 122.59 8.22 4.36 1.88, 1.88 2.35, 2.41 
  
6 Phe 121.22 8.15 4.61 2.94, 3.10 
   
7 Ala 127.14 8.15 4.54 1.31 
   
8 Pro * 
      
9 Glu 120.46 8.50 4.11 1.98, 1.83 2.11, 2.11 
  
10 Phe 120.21 8.13 4.74 3.22, 2.97 
   
11 Gly 110.36 8.17 
4.09, 
4.06     
12 Pro * 
      
13 Glu 119.73 8.57 4.21 2.00, 1.92 2.25, 2.20 
  






15 Pro * 
      
16 Phe 119.37 8.09 4.56 3.13, 2.93 
   
17 Arg 122.82 7.87 4.33 1.84, 1.82 1.72, 1.56 
3.16, 
3.14 
Hε 7.16,  
Nε 
126.99 
18 Thr 120.70 7.78 4.22 4.11 1.17, 1.14 
  
Table 17 1H and 15N chemical shift assignment (ppm) of PRP17 peptide 
(residues 84-101). The following conditions were used: 400 µM peptide, 
25 mM sodium phosphate, 100 mM NaCl, 1 mM DTT, 5% D2O, pH 7.0. (* 
Proline residues are absent from 1H 15N HSQC and 1H 15N HSQC-TOCSY 
spectra, due to lack of an amide proton. The two N terminal residues were 
also absent in these spectra.) Resonances are numbered according to their 
position in the peptide (i.e. residue 1, corresponds to residue 84 of full length 
PRP17).
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Figure 52 Example region of HSQC-TOCSY (blue) and HSQC-ROESY (red) 
spectra used for assignment of PRP17 peptide. The sequential 
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6.2.4.2 ZZ exchange experiments  
ZZ exchange experiments were again used to monitor proline isomerisation 
on PRP17 (84-101) peptide. However, it was now possible to monitor proline 
isomerisation on neighbouring amides, rather than directly on proline, due to 
the availability of a uniformly labelled peptide. Proline peptide bond isomers 
cause resonance doubling for surrounding residues; hence it is possible to 
monitor proline isomerisation on surrounding residues.  ZZ exchange 
experiments are preferentially performed on residues with amide groups 
rather than proline residues, as it means that magnetisation can be passed 
directly from 1H to 15N rather than via 13C! (as proline lacks an amide 
proton). This means that the time taken to acquire a spectrum is significantly 
reduced and it was therefore possible to carry out the many experiments 
required for calculation of proline isomerisation rates. 
1H 15N ZZ exchange spectra were acquired in the presence and absence of 
sub-stoichiometric concentrations of PPIL1 (4 µM). Upon addition of PPIL1, 
new exchange peaks appear in the spectrum (Figure 53); this is indicative of 
increased exchange between minor (cis) and major (trans) states. This 
therefore indicates that addition of PPIL1 causes increased proline 
isomerisation in PRP17, consistent with previous experiments (section 
6.2.3). Residues 4Thr, 5Met, 7Ala, Glu9, Phe10, Gly11, Glu13, Asn14 and 
Arg17 all show major and minor resonances corresponding to trans and cis 
states. Proline isomerisation can clearly be seen for all residues with major 
and minor states. (Exchange peaks may be present for other residues, which 
cannot be observed due to overlapping chemical shifts with auto peaks).  
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Figure 53 1H 15N ZZ exchange spectra of PRP17 (84-101) with (red) and without 
(black) PPIL1. Exchange signals appear upon addition of PPIL1, due to 
exchange between cis and trans peptide bond conformations. Exchange 
peaks are connected to the corresponding auto peaks with dashed lines 
(blue). (4 µM PPIL1 was added to 400 µM PRP17 peptide).  
 
To determine rates of exchange (i.e. of proline isomerisation), 1H 15N ZZ 
exchange experiments were repeated with different mixing times (Figure 54). 
This allowed auto and exchange peak intensities to be monitored as a 
function of mixing time (Figure 54; Figure 55). Example build up curves are 
shown for Glu13 (Figure 55), which has well separated and clearly resolved 
auto (cis and trans) and exchange signals (Figure 54). The auto (cis and 
trans) peaks decay biexponentially as a result of both relaxation and the 
exchange process; whereas the exchange (cis-trans, trans-cis) peaks have 
an initial build-up phase due to the exchange process but also show 
competing decay due to relaxation (Figure 54; Figure 55). Two state 
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exchange equations described by Kleckner and Foster129 were fitted to the 
resulting build up curves, allowing the rate of exchange (kex) to be calculated 
(Figure 55; Table 18, Appendix Figure 64). Exchange rates were calculated 
for all residues with clear cis and trans resonances that were sufficiently 
separated and resolved for analysis (Table 18).  
 
 
Figure 54 1H 15N ZZ exchange spectra of PRP17 (84-101), recorded in the 
presence of PPIL1, using different mixing times. Cis and trans auto peak 
intensities reduce bi-exponentially with increased mixing time due to R1 
relaxation and the exchange process. Exchange peaks initially increase in 
intensity due to increased exchange events during the longer mixing time; but 
subsequently decrease in intensity due to R1 relaxation. An example region of 
the spectra is enlarged to demonstrate this (the resonances correspond to 
Glu13 auto resonances [cis and trans] and exchange resonances [cis->trans, 
trans->cis]).  
 




Figure 55 Proline isomerisation build up curves of PRP17 peptide, shown for 
Glu13. The normalised intensities of auto (cis and trans) and exchange peaks 
(trans-cis, cis-trans) from 1H 15N ZZ exchange spectra were plotted as a 
function of mixing time (seconds) and fit to two state exchange equations (see 
Chapter 2: materials and methods). Two experiments were collected in 
duplicate (experiments with 150 ms and 250 ms mixing times). 
 
 
Residue pcis (%) kex (s-1) 
4Thr 6.8 ± 0.3  2.5 ± 0.4  
7Ala 6.2 ± 0.2  2.3 ± 0.3  
Glu9 5.5 ± 0.3  2.9 ± 0.4  
Phe10 7.1 ± 0.3  2.7 ± 0.4  
Gly11 11.1 ± 0.2  5.5 ± 0.3  
Glu13 8.2 ± 0.2  5.8 ± 0.4  
Asn14 9.8 ± 0.3  5.9 ± 0.6  
Arg17 12.1 ± 0.3 5.3 ± 0.3  
Table 18 The cis population (pcis) and proline isomerisation rates (kex) of 
PRP17 peptide, measured across different PRP17 residues. (The error 
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The calculated rates of PPIL1 WT catalysed proline isomerisation on PRP17 
fall between 2-6 s-1 (Table 18). Notably, proline isomerisation monitored on 
residues 4-10 shows a lower rate of exchange compared to residues 11-17. 
Residues 4-10 also show a lower cis population compared to residues 11-17 
(Table 18). PRP17 peptide contains three proline residues and therefore the 
differences in exchange rates and cis populations are likely due to proline 
isomerisation of more than one proline in PRP17 (see discussion). The 
presence of more than one minor (cis) state is also shown in the 1H 15N 
HSQC spectrum of PRP17 peptide, where Gly11 has two minor resonances 
(Figure 51). This was also noted on PRP17 peptide with labelled Pro (section 
6.2.3), where two minor states were observed (Figure 48). In this thesis it 
has already been shown that PRP17 Pro 95, which corresponds to Pro12 of 
this peptide is isomerised by PPIL1 (section 6.2.3). Due to the position in the 
sequence, it is likely that Pro8 and Pro12 contribute towards the observed 
resonance doublings and are isomerised by PPIL1; however further 
experiments would be required to confirm this (see discussion).  
 
6.3 Discussion 
Overall this work strongly supports the hypothesis that PPIL1 binds to 
PRP17, as suggested by the Cryo-EM spliceosome data (C* human 
spliceosomes47 and S. pombe ILS spliceosome48). While working on this 
project further spliceosome structures (human Bact, C, P, ILS spliceosome 
complexes) have been published, which also suggests this 
interaction13,35,36,49,50,77. The interaction has been confirmed using both a 
peptide, corresponding to the proposed interaction region (PRP17 89-101), 
and also the N-terminal region of PRP17 (residues 1-172). These results 
suggest binding occurs at the active site of PPIL1 and is localized to a small 
region in PRP17, as also shown in the published Cryo-EM data47,48,77. 
Binding studies with the peptide confirm that binding occurs on the fast-
intermediate timescale with weak affinity; as shown by the dissociation 
constants of 231.4 and 111.9 µM (using NMR and ITC respectively). 
Although dissociation constants could not be determined using the longer 
region of PRP17 (1-172), due to the high concentrations of protein required 
for such a low affinity interaction, the pattern of resonance shifts in this NMR 
data is consistent with binding on an intermediate time-scale (i.e. kex [s-1] ≈ 
Δδ).  
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The KD values for the PRP17: PPIL1 interaction, calculated using ITC and 
NMR, are of similar orders of magnitude (111.9 µM and 231.4 µM 
respectively). The difference between calculated KD values for NMR and ITC 
experiments, is relatively small considering the different experimental 
techniques and conditions used. ITC results may be more accurate as a 
larger number of  titrations were used meaning the complex was closer to 
saturation at the end of the titration. Overall the affinity of the PPIL1-PRP17 
interaction, calculated using both methods, is in close agreement.  
Comparison of binding between WT and mutant PPIL1 proteins with PRP17, 
yielded some unusual results for PPIL1 T107A. PPIL1 T107A shows clear 
evidence of binding to PRP17, also via the PPIL1 active site. However, the 
unusual chemical shift perturbation patterns caused by binding to PRP17, in 
the HSQC spectra, suggests something more complicated may be 
happening upon binding. Comparison of PPIL1 WT and mutant protein 
binding to PRP17, in ITC experiments, confirms that the PPIL1 T107A 
substitution does not significantly affect the overall binding affinity, compared 
to PPIL1 WT.  It is unclear at present, what the cause of these differences 
may be and it is not possible to deduce the cause from this data alone. 
Possible causes of non-linear chemical shifts in HSQC spectra include: 
conformational change of PRP17 or PPIL1 upon binding or deviations from 
1:1 binding stoichiometry. The residues with non-linear shifts, are found in 
the β4-β5 loop that lies beneath the PPIL1 S2 pocket, suggesting it is this 
region of PPIL1 which may be involved in either conformational change or 
deviations from 1:1 binding stoichiometry.  
It is most likely that, in addition to bound and unbound states of PPIL1, there 
is a third state. The third state may correspond to a weaker secondary 
binding event or peptide binding induced dimerisation of PPIL1 and this 
could be investigated using analytical ultracentrifugation. To investigate 
conformational change of peptide or protein upon binding, further NMR 
experiments could be used. Specifically, Carr-Purcell-Meiboom-Gill 
sequence (CPMG) spin echo or Chemical Exchange Saturation Transfer 
(CEST) NMR experiments could be used to detect conformational changes 
upon binding, if they occur on timescales of milliseconds or less than a 
second respectively. To detect concentration dependent exchange, NMR 
Residual Dipolar Couplings (RDCs) could be used. In addition, transferred-
NOEs or NOEs are NMR methods which could also be used determine 
conformation of the PPIL1:PRP17 complexes.  
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Many cyclophilins participate in the spliceosome, and until now the role of the 
cyclophilin active sites has been unclear. It has been proposed that 
cyclophilin active sites may be required to bind proline rich regions of the 
spliceosome, potentially acting as a chaperone or alternatively that PPIase 
activity itself is important43,46. Evidence here supports the latter: PPIL1 binds 
to PRP17 with weak affinity rather than engaging in a stable interaction with 
PRP17 which could stabilize a conformation of PRP17. Instead using NMR 
ZZ exchange experiments, here it has been shown for the first time that 
PPIL1 has PPIase activity on PRP17 and is therefore the likely substrate of 
PPIL1 in the spliceosome. In this chapter, it has been confirmed that PPIL1 
has PPIase activity on the Gly94-Pro95 peptide bond, which is the peptide 
bond occupying the PPIL1 active site in the cryo-EM structures47,48. The work 
presented here is the first evidence that a cyclophilin has PPIase activity on 
a spliceosomal substrate.  
The role of proline isomerisation in PRP17, in the context of the spliceosome 
is currently unclear. The spliceosome undergoes a large number of 
conformation changes during assembly, catalysis and disassembly and it has 
been suggested that proline isomerisation may contribute towards these 
conformational changes30. Work in this thesis showed that PRP17 is 
predominantly disordered, a property which means that PRP17 does not 
have a fixed structure and instead rapidly samples a wide range of 
conformations. It was therefore investigated whether interaction with PPIL1 
may stabilise PRP17 and promote a particular conformation of PRP17. 
However, binding appears to be localised to a small number of residues and 
does not induce a large disorder to order transition of PRP17. It is possible 
the consequence of proline isomerisation cannot be observed outside of the 
spliceosome. Alternatively, it is possible that the small localised changes in 
PRP17 are sufficient to contribute to spliceosome assembly or catalysis.  
Work presented here provides a methodology for monitoring proline 
isomerisation rates of PRP17. Proline isomerisation rates were calculated 
using PRP17 peptide (PRP17 84-101). The results presented strongly 
suggest that more than one proline in PRP17 undergoes PPIL1 catalysed 
proline isomerisation in PRP17 peptide. It will be necessary to confirm which 
prolines in PRP17 are isomerised, by substituting these residues with 
another residue such as alanine in PRP17 peptide. There is clear evidence 
that Pro95 is isomerised; however further work is required to confirm whether 
further proline residues (pro91 or pro98) also undergo proline isomerisation. 
Future experiments should be carried out to compare rates of PPIL1 
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catalysed proline isomerisation on PRP17 with WT vs mutant PPIL1 proteins, 
in order to determine whether patient PPIL1 variants affect this activity. This 
will offer further insights into the mechanism of the novel form of 
microcephaly and pontocerebellar hypoplasia, caused by mutations in PPIL1.  
Despite potentially interacting with more than one proline in this loop region, 
PPIL1 clearly shows some binding specificity to particular proline peptide 
bonds in PRP17 1-172. Binding between PPIL1 and PRP17 is localised to a 
small number of residues in PRP17, despite PRP17 1-172 containing 
thirteen proline residues (which are all likely solvent accessible due to the 
disordered nature of PRP17 1-172). Piotukh et al. shows that for peptides 
binding to another cyclophilin’s (CypA) active site, phenylalanine is 
favourable at position i-2 relative to proline (i), as it fits well into the S2 
pocket161. PPIL1 is highly conserved compared to CypA and therefore PPIL1 
may also exhibit a preference for phenylalanine at position i-2. Only Pro95 
and Pro91 have a phenylalanine residue at position i-2, and therefore this 
may be the reason for PPIL1’s specificity.  
The role of other cyclophilin active sites in the spliceosome is still unclear. As 
this work was being completed, a study was published which showed the 
interaction of PPIH (spliceosome cyclophilin) and PRPF4 (spliceosome 
protein) involves two binding sites of PPIH, one of which involves PPIH 
PPIase active site167. Further cryo-EM spliceosome structures have since 
been published which also show interactions of spliceosomal proteins and 
cyclophilin active sites77. However some spliceosomal cyclophilins do not 
have PPIase activity on a model substrate39, and it is therefore unlikely that 
all cyclophilins have PPIase activity in the spliceosome. This raises the 
intriguing question of the function of other cyclophilins which do not catalyse 
proline isomerization in the spliceosome.  
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Chapter 7 Conclusions and future perspectives 
 In this thesis it has been shown that the PPIL1 variants, identified in 
patients with microcephaly and pontocerebellar hypoplasia, clearly have 
deleterious effects on PPIL1 protein function (Chapters 3-5). All of the 
identified patient variants result in amino acid substitutions or 
duplications (A99T, T107A, R131Q and G109C;101_106dup). Following 
the expression and purification of  PPIL1 WT and mutant proteins, it has 
been shown in an in-vitro system that PPIL1 A99T and G109C; 
101_106dup protein changes significantly perturb PPIL1 protein 
structure and render these proteins insoluble (Chapter 4). T107A and 
R131Q amino acid substitutions also significantly affect PPIL1 protein 
folding and reduce protein stability, although to a lesser extent than 
A99T and G109C; 101_106dup (Chapter 4). PPIL1 R131Q abolishes 
binding to the PPIL1 spliceosome binding partner, SKIP (Chapter 5). It 
has also been shown that the PPIL1 T107A patient variant significantly 
reduces the PPIase enzyme activity of PPIL1 on a model substrate 
(Chapter 5). These findings strongly support the hypothesis that the 
novel syndrome of microcephaly and pontocerebellar hypoplasia is 
caused by the identified variants in PPIL1. It is interesting that the 
different patient variants affect different aspects of PPIL1 protein 
function: protein folding, interaction with SKIP, or PPIase activity of 
PPIL1. The severity of the phenotype varies between patients and 
interestingly patients with the T107A variant have the most severe 
phenotype (see Chapter 1: Introduction).  
 The discussed findings have important implications for the understanding 
of microcephaly and related brain development disorders. Together with 
findings by collaborators (Guoliang Chai and Joseph Gleeson, UCSD), 
there is strong evidence that variants in PPIL1 cause a novel syndrome 
of microcephaly and pontocerebellar hypoplasia (publication in progress 
“Biallelic mutations in the proline isomerase PPIL1 disrupt pre-mRNA 
splicing and cause microcephaly and pontocerebellar hypoplasia”). As 
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this thesis was being completed, further variants in PPIL1 were detected 
in patients with similar phenotypes to those reported here (data not yet 
published).  These variants were: homozygous p.Y78C, compound 
heterozygous p.F82S; p.R131Q and compound heterozygous c.397A>G 
p.T127A; c.280+1G>A variants. These variants were identified 
independently in other laboratories, thus providing further independent 
evidence that variants in PPIL1 cause microcephaly and pontocerebellar 
hypoplasia.  
 This is the first time that variants in PPIL1 have been identified as the 
cause of a brain development disorder. Identifying the cause of genetic 
diseases has important implications for genetic counselling and therapy. 
Despite advances in identifying the underlying variant, a gene 
responsible can only be detected in approximately half of microcephaly 
cases6; therefore further work into the cause of microcephaly and 
associated disorders continues to be hugely important.   
 The experimental techniques used to investigate PPIL1 variant 
pathogenicity required use of purified protein and were therefore 
performed in an in vitro setting, which is a limitation of this study. 
However, the conclusions drawn from SPR experiments, to study the 
PPIL1-SKIP interaction, are in agreement with conclusions drawn from 
immunoprecipitation (IP) experiments (conducted by Guoliang Chai, 
UCSD) which are conducted in a more physiologically relevant situation. 
SPR results, however, offer advantages over IP experiments, as the 
direct interaction can be monitored and other indirect effects of the 
patient variants on protein interactions can be ruled out. It is currently not 
possible to study PPIase enzymatic activity in a cellular context (see 
below). The protein folding techniques used, also required the use of 
purified protein.  
 In order to gain a further understanding of the mechanism of the disease, 
the function of PPIL1 in the spliceosome was investigated. Previously it 
was only known that PPIL1 participates in the spliceosome, but little was 
known about its specific function in this complex. By modelling cryo-EM 
data PRP17 was identified as a putative substrate of PPIL1 in the 
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spliceosome (Chapter 3). It was subsequently shown, using NMR and 
ITC, that as suggested by the cryo-EM data47-50,77, PRP17 binds to the 
PPIase active site of PPIL1. Further NMR experiments on PRP17 
peptide, have demonstrated that PPIL1 exhibits PPIase activity on 
PRP17; providing strong evidence to support the hypothesis that PRP17 
is the substrate of PPIL1 in the spliceosome (Chapter 5). This is the first 
time that a spliceosome cyclophilin has been shown to exhibit PPIase 
activity on a spliceosome substrate. It was previously unclear what the 
role of cyclophilin proteins, such as PPIL1 in the spliceosome might 
be39,43. These findings also have implications for the understanding of 
spliceosome biology in general. Aberrations in splicing cause a range of 
genetic diseases and cancers96; therefore knowledge of the spliceosome 
is important for the understanding many diseases. 
 Studies of proline isomerisation are currently limited to in vitro assays 
with purified protein, as NMR (and chromogenic peptide assays for 
model substrates152) are the only techniques capable of detecting proline 
isomerisation. A new in vivo method to detect proline isomerisation, 
using live cells and substrates labelled with a fluorescent probe is in 
development168. However, this method still requires further optimisation, 
such as increasing signal to noise, to be a reliable indicator of PPIase 
activity. In addition, this assay is only suitable for model substrates. The 
recent and ongoing development of “in cell NMR” means that there are 
now many examples of protein structural information derived from a 
cellular context. However this field is still in its infancy and has not been 
used to monitor proline isomerisation169.  
 Further work will be required to understand the effect of the PPIL1 
patient variants. It would be valuable to explore the effects of the newly 
identified PPIL1 variants on PPIL1 function, by expressing and purifying 
these proteins and repeating the assays used in this thesis (e.g. protein 
folding and stability, interaction with SKIP and PPIase activity assays). 
Furthermore, having established a protocol to determine rates of PPIL1 
catalysed proline isomerisation of PRP17, it would be possible to 
compare the effect of the PPIL1 variants on this activity.  
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 It still remains unclear how a mutation in a ubiquitous essential complex, 
the spliceosome, can cause symptoms which are limited to the brain. It 
was not possible to obtain patient cells to study splicing as the patients in 
the UK are deceased and cells obtained prior to this point did not 
survive. However collaborators (Joseph Gleeson and Guoliang Chai, 
UCSD) produced a mouse model (Ppil1A99T/A99T) and performed RNA-
seq analysis on E14.5 brains. Analysis using rMATS detected 3,797 
significant differential splicing events, between mutant and WT brains, 
out of found 236,870 total splicing events. Significant differential splicing 
events affected all categories of splicing events (skipped exon, retained 
intron, alternative 5’SS, alternative 3’SS and mutually exclusive exons) 
and caused either increased inclusion or exclusion for different splicing 
events. GO-analysis showed that genes affected by differential splicing 
events in mutant brains are enriched for critical cellular functions 
including: RNA metabolism, protein translation/processing and cell cycle 
regulation.   
 The data above supports the conclusion that PPIL1 mutations affects the 
splicing of specific groups of genes, rather than a general inhibition of 
splicing (manuscript in progress as above). It may be that the additive 
effect of these changes accumulates over time. This model is further 
supported by previous work that shows that knockdown or mutation of 
spliceosome components, frequently affects the splicing of specific 
genes rather than a general inhibition of splicing84,170,171. High levels of 
alternative splicing takes place during brain development and AS is 
required at each stage of development, such as cell-fate determination, 
neuronal cell migration, axon growth and guidance and formation of 
synapses172.  
 Many further genetic diseases, affecting a large range of tissues, are 
caused by mutations in spliceosome components. For example, 
mutations in several spliceosome components lead to autosomal 
dominant retinitis pigmentosa (RP), a genetic disorder which affects the 
retina. All spliceosome genes identified in RP (PRPF3, PRPF6, PRPF8, 
PRPF31, RP9 (PAP1), and SNRNP200) are components of the tri-
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snRNP complex of the spliceosome. The tissue specificity has been 
attributed to the high demand of splicing in the retina; supported by the 
high expression of spliceosome snRNAs compared to other tissues173. 
However, mutations in genes encoding spliceosome components affect 
tissues beyond the retina and a range of craniofacial disorders (Nager 
syndrome, cerebrocostomandibular syndrome, Richieri-Costa–Pereira 
syndrome, Mandibulofacial dysostosis and Burn-McKeown syndrome) 
are also caused by spliceosome mutations (SF3B4, SNRPB, EIF4A3, 
EFTUD2 and TXNL4A respectively)174. Spinal muscular atrophy is a 
neuromuscular disorder and is also caused by variants in SMN1 which 
encodes a protein involved in assembly of spliceosome snRNPs175. 
Therefore, it is clear that tissue specificity in genetic disorders caused by 
spliceosome mutations is more complex, than originally thought.  
 Due to the complex combinatorial regulation of splicing by spliceosome 
components and regulatory factors30,84, it is difficult to predict precisely 
how PPIL1 variants affect overall spliceosome conformation and 
function. Further spliceosome structures will be highly valuable to 
understand the mechanism of the spliceosome and function of individual 
components. This includes analysis of further states in the assembly and 
catalytic cycle of the spliceosome. In addition, analysis of spliceosome 
structures on alternatively spliced pre-mRNAs will provide valuable 
insights into regulation of the spliceosome and the mechanisms behind 
alternative splicing.  
 It has previously been shown that mutations in spliceosome components 
may affect stoichiometry of the spliceosome, which in turn leads to 
specific alternative splicing defects173. Tanackovic et al. showed that 
patient variants in PRPF31, PRPF3 or PRPF8 (which cause retinitis 
pigmentosa) caused alternations in composition of spliceosome 
subunits, using Northern and Western blotting173. Equivalent 
experiments in cell lines containing the patient PPIL1 variants would be 
valuable to further understand how PPIL1 variants lead to aberrant 
splicing. 
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 It would also be valuable to investigate whether other cyclophilins have 
PPIase activity on the proteins which bind their active site in spliceosome 
structures. For example, Zhan et. al recently showed that CypE, and two 
further cyclophilin domains (tentatively assigned as PPWD1 and PPIG) 
have putative substrates in the C spliceosome (SmB, CCDC49 and 
Prp8)77. Further spliceosome structures may allow identification of further 
putative substrates of spliceosome cyclophilins. Two spliceosome 
cyclophilins are inactive on a model substrate (suc-AGPF-pNA), PPIL2 
and CWC2739; therefore it would be interesting to understand the role of 
their PPIase active sites. These cyclophilins may bind to and stabilise 
proline rich regions of spliceosome components or it is possible that they 
have PPIase activity with high specificity; i.e. these cyclophilins may only 
be active on specific substrates and not the model substrate (suc-AGPF-
pNA). This research will not only provide insights into the mechanism of 
the spliceosome, but also cyclophilin PPIase proteins. There are 19 
cyclophilins in the human genome, many of which are implicated in 
human diseases, (e.g. PPIA59 and PPID176).  
 Overall, this thesis provides strong evidence that variants in PPIL1 cause 
a syndrome of microcephaly and pontocerebellar hypoplasia and has 
provided novel insights into the role of PPIL1 in the spliceosome. Further 
research will be vital, not only for further understanding of this disease, 
but also to contribute towards understanding of the spliceosome and 
cyclophilin family of proteins (both of which are implicated in a wide 
range of human diseases).  




Figure 56 PPIL1 residue A99 is positioned in the hydrophobic core of PPIL1. 
Hydrophobic residues are coloured in red and hydrophilic residues are 
coloured in blue (using Chimera kdHydrophobicity values) on the published 
crystal structure of PPIL156). Buried residues are represented as spheres (and 
were calculated using normalised solvent accessibility data from STRIDE; <10 
% solvent accessibility of residues177-179).  
A99TA99T
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Figure 57 PPIL1 (grey) and SKIP (green) interaction, as shown by published 
NMR (A) and spliceosome cryo-EM (B) structures. NMR studies only 
modelled the interaction using a small fragment of SKIP (59-79)86; however, 
the cryo-EM model is based on full length SKIP and the PPIL1 interacting 
region (59-129) is shown here. The cryo-EM model shown is the human C* 
spliceosome complex47. The cryo-EM structure indicates that a second region 
of SKIP may bind to PPIL1 (SKIP 89-97). Images were created using data 






PPIL1 and SKIP 59-79
Cryo-EM structure:
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Figure 58 SPR data fitting for binding of PPIL1 proteins (WT [A], T107A [B]) to 
SKIP 59-129. SKIP 59-129 was immobilised on the chip surface and PPIL1 
proteins were injected across the chip at a range of concentrations (15.6, 31.3, 
62.5, 125, 250, 500 1000, 2000 nM; coloured lines). Binding curves were fit to 
a 1:1 Langmuir binding model, using BIAevaluation software (black lines). The 
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Figure 59 Comparison of amino acid conservation between the human 
cyclophilin protein family. Conserved residues are shown with red letters 
and strictly conserved amino acids are highlighted in red with white letters. 
Positions of the patient mutations are indicated with green boxes for amino 
acid substitutions and a cyan box for the duplication region. Active site and S2 
pocket residues defined by Davis et al. are indicated with black and grey 
vertical arrows respectively39. Sequences were aligned using Clustal Omega 
and rendered for sequence similarities using ESPript.  
 
 




Figure 60 Representative time of flight mass spectrometry data, showing 
results for PPIL1 R131Q. Peak hight (%) is plotted against the mass-to- 
charge ratio (m/z) [top] or mass [bottom]. 
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Figure 61 Reverse phase HPLC data provided by Peptide Synthetics for 
PRP17 peptide (labelled proline). The area under the curve confirms that the 
peptide is of >98 % purity. 
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Figure 62 Mass spectrometry results provided by Peptide Synthetics. (Peaks 
of species with +2 and +3 charges are shown). Results therefore show that 
the peptide has a single mass of 15557 Da (within 1 kDa of the predicted 
molecular weight, 1556 kDa). 
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           Residues 16-18 
 
Figure 63 Enlarged regions of 1H 15N HSQC-TOCSY (blue) and 1H 15N HSQC-ROESY (red) spectra used for assignment of PRP17 
peptide (84-101). Sequential connections could be observed between all consecutive residues, except where interrupted by proline 

































Figure 64 PRP17 peptide proline isomerisation build up curves. Build up curves 
were plotted for each residue of PRP17 with clearly resolved cis, trans and 
exchange peaks. The normalised intensities of auto (cis and trans) and 
exchange peaks (trans-cis, cis-trans) from 1H 15N ZZ exchange spectra were 
plotted as a function of mixing times and fit to two state exchange equations 
(see Chapter 2: materials and methods). Two experiments were collected in 
duplicate (experiments with 150 ms and 250 ms mixing times).
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Figure 65 PRP17 conservation across species: Homo sapiens (NP_056975.1), 
Mus musculus (NP_082155.1), Danio rerio (NP_001009990.1), Drosophila 
melanogaster (NP_651005.1), Caenorhabditis elegans (NP_492851.1), 
Arabidopsis thaliana (NP_172528.2), Schizosaccharomyces pombe 
(NP_596089.1) and Saccharomyces cerevisiae (NP_010652.3). The PPIL1 
interaction site, based on spliceosome cryo-EM structures
47,48
 is indicated. 
The N terminal region of PRP17, including the PPIL1 binding site, is absent in 
S. cerevisiae, which also lacks a PPIL1 homologue. The WD40 C-terminal 
domain is conserved between species, from Human to S. cerevisiae. 
Sequences were aligned using Clustal Omega
32








































Figure 66  Example PPIL1 pET22b+ vector sequence chromatograms. Full 
length PPIL1 was cloned into the multiple cloning site; A) shows codon 1 and 
B) shows the C-terminal His-tag in frame with PPIL1 coding sequence. Arrows 
mark the positions of point mutations in the four mutant vectors C) A99T D) 
T107A E) R131Q and F) G109C and the duplication in the final vector is 
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Brain Malformation Disorders Gene Panel 
 Genes Symbol MIM HGNC 
 actin, beta ACTB 102630 132 
 actin, gamma 1 ACTG1 102560 144 
 adhesion G protein-coupled receptor G1 ADGRG1 604110 4512 
 ADP-ribosylation factor guanine nucleotide-
exchange factor 2 ARFGEF2 605371 15853 
 AKT serine/threonine kinase 3 AKT3 611223 393 
 aristaless related homeobox ARX 300382 18060 
 calcium/calmodulin dependent serine protein 
kinase CASK 300172 1497 
 cyclin D2 CCND2 123833 1583 
 doublecortin DCX 300121 2714 
 dynein, cytoplasmic 1, heavy chain 1 DYNC1H1 600112 2961 
 ER membrane associated RNA degradation ERMARD 615532 21056 
 filamin A FLNA 300017 3754 
 fukutin FKTN 607440 3622 
 fukutin related protein FKRP 606596 17997 
 G protein signalling modulator 2 GPSM2 609245 29501 
 isoprenoid synthase domain containing ISPD 614631 37276 
 KIF1 binding protein KIF1BP 609367 23419 
 kinesin family member 2A KIF2A 602591 6318 
 kinesin family member 5C KIF5C 604593 6325 
 laminin subunit alpha 2 LAMA2 156225 6482 
 
    Disorders Symbol MIM 
Baraitser-Winter Syndrome 1 BRWS1 243310 
Baraitser-Winter Syndrome 2 BRWS2 614583 
Cerebellar Ataxia, Mental Retardation, And 
Dysequilibrium Syndrome 1 CAMRQ1 224050 
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Pontocerebellar Hypoplasia Disorders Gene Panel 
Genes Symbol MIM HGNC 
arginyl-tRNA synthetase 2, mitochondrial RARS2 611524 21406 
calcium/calmodulin dependent serine protein 
kinase CASK 300172 1497 
charged multivesicular body protein 1A CHMP1A 164010 8740 
exosome component 3 EXOSC3 606489 17944 
Chudley-Mccullough Syndrome CMCS 604213 
Cortical Dysplasia, Complex, With Other Brain 
Malformations 2 CDCBM2 615282 
Cortical Dysplasia, Complex, With Other Brain 
Malformations 3 CDCBM3 615411 
Cortical Dysplasia, Complex, With Other Brain 
Malformations 4 CDCBM4 615412 
Cortical Dysplasia, Complex, With Other Brain 
Malformations 5 CDCBM5 615763 
Cortical Dysplasia, Complex, With Other Brain 
Malformations 6 CDCBM6 615771 
Cortical Dysplasia, Complex, With Other Brain 
Malformations 7 CDCBM7 610031 
Cortical Dysplasia, Complex, With Other Brain 
Malformations 8 CDCBM8 613180 
Cortical Malformations, Occipital OCCM 614115 
Goldberg-Shprintzen Syndrome GOSHS 609460 
Lissencephaly 1 LIS1 607432 
Lissencephaly 2 LIS2 257320 
Lissencephaly 3 LIS3 611603 
Lissencephaly 4 LIS4 614019 
Lissencephaly 5 LIS5 615191 
Lissencephaly, X-Linked, 1 LISX 300067 
Lissencephaly, X-Linked, 2 LISX2 300215 
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Sep (O-phosphoserine) tRNA:Sec 
(selenocysteine) tRNA synthase SEPSECS 613009 30605 
tRNA splicing endonuclease subunit 2 TSEN2 608753 28422 
tRNA splicing endonuclease subunit 34 TSEN34 608754 15506 
tRNA splicing endonuclease subunit 54 TSEN54 608755 27561 
vaccinia related kinase 1 VRK1 602168 12718 
    Disorders Symbol MIM 
Mental Retardation And Microcephaly With 
Pontine And Cerebellar Hypoplasia MICPCH 300749 
Pontocerebellar Hypoplasia, Type 1a PCH1A 607596 
Pontocerebellar Hypoplasia, Type 1b PCH1B 614678 
Pontocerebellar Hypoplasia, Type 2a PCH2A 277470 
Pontocerebellar Hypoplasia, Type 2b PCH2B 612389 
Pontocerebellar Hypoplasia, Type 2c PCH2C 612390 
Pontocerebellar Hypoplasia, Type 2d PCH2D 613811 
Pontocerebellar Hypoplasia, Type 4 PCH4 225753 
Pontocerebellar Hypoplasia, Type 6 PCH6 611523 
Pontocerebellar Hypoplasia, Type 8 PCH8 614961 
Table 19 Brain Malformation Disorders Gene Panel and Pontocerebellar 
Hypoplasia Disorders Gene Panel - Yorkshire Regional Genetics Service 
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